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CHAPTER I 
INTRODUCTION 
Striated muscle plays an important role in locomotion and posture of animals and 
man. It is a very specialized tissue and is well adapted for energy production. Although 
the metabolic capacity per kg tissue is less in muscle than in liver and kidney, the large 
mass of striated muscle makes it an important tissue in the homeostasis of lipid, carbohy-
drate and protein metabolism of the body. This is particularly the case in man and larger 
animals, in which the weight of skeletal muscle exceeds manyfold that of liver (Table 
1.1.). 
Table 1.1. Ratio between muscle and liver weight in various mammalian species. 
Species Body weight (kg) Weight ratio muscle/liver 
Mouse 0.03 8.5 
Rat 0.16 11 
Rabbit 1.5 15 
Dog 25.5 21 
Bullock 450 32 
Horse 690 35 
Man 65 18 
Animal values were obtained from Munro (1978). 
It will be clear that alterations or deficiencies in skeletal muscle metabolism will 
stress the other tissues and may affect health. It might even be questioned whether 
changes in the pattern of man's motility by cultural changes and neglect of posture could 
influence his well-being. 
Large differences exist in the energy metabolism of different tissues, like liver, 
muscle, kidney and fibroblasts. In addition there are marked differences in the energy 
metabolism of muscles of different animal species. Our knowledge about the energy meta-
bolism of human muscle is limited. This has led us to a biochemical investigation on ener-
gy production from fatty acids and leucine by striated muscle of man and rat. Simultane-
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ously with our study, various aspects of skeletal muscle energy production were examined 
by other investigators (Bookelman, 1978; Willems, 1978;Essén, 1978;Sahlin, 1978). 
In this first chapter we describe the general properties of striated muscle tissue (sec-
tion 1.1) and give a survey of the present insights in energy production and utilization in 
skeletal muscle (section 1.2). Since our investigation concerns the role of carnitine in the 
metabolism of fatty acids and leucine, data on carnitine metabolism are also summarized 
(section 13). After a short description of the main aspects of myopathies caused by dis-
turbances of fatty acid or branched-chain amino acid oxidation (section 1.4), the area of 
our study is outlined (section 1.5.). 
1.1. General properties of striated muscle cells 
Striated muscular tissue is built up of many bundles of parallel orientated fibers. 
These bundels, which consist of 50-200 muscle fibers, are enclosed in connective tissue. 
The muscle itself is also enclosed in connective tissue, which thickens towards the ends of 
the muscle, thus forming the tendons, by which the muscle is fixed to the skeletal parts. 
Cooperative action between the bony skeleton and the motile force originating from mus-
cular contraction results in motion. A network of blood vessels lies between the muscle 
fibers. It supplies substrates and oxygen for the muscle fiber, and removes products and 
carbon dioxide. Nerves invade the muscle and their branches make contact with each 
muscle fiber. At this place of contact the membrane of the muscle fiber (sarcolemma) has 
many folds (motoric end plate). By means of a chemical messenger the nerve impulse is 
transmitted from the terminal end of the axon, to the muscle fiber. This initiates the con-
traction. 
1.1.1. Development 
The muscle fiber is a multikaryotic cell, which has stopped its DNA synthesis and is 
highly specialized towards its contractile function (Fischman, 1972). Its development 
starts early in embryogenesis with proliferation of myoblasts. These mononucleated cells 
fuse together in such a way that long multinucleated syncitia originate, the myotubes. 
These myotubes start the synthesis of large amounts of actin and myosin, the main pro-
teins of the myofibrils. Subsequent development of the muscle cells entails the coordinated 
assembly of myofibrils and the sarcotubular system, mitochondrial proliferation and the 
deposition of glycogen and fat. Subsequently, the muscle fibers are innervated. A further 
enzymic differentiation of the various types of muscle fibers takes place thereafter. In 
animals, such as rat and mouse, which are relatively immature at birth, the differences be-
tween the fibers are not yet apparent in the neonatal animal (Dubowitz, 1965). However, 
in guinea pig and the human infant differences between the fibers are already discernible 
at birth (Dubowitz, 1965; Fenichel, 1966). During further postnatal development the en-
zymic differentiation leads to a distinct pattern of different types of muscle fibers, which 
are summarized in section 1.1.4. 
A part of the myoblasts is not involved in the fusion process, but remains as resting 
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cells enclosed by the basement membranes of the muscle fibers. These cells are called sat­
ellite cells, and represent loci for regeneration. They can start to multiply again and form 
new muscle fibers, when part of the original muscle fibers is degenerated. 
Heart muscle is not built up of multinucleated muscle fibers, but consists of separate 
cellular units, which have identical metabohc and contractile properties (Bloom & Fawcett, 
1975). The fibers are not simple cylindrical units but many of them bifurcate and connect 
with adjacent fibers to form a compUcated three dimensional network. Oxidative capacity 
of heart muscle tissue is much higher than that of skeletal muscle. Also heart cells have 
more intercellular junctions, which are necessary for a coordinated pump action. 
1.1.2. Submicroscopic architecture of the muscle fiber 
The major subcellular components of skeletal muscle fiber are shown in Fig. 1.1. 
The sarcoplasm is nearly completely filled with myofibrils of about 1 μ diameter, which 
are oriented in the direction of the fiber, and which are surrounded by a lace-like network 
of tubules (Peter, 1973). The composition of the myofibril is illustrated in Fig. 1.2. The 
tubules represent the T-system and the sarcoplasmic reticulum, and are both involved in 
the onset of contraction (see section 1.13.). The T-system is formed by invaginations of 
the sarcolemma, which run at regular distances into the interior of the muscle fiber. It is 
in close contact with the sarcoplasmic reticulum, which surrounds the myofibril with a 
network of interconnected membrane pockets. The sarcoplasmic reticulum forms a sepa­
rate compartment in the muscle fiber in which C a + + ions are stored during rest (Peter, 
1973). 
Mitochondria are situated between the myofibrils and in subsarcolemmal areas. Their 
number, size and distribution varies considerably in different types of skeletal muscle and 
in heart. Oxidative muscle fibers and heart cells contain many mitochondria, often at three 
locations (Peter, 1973): 1. in longitudinal rows between the myofibrils; 2. in pairs in a 
bracelet-like arrangement around the myofibrils at the I-band; and 3. in dense subsarco­
lemmal accumulations. In diaphragm muscle of young rats mitochondria are found at 
similar places, but in adult rat diaphragm mitochondria are fused and form a network 
through the whole muscle fiber, the mitochondrial reticulum (Bakeeva et al., 1978). 
Part of the muscle fibers (type II in man, fast-twitch-glycolytic in animals; see 1.1.4) 
contain only the bracelet-like mitochondria. In human oxidative muscle fibers there is less 
sarcolemmal accumulation of mitochondria than in those of animals (Peter, 1973). In 
pathological muscle fibers of man a bulk proliferation of subsarcolemmal mitochondria is 
sometimes observed, e.g. in ragged red fibers (Olson et al., 1972), whereas in the interior 
of these fibers mitochondria seem to disappear. 
In skeletal muscle fibers of healthy man nuclei are mainly situated subsarcolemmally. 
In the vicinity of the nucleus ribosomes, Golgi complexes and other organelles for cellular 
maintainance are found. Glycogen particles, lipid droplets and soluble enzymes, e.g. gly­
colytic enzymes are found throughout the whole muscle fiber. lipid droplets are often 
seen close to one or more mitochondria. 
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Fig.l .1. Schematic presentation of a skeletal muscle fiber. 
The sarcoplasma is mainly filled with myofibrils. These myofibrils are surround­
ed by the sarcoplasmic reticulum (Sr). In glycolytic muscle fibers only bracelet­
like mitochondria at the Z-band level are encountered (lower part). In oxidative 
muscle fibers mitochondria are also found between the myofibrils and in subsar-
colemmal regions (upper part). Lipid droplets (black) and glycogen granules 
(small dots) are found between and around the myofibrils. The sarcoplasma is 
surrounded by the sarcolemma. Invaginations of the sarcolemma, T-tubuli (T), 
penetrate in the sarcoplasma. The sarcoplasmic reticulum is in contact with the 
T-tubuli at the triad (Tr). Вт: basement membrane, (modified from Lentz, 
1971). 
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Fig.l .2. Schematic presentation of a myofibril (after Peter, 1973). 
1.1.3. Muscular contraction 
Muscular contraction results in a shortening of the muscle or, when the length of a 
muscle cannot change, in the development of a tension. Contraction is caused by an inter-
action of the actin and myosin filaments in the myofibril. During dynamic contraction 
the actin and myosin filaments slide over each other, which leads to a shortening of the 
sarcomere (Huxley, 1972). This process needs energy, which is obtained from the hydro-
lysis of ATP. ATP is regenerated from the oxidation of substrates (see section 1.2). 
Contraction is initiated by the binding of Ca+ + ions to the troponin protein, which 
is associated with the actin filaments (Huxley, 1972; Morel & Pinset-Härström, 1975a). 
When a nerve pulse is transmitted to the muscle membrane at the motoric end plate, the 
membrane potential of the sarcolemma falls. The resulting wave of depolarisation spreads 
over the sarcolemma and is conducted into the T-system. The stimulus is transmitted to 
the sarcoplasmic reticulum and causes a rapid efflux of C a + + ions, whereupon contract-
ion is initiated in the presence of ATP. Immediately thereafter the C a + + ions are pump-
ed back into the sarcoplasmic reticulum and the muscle fiber relaxes and is ready for a 
new stimulus. 
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1.1.4. Types of muscle fibers 
In adult muscle various types of muscle fibers can be discerned. These muscle fibers 
show differences in kinetic properties of the contraction and in metabolic patterns (Close, 
1972). During evolution differentiation has made it possible to use muscle for several pur-
poses at minimal energy expense. Fast muscles have a high contraction speed and are well 
adapted to short heavy bursts of contraction. Muscles or muscle fibers, which have a role 
in the posture of the organism have evolved a slower contraction mechanism, which ena-
bles them to produce isometric contraction at less energy expenditure than would be re-
quired if they had a fast myosin ATPase and a short contraction time (Goldspink, 1975). 
In larger mammals and in man relatively more slow muscle fibers are present than in 
small animals, such as rat and guinea pig. This adaptation may be partially related to the 
length of the muscles. Since the overall rate of contraction of a muscle does not only de-
pend on the rate of shortening of each sarcomere, but also on the number of sarcomeres 
in series, large muscles would develop forces at such a rate that their tendons could be 
pulled off the bones (Hill, 1950). 
Since in our study we used homogenates and mitochondria of whole muscle, it is im-
portant to realize that they are gained from a mixture of different fiber types with dif-
ferent metaboUc properties. Therefore, we shall briefly summarize the characteristics of 
the major fiber types in skeletal muscle. It must, however, be mentioned that in specially 
adapted muscles (e.g. in eye muscles, tongue and heart) and in some pathologically affect-
ed muscles fibers can exist with different metabolic and contractile characteristics. 
Although in all mammalian species differences in contractile and metabolic proper-
ties underlie muscle fiber differences, no quantitative comparison can be made between 
different species. What is a low metabolic activity in one species, may be higher than the 
high activity in another species. Since a qualitative comparison of muscle fibers of animals, 
such as rat and guinea pig, and those of man is still a debatable matter (see Peter, 1973), 
we will summarize their characteristics separately. We prefer for animal muscle fibers the 
classification of Peter et al. (1972), which discriminates on the basis of contractile as well 
as metabolic properties. Human muscle fibers are classified after Engel (1962), which clas-
sification is commonly used in clinical practice. 
Animal muscle fiber types. On the basis of electrophysiological, contractile and meta-
bolic characteristics the muscle fibers of animals, like rat and guinea pig, can be classified 
in three distinct groups (Peter, 1973). The general features of these classes are summarized 
in Table 1.2. Oxidative muscle fibers are usually found in the deep part of a muscle group, 
whereas fast-twitch-glycolytic fibers are superficially located. A detailed description of 
muscle fiber composition of the m. quadriceps of the rat, which was used in our experi-
ments, is given by Baldwin et al. (1972). 
Human muscle fiber types. On the basis of histochemical ATPase staining techniques, 
two main types of muscle fibers are discernable in human skeletal muscle, type I and II 
(Engel, 1962; Dubowitz & Brooke, 1973). General characteristics of these two muscle fi-
ber types are given in Table 1.3. The difference in metabolic pattern between these fiber 
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Table 1.2. Characteristics of animal skeletal muscle fiber types. 
A. Contraction characteristics 
myosine ATPase 
time to peak tension (msec) 
sarcomere height 
Z-line 
B. Metabolic characteristics 
mitochondrial content 
distribution mitochondria 
glycogen content 
myoglobin content 
С Enzymatic characteristics 
oxidative enzyme activities 
mitochondrial ATPase 
cytochromes a and с 
glycolytic enzymes 
Phosphorylase 
fast-twitch-
glycolytic 
high 
20-30 
high 
narrow 
low 
diffuse 
inteimediate/ 
high 
low 
low 
low 
low 
high 
high 
slow-twitch-
oxidative 
low 
82-85 
low 
intermediate 
moderate 
diffuse 
low 
high 
high/inteime-
diate 
intermediate 
intermediate 
low (variabel) 
low 
fast-twitch-oxi-
dative-glycolytic 
high 
20 
low 
broad 
high 
diffuse/subsarco-
lemmal 
high 
high 
high/interme­
diate 
high 
high 
high 
high 
Data on rat and guinea pig muscle fiber types were obtained from Baldwin et al. (1972), 
Close (1972), Barnard et al. (1971) and Peteret al. (1972). 
types is less distinct than in animal muscle (Cullen & Weightman, 1975; Essén, 1978). In 
contrast to the situation in animal leg muscles, muscle fiber types of thigh and calf of 
healthy man are not clumped, but are randomly scattered within the muscle (Fig.l .3). Al-
though many attempts have been made to subdivide these types (see Dubowitz & Brooke, 
1973), the boundaries between these subdivisions are still unclear (Saltin et al., 1977). 
Sex differences exist in the diameter of type II, but not of type I fibers (Goldspink, 
1972). Both fiber types have a similar content of ATP, creatine phosphate and glycogen 
(Essén, 1978), but type I fibers contain 3 times more lipid than type II fibers (Essén et 
al., 1975). Both fiber types have a capacity for glycolysis. Oxidative capacity of type I 
fibers is greater than that of type II fibers, but during prolonged exercise that of type II 
fibers is enlarged (Janssen & Kaijser, 1977; Andersen & Hendriksson, 1977). The ratio 
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Table 1.3. Characteristics of human muscle fiber types. 
A. Contraction characteristics 
myosine ATPase 
'time to peak tension' 
contraction time 
Z-band width 
B. Metabolic characteristics 
mitochondrial shape 
location mitochondria 
lipid content 
glycogen content 
capillary supply 
С Enzymatic characteristics 
glycolytic enzymes 
mitochondrial enzymes 
Type I 
low 
slow (80 msec) 
long 
HOnm 
large and polymorphous 
intermyofibrillar and 
subsarcolemmal 
high 
high 
high 
moderate 
high 
Type II 
high 
rapid (30 msec) 
short 
80 nm 
small and oval 
only intermyofibrillar, 
but not at the A-band 
level 
low 
high 
low/moderate 
high 
low/moderate 
Data were obtained from Eberstein & Goodgold (1968), Buchtal & Schmalbruck (1970), 
Verity & Coleman (1973), Essén et al. (1975), Wroblewski & Jansson (1975), Thorsten-
ston et al. (1977) and Saltin et al. (1977). 
between the two fiber types varies with the kind of muscle, the age (Larsson et al., 1978) 
and probably genetic determinants (Costili et al., 1976). Depending on the kind of muscle, 
type I fibers represent 45 - 70 % of the muscle fibers in thigh and calf muscles of man 
(Edgerton et al., 1975). The muscle fibers, belonging to one motor unit, are all of the 
same type (see Dubowitz & Brooke, 1973). They are separated from each other by mus-
cle fibers of other motor units. 
1.2. Energy production and utilization in skeletal muscle 
Energy is needed in muscle for contraction, accumulation of Ca"'""'" ions into the sar-
coplasmic reticulum, and for restoration of the membrane potential of the sarcolemma 
and T-system after a nerve stimulus. It is also necessary for the maintenance of cellular or-
ganization, for anabolic purposes, and for heat production during rest. The energy for 
most of these processes is obtained from hydrolysis of ATP. Resynthesis of ATP is neces-
sary for sustained muscular function. The energy required for ATP synthesis is mainly ob-
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Fig. 1.3. Transverse section of m. quadriceps muscle fibers of a 3 years old child (with 
slight variation in muscle fiber diameter). A chess-board like pattern is observed 
after NADH-diaphorase staining. Dark fibers represent type I muscle fibers rela-
tively rich in mitochondria. 
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Fig. 1.5. Schematic presentation of respiratory chain and oxidative phosphorylation. 
tained from the degradation of carbon-hydrogen bonds of various substrates: fatty acids, 
carbohydrates and amino acids (Fig.1.4). Phosphorylation of ADP can occur during gly-
colysis without oxygen. The redox state of the cell is in this condition maintained by the 
conversion of pyruvate into lactate. However, the amount of ATP generated during an-
aerobic glycolysis is limited, and only glucose and glycogen can be used as substrates. 
Therefore, this anaerobic pathway appears to be only of interest during a short period of 
muscle work (Morel & Pinset-Härström, 1975). 
Much more energy can be obtained from the oxidative degradation of substrates 
which is coupled to phosphorylation and OCCUR in mitochondria. During substrate de-
gradation electrons are transferred via NAD+ or flavoproteins (containing FAD or FMN) 
to molecular oxygen (Fig. 1.5). Concomittant with the electron flux through the respi-
ratory chain, a proton gradient is generated over the mitochondrial inner membrane. The 
electrochemical gradient thus generated drives the synthesis of ATP and other processes, 
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e.g. translocation of cations. These coupled processes occur only in intact mitochondria. 
The action of so called 'uncouplers' is not due to a real uncoupling, but to their ability to 
carry protons back into the mitochondrion. This prevents the generation of a membrane 
potential and thus stops ATP production. 
In addition to these pathways, which involve many enzymes, muscle contains two 
mechanisms which can replenish the ATP pool instantaneously by a single enzymatic step 
(Morel & Pinset-Härström, 1975). During very fast contraction ATP is mainly suppleted 
from phosphocreatine by creatinephosphokinase. During rest or prolonged moderate ex-
ercise creatine is rephosphorylated, after which it is available for a new burst of exercise. 
Recently, it was suggested that the creatine Phosphokinase system does not only represent 
a side reaction in the supply of energy for contraction, but plays a key role in the intra-
cellular energy transport from mitochondria to myofibrils and other sites of energy uti-
lization (Saks et al., 1978). Under extreme conditions, when ATP may be lacking, ATP is 
generated by the transphosphorylation of 2 mol ADP, by which one AMP and one ATP is 
formed. 
The main sources for oxidative catabolism in skeletal muscle are fatty acids, glycogen 
and glucose. Amino acids, especially branched-chain amino acids, and ketone bodies may 
be used under certain conditions (see section 1.2.5.). Lactate formed by other tissues or 
by muscle during anaerobic glycolysis can also be oxidized when oxygen is available 
(McGrail et al., 1978). The relative importance of these substrates changes with various 
conditions (see section 1.2.5). 
1.2.1. Glucose-glycogen-lactate 
Skeletal muscle fibers contain many glycogen granules which can be used for ox-
idation during the onset of exercise or during heavy exercise (Essén, 1978). Glycogen and 
glucose are converted via glycogenolysis and glycolysis into pyruvate (Newsholme & Start, 
1973; Newsholme et al., 1978). Lactate formed during anaerobic glycolysis is converted 
by lactate dehydrogenase into pyruvate, when oxygen becomes available (McGrail et al., 
1978; Baldwin et al., 1978; Hermansen & Vaage, 1977). The reactions occur in the cyto-
plasmic compartment of the muscle fiber. The reduction equivalents of the NADH which 
are generated by these processes must be transferred into the mitochondrion. This pro-
ceeds mainly by the aspartate-malate shuttle and the α-glycerophosphate shuttle. Pyruvate 
is further oxidized by pyruvate dehydrogenase in the mitochondrion to acetyl-CoA. This 
is coupled to oxaloacetate to form citrate, which is degraded in the citric acid cycle. (Fig. 
1.6). Energy for ATP production is mainly obtained from the dehydrogenase reactions 
during these pathways. Details of pyruvate oxidation and the shuttle mechanisms in skel­
etal muscle of man and rat are given by Bookelman (1978). 
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1.2.2. Fatty acids 
Uptake and storage of fatty acids 
Albumin-bound free fatty acids (FFA) of plasma are considered to be the major 
source of fatty acids for skeletal muscle and heart (Bing et al., 1954; Dole, 1956; Gold & 
Spitzer, 1964; Neely & Morgan, 1974; Zierler, 1976). Although their concentration in 
plasma is low, turnover is high and they are rapidly replenished by the adipose tissue. 
With the exception of arachidonic acid, no differences in the fractional extraction of indi­
vidual FFA by muscle were observed (Hagenfeldt, 1975). The uptake of FFA by the 
muscle tissue depends on their concentration in plasma (Armstrong et al., 1961; Evans, 
1964; Shtacher & Shafrir, 1963). Since palmitate and oleate and to a lesser degree stéarate 
and linoleate represent the bulk of FFA in plasma (Hagenfeldt, 1975), they are the main 
FFA taken up into the muscular tissue. Plasma concentrations and hence the uptake of 
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fatty acids are sharply elevated under a variety of metabolic conditions, such as starvation 
(Böhmer, 1967) and prolonged exercise (Gollnick, 1977). No membrane carrier system 
for the transport of FFA into the muscle cell has been observed, and it is assumed that 
the uptake of fatty acids occurs by simple diffusion through the plasma membrane of 
the muscle. Whether a fatty acid binding protein is involved during passage of the intersti-
tial fluid is still uncertain. 
Extraction of plasma chylomicron triglycerides by heart and skeletal muscle can also 
be demonstrated (Bragdon & Gordon, 1958). This uptake is accompanied by hydrolysis 
of triglyceride by lipoprotein lipase. Lipoprotein lipase activity was demonstrated in rat 
heart (Kom, 1955) and has recently been purified and characterized (Chung & Scanu, 
1977). It was also demonstrated in skeletal muscle of rat (Borensztajn et al., 1975; Linder 
et al., 1976; Tan et al., 1977) and man (Lithell & Boberg, 1978). Its activity was highest 
in muscles with a high portion of oxidative muscle fibers (Lithell & Boberg, 1978; Linder 
et al., 1976; Tan et al., 1977). In contrast to the lipoprotein lipase of adipose tissue, the 
activity of this enzyme in heart and skeletal muscle increases with exercise (Nikkilä et al., 
1963; Borensztajn et al., 1975) and starvation (Lithell et al., 1978). No sex differences 
were observed in lipoprotein lipase activity of human skeletal muscle (Nikkilä et al. 
1978). 
Once the fatty acid has penetrated the muscle cell, it must be transported to the 
mitochondria, which are partly located in the interior of the muscle fiber (section 1.1.2). 
Probably, fatty acid binding proteins are involved in the transport process. In liver, intes-
tine, heart and skeletal muscle a fatty acid binding protein was demonstrated (Ockner et 
al., 1972; Mishkin et al., 1972). In rat liver, intestine and heart this protein has a molecul-
ar weight of 12,000 (Ockner et al., 1974; Foumier et al., 1978), and is probably identical 
to the Ζ protein (Levy et al., 1969). In rat skeletal muscle fatty acid binding properties 
were found in a protein fraction (Mw 16,000), in which myoglobin was present (Gloster 
& Harris, 1977). 
Havel et al. (1967) suggested that some of the FFA entering the muscle cell is direct­
ly oxidized with the remainder going into cellular lipid pools. The level of these lipid 
pools in monkey muscle was little or not changed under normal diet conditions (Masoro 
et al., 1966), or during severe exercise (Masoro, 1966). In man a decrease in the concen­
tration of muscular triglycerides was observed during exercise (Essén, 1977; 1978). This 
decrease occurred mainly during the initial phase of moderate exercise, when the blood 
supply of FFA is not yet elevated (Essén, 1978) and during prolonged severe exercise 
(Essén, 1977). Dagenais et al. (1977) suggested that the FFA taken up by the muscle 
enter a lipid pool and that at the same time an equivalent amount of FFA is derived from 
this pool for oxidation. This suggestion was based on the observation that after infusion 
in man labeled oleic acid was immediately taken up in the skeletal muscle fibers, but that 
it took at least 30 min before ^COj was released. However, this lag in ' 4 C02 produc-
tion may also be due to accumulation of 14C-activity in intermediates of the 0-oxidation 
and citric acid cycle (cf. section 3.3). Dagenais et al. could not demonstrate the release of 
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labeled perchloric acid-soluble products by the muscle. However, it is not expected that 
citric acid cycle intermediates would leave the muscle fibers, since di- and tricarboxylic 
acids do not penetrate the sarcolemma. Analysis of the perchloric acid-soluble products 
inside the muscle fibers is therefore required to establish the possible involvement of a 
lipid pool. 
Catabolismi of fatty acids 
For oxidation of fatty acids it is required that the relatively unreactive carboxylic 
group is converted into the more reactive thioester (Groot et al., 1976). The energy for 
the formation of these thioesters is obtained from hydrolysis of ATP, by which AMP is 
formed. GTP-dependent fatty acid activation could not be demonstrated in heart and 
skeletal muscle of the rat (Van den Bergh, 1967; Pande & Mead, 1968). Long-chain acyl-
CoA synthetase (AMP forming) was localized in the mitochondria and predominantly in 
the microsomal fraction of skeletal muscle and heart (Groot et al., 1976). Its activity in 
these tissues was maximal with laurate and palmitate, but only 10 - 25% as high with 
octanoate in skeletal muscle (Aas, 1971; Groot & Hülsmann, 1973). The existence of two 
long-chain acyl-CoA synthetases with optimal activities towards laurate and palmitate, 
respectively, was suggested (Aas, 1971; Pande, 1972). However, studies of fatty acid 
competition did not give any support for the presence of more than one long-chain acyl-
CoA synthetase in microsomal and mitochondrial fractions of rat skeletal muscle (Groot 
& Hülsmann, 1973) and liver (Suzue & Marcel, 1972). It seems therefore more probable 
that the lower activity to myristate is caused by differences in the physical properties of 
the fatty acids (Groot & Hülsmann, 1973). In contrast to heart and liver, in which active 
short-chain and medium-chain acyl-CoA synthetases are present, skeletal muscle of rat 
and guinea pig only contain a very low short-chain acyl-CoA synthetase activity (Schölte 
& Groot, 1975). However, only long-chain fatty acids are normally important as a fuel for 
muscular tissue. 
Degradation of the carbon skeleton of the fatty acids occurs via the |3-oxidation route 
within the mitochondria. Since in muscle fatty acids cannot penetrate the mitochondrial 
membrane,acyl-residues are transported into the mitochondrion via a camitine-dependent 
shuttle mechanism (Bremer, 1962; Fritz & Yue, 1963). By this mechanism the cyto-
plasmic and mitochondrial pools of coenzyme A are strictly separated. Three carnitine 
acyl transferases are present in muscular tissue: carnitine acetyl transferase (Fritz et al., 
1963), carnitine octanoyl transferase (Solberg, 1971,1972) and carnitine palmitoyl trans-
ferase (Norum, 1964). These enzymes convert acyl esters with chain length of 2 - 10,6 -
10 and 8 carbon atoms or higher, respectively. Carnitine palmitoyl transferase was shown 
to be exclusively a mitochondrial enzyme (Bremer & Norum, 1967; Markwell et al., 
1973), but carnitine acyl transferase activity towards short-chain acyl esters was also 
present in peroxisomal and microsomal fractions of rat liver (Markwell et al., 1973, 1976). 
In all tissues carnitine palmitoyl transferase is needed for oxidation of long-chain fatty 
acids, but in contrast to muscular tissue (Groot & Hülsmann, 1973) liver mitochondria 
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can oxidize octanoate in the absence of carnitine (Van Tol, 1975). Long-chain acyl-CoA 
esters are converted to acyl-camitines by carnitine palmitoyl transferase I, which is 
localized on the outer surface of the mitochondrial inner membrane (Bremer & Norum, 
1967; Hoppel, 1975). The resulting acyl-camitine esters then pass through the mitochon-
drial inner membrane into the matrix by a special transport system and are reconverted to 
the coenzyme A esters. In the latter process carnitine paJmitoyl transferase II is involved. 
The two carnitine palmitoyl transferases represent different enzymes with different 
properties (West et al., 1971 ; Hoppel & Tornee, 1972; Hoppel, 1975) and developmental 
features (Tomec & Hoppel, 1975). 
The suggestion of Levitsky & Skulachev (1972) that the transport of palmitoyl-car-
nitine into the mitochondria is driven by the protonmotoric force has been questioned 
(Osmundsen & Bremer, 1976). The low concentration of carnitine in rat liver mitochon-
dria (less than 0.1 nmol/mg protein) and the apparent impermeability of the inner mem-
brane of these mitochondria to carnitine (Yates & Garland, 1966; Brosnan & Fritz, 
1971), have led to the hypothesis that the carnitine palmitoyl transferase II is a vectorial 
enzyme and catalyses acyl exchange between external carnitine and matrix coenzyme 
A (Yates & Garland, 1970; Hoppel & Tomec, 1972). However, heart mitochondria con-
tain 2 - 4 nmol carnitine per mg protein (Ramsay & Tubbs, 1974; Pande, 1975; Idell-
Wenger et al., 1978) and a camitine:acylcarnitine exchange across the mitochondrial 
inner mebrane has been demonstrated in these mitochondria (Ramsay & Tubbs, 1975; 
Pande, 1975). The characterization of a camitine:acylcamitine translocase system 
(Pande, 1975; Pande & Parvin, 1976; Parvin & Pande, 1978) in the heart mitochondria 
and the occurrence of an exchange system in other tissues with high carnitine levels, such 
as kidney, spermatozoa and flight muscle (Calvin & Tubbs, 1976; Danks & Chappell, 
1975) indicate that in muscular tissue the carnitine-dependent transport of long-chain 
fatty acids is mediated by three enzymes: carnitine palmitoyl transferase I, carnitine 
acylcamitine translocase and carnitine palmitoyl transferase II (Fig.1.7.). 
Degradation of fatty acids in the mitochondrion occurs via /3-oxidation, a repeated 
sequence of processes (oxidation, hydratation, oxidation and cleavage), by which acetyl-
CoA residues are split off from the carboxylic end of the fatty acid. These reactions are 
catalyzed by four enzymes: fatty acyl-CoA dehydrogenase, enoyl-Co A hydra tase, 3-oxo-
acyl-CoA thiolase and L-3-hydroxyacyl-CoA dehydrogenase. These enzymes are thought 
to be closely connected in a multienzyme complex (Garland & Yates, 1967; Greville & 
Tubbs, 1968), and they need coenzyme A, NAD and oxidized flavins. Their properties 
were recently reviewed by Engel (1978) and Middleton (1978). It is suggested that for 
each step in the j3-oxidation process enzymes exist with specificity for long-chain or short-
chain acyl-CoA (Middleton, 1978). There are two or three different acyl-CoA dehydroge-
nases with different but overlapping chain length specificity (Engel, 1978). Pig liver con-
tains a short-chain acyl-CoA dehydrogenase, a general chain acyl-CoA dehydrogenase, and 
a long-chain acyl-CoA dehydrogenase, which seem to be closely associated to each other 
(Crane et al., 1956; Hall & Kamin, 1975). In beef heart mitochondria only two acyl-CoA 
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Fig.l .7. Schematical presentation of the pathway of long-chain fatty acid oxidation. 
dehydrogenases are present: a short-chain acyl-CoA dehydrogenase and an acyl-CoA de-
hydrogenase, with general-chain substrate specificity (Hall et al., 1976). The natural ac-
ceptor for the acyl-CoA dehydrogenases is another flavoprotein, the electron-transferring 
flavoprotein (Beinert, 1963), which transfers the electrons to the electron transport 
chain, presumably via a Fe-S protein (Ruzicka & Beinert, 1975). The second oxidation 
step in ^-oxidation,catalyzed by the L-hydroxyacyl-CoA dehydrogenase's NAD -linked. 
Only part of the energy present in the fatty acid molecule is liberated during the (3-oxida-
tion for production of ATP. The major part is released during the oxidation of the result-
ing acetyl-CoA in the citric acid cycle (Fig.l.6.). When the rate of the citric acid cycle is 
lower than that of /J-oxidation (see section 6.4), acetyl-carnitine can be formed and re-
leased from the mitochondrion. In contrast to liver mitochondria, those of skeletal and 
heart muscle lack the abihty to convert acetyl-CoA into ketone bodies (Williamson & 
Hemms, 1970). During oxidation of fatty acids by liver mitochondria intermediates in the 
form of saturated acyl-CoA esters (Stanley & Tubbs, 1975) and saturated acyl-camitine 
esters (Lopes-Cardozo et al., 1978) were observed, suggesting that the acyl-CoA dehydro-
genase is rate-limiting. These data are discussed in section 4.4. 
Several other pathways are known for the degradation of fatty acids. These involve 
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cytoplasmic ω-oxidation (Robbins et al., 1968; Björkheim et al., 1978; Kam et al., 1978), 
and a 0-oxidation system in liver peroxisomes (Lazarow & DeDuve, 1976; Ostimi & Hashi-
moto, 1978). However, these pathways seem to be of little importance for fatty acid ox-
idation in skeletal muscle and heart. 
When the concentration of FFA in the blood increases after food deprivation, the 
concentration of long-chain acyl-camitines is elevated in all tissues of the rat (Böhmer, 
1967) and simultaneously the rate of fatty acid oxidation goes up. The redox state of the 
mitochondrion and the availability of coenzyme A may be the main mechanisms by 
which the rate of fatty acid oxidation is regulated in muscular tissue (Bremer et al., 1978; 
cf. sections 3.4 and 6.4). In liver, fatty acid oxidation is also regulated by other factors. 
Palmitoyl-CoA can be directed to oxidation or esterification by the relative rates of carni-
tine palmitoyl transferase I and glycerophosphate acyl transferase (Borrebaek, 1975; 
Borrebaek et al., 1976; Bremer et al., 1976). Since malonyl-CoA inhibits the carnitine pal-
mitoyl transferase I (McGany et al., 1977, 1978a,b), oxidation is decreased in the nour-
ished state. During fasting carnitine palmitoyl transferase activity may be further stimu-
lated by an elevation of the carnitine concentration (McGany et al., 1975; Snosswell & 
Henderson, 1970), which is secondary to weight loss of the liver cells (Brass & Hoppel, 
1978). However, Mannaerts et al. (1978) found no increase in the carnitine level in liver 
of fed and fasted rat. It is still unknown whether malonyl-CoA is involved in regulation of 
fatty acid oxidation by muscular tissue. 
1.2.3. Ketone bodies 
During fasting ketone bodies are produced by the liver and are oxidized by brain and 
heart (Williamson & Hems, 1970). Ketone bodies can also be consumed by skeletal 
muscle of rat (Winder et al., 1974), guinea pig (Kark et al., 1971) and man (Baiasse et al., 
1978). The capacity of rat skeletal muscle to oxidize ketone bodies increases after train-
ing (Winder et al., 1974, 1975). In normal conditions ketone bodies are unimportant sub-
strates for skeletal muscle (Wahren et al., 1978; Berger et al., 1978), but they may be-
come of interest during prolonged exercise or after training (Berger et al., 1978) and after 
prolonged starvation (Owen et al., 1971). 
1.2.4. Amino acids 
Although the relative contribution of amino acids to the energy supply of striated 
muscle is still a matter of debate, it is now firmly established that skeletal and cardiac 
muscles are involved in the catabolism of the branched-chain amino acids leucine, valine 
and isoleucine and in the synthesis of alanine and glutamine (Felig, 1975; Ruderman, 
1975; Goldberg & Chang, 1978; Bergman & Heitmann, 1978). Oxidation of other amino 
acids mainly proceeds in the liver (Miller, 1961). The first indication that muscle repre-
sents an important site of branched-chain amino acid oxidation was that these amino 
acids were degraded at similar rates by normal and hepatectomized dogs (Miller, 1961). 
It was demonstrated that the branched-chain amino acids are transaminated and oxidized 
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Fig.1.8. Schematic presentation of the oxidative pathway of branched-chain amino acids 
in rat liver. 
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in isolated rat diaphragm and heart muscle (Manchester, 1965; Odessey & Goldberg, 
1972; Buse et al., 1972). However, the degree to which branched-chain amino acids are 
oxidized in skeletal muscle is still uncertain (cf. section 9.4). The oxidative pathways for 
the branched-chain amino acids were elucidated in studies on liver and heart preparations 
(see Meister, 1957) and are summarized in Fig.1.8. The oxidation of valine leads to the 
formation of the citric acid cycle intermediate succinyl-CoA, of which the carbon atoms 
can be used in liver and kidney for gluconeogenesis. In contrast to valine, leucine is keto-
genic. It can only produce acetyl-CoA and acetoacetate and cannot contribute carbon 
atoms for netto gluconeogenesis. Isoleucine has both glucogenic and ketogenic capacities. 
Leucine is not only important as an essential substrate for protein synthesis and as 
fuel, but it is also a sterol precursor in muscle and adipose tissue (Rosenthal et al., 1974; 
Miettinen & Penttilä, 1968). Leucine stimulates insulin secretion (Milner, 1970). It is 
suggested to act as a regulator of protein synthesis in skeletal muscle (Buse & Reid, 1974; 
Fulks et al., 1975; Buse & Weigand, 1977) and stimulates synthesis of soluble and con-
tractile proteins to a similar extent (Goldberg & Chang, 1978). Leucine has no effect on 
the protein balance in liver. 
In the postabsorptive state there is a muscular uptake of branched-chain amino acids, 
which are incorporated into proteins. After 24 h fasting, there is a marked elevation in 
the concentration of branched-chain amino acids in blood plasma of man (Pozefsky et al., 
1976; Adibì, 1976). In rats such elevation only occurs after 4 - 6 days of fasting (Wu et al., 
1954; Adibì, 1971); There are several indications that muscle is the major source of the 
hyperbranched-chain amino acidemia of fasting rat and man (Adibì, 1976). Although 
there is a 45 - 95%increase in the pools of the branched-chain amino acids in muscle 
during fasting, this increase is much less than the amounts of these amino acids, which are 
released by enhanced muscle protein degradation (Adibi, 1971,1976). Therefore, skeletal 
muscle can be considered to act as a pool of branched-chain amino acids (Daniel et al., 
1977). 
Skeletal muscle of rat contains 84 % of the total transaminase activity of the whole 
body, estimated from a comparison of leucine transamination in various tissues of the rat 
(Shinnick & Harper, 1976). Three isoenzymes of branched-chain transaminase were de-
scribed (Ogawa et al., 1970). In muscle enzyme I only is present. This isoenzyme was 
found in all tissues, whereas enzymes II and III only were demonstrated in liver and brain, 
respectively. In liver the activities of transaminases I and II are very low, but that of 
enzyme II can be induced to some extent (Crabb & Harris, 1978). 
The production of alanine and glutamine by skeletal muscle is coupled to branched-
chain amino acid transamination (Chang & Goldberg, 1978a,b). Muscle cannot synthesize 
urea. Therefore it can only oxidize amino acids when a sufficient amount of amino-group 
acceptor is present. 2-Oxoglutarate is used as the amino-group acceptor (section 7.3). 
Since the amount of 2-oxoglutarate in muscle is limited and sequestration of 2-oxogluta-
rate would deplete the citric acid cycle, the amino-group of the formed glutamate is trans-
ferred to pyruvate or a second molecule of glutamate, by which alanine and glutamine are 
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fornied and 2-oxoglutarate is released (Chang & Goldberg, 1978a,b). Via a glucose-alanine 
cycle (Felig et al., 1970; Mariette et al., 1969) there is a continuous flow of amino groups 
from skeletal muscle to the liver. The catabolism of branched-chain amino acids is in-
creased during fasting. The flux in muscle through transamination is then enhanced by 
the increased pool of substrates and by an increase in transaminase activity (Adibì et al., 
1975). 
The branched-chain oxo acid dehydrogenase complex appears to differ from the 
pyruvate dehydrogenase complex (Connelly et al., 1968; Parker & Rändle, 1978,1978a). 
Although it was suggested that several branched-chain oxo acid dehydrogenases would 
exist (Sullivan et al., 1976), this was not sustained by competition experiments (Parker & 
Rändle, 1978a,b; Danner et al., 1978). The branched-chain oxo acid dehydrogenase iso-
lated from ox and rat liver is active towards all three oxo analogues of the branched-chain 
amino acids (Parker et al., 1978, 1978a; Danner et al., 1978). Branched-chain oxo acid 
dehydrogenase activity appeared to be high in liver and low in skeletal muscle (Shinnick 
& Harper, 1976; Wohlhueter & Harper, 1970). However, the activity in skeletal muscle 
was underestimated in these studies (see section 9.1). Oxidative decarboxylation of 
branched-chain oxo acids in rat muscle is enhanced during fasting (Goldberg & Odessey, 
1972; Meikle & Klain, 1972; Adibì et al., 1975; Paul & Adibì, 1978), after training 
(Dohm et al., 1977) and in diabetes (Buse et al., 1973). The cause of the increased dehy-
drogenase activity is still unclear. Several observations suggest that the branched-chain 
oxo acid dehydrogenase may be regulated by phosphorylation and dephosphorylation 
(Goldberg & Chang, 1978). 
It is still uncertain to what extent further oxidation of branched-chain amino acids 
proceeds in muscular tissue (see section 9.4). It is believed that the further oxidation 
route will be similar to that in liver (Fig.l .9), but this has not yet been verified. 
1.2.5. Contribution of substrate reserves to muscular energy production 
Carbohydrates, lipids and proteins are the main nutrients forman, and represent the 
energy reserves after food absorption (Table 1.4). Lipids amount to 85% of the total body 
fuel reserve (Wahren et al., 1978). The intramuscular triglyceride concentration is limited 
and the blood content of FFA is small, but these pools are rapidly supplied by lipolysis 
of the adipose tissue triglycerides during exercise. Carbohydrates represent a relatively 
small, but highly dynamic portion of the total body energy reserve. Carbohydrates and 
lipids are the main fuels in the muscle. Oxidation of amino acids involves the breakdown 
of muscle proteins. It will only contribute to the energy supply of the muscle during 
prolonged exercise and during fasting (Adibì, 1976; Dohm et al., 1977). The relative 
contributions of the various substrates during rest and moderate exercise after food ab-
sorption are summarized in Table 1.5. 
The relative contribution of various substrates in muscle is influenced by nutritional 
and hormonal conditions (Felig & Wahren, 1975; Wahren et al., 1978), the duration, 
intensity and nature of the exercise (Essén, 1978; Maughan et al., 1978; Holm et al., 
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Table 1.4. Energy reserves in man after eating. 
Circulating substrates 
Glucose 
Free Fatty Acids 
Tissue deposits 
Glycogen (liver) 
Glycogen (muscle) 
Triglycerides (adipose tissue) 
Triglycerides (muscle) 
Protein (muscle) 
Weight 
(kg) 
0.020 
0.004 
0.085 
0.400 
15 
0.250 
6 
Energy 
(kJ) 
330 
16 
1,500 
6,500 
600,000 
10,000 
100,000 
Data were obtained from Wahren et al. (1978) and Essén (1977). 
Table 1.5. Contributions of substrates to muscular energy production in man. 
Resting state Moderate exercise 
Early phase 1 h 4 h 
Compound 
Glucose - - + + + 
Glycogen — + + - — 
Fatty acids + + +H- + + 
Branched-chain amino acids - — - + 
Ketone bodies — — — + 
Lactate + — - -
1978), the blood flow through the muscle, training (Holloszy & Booth, 1976; Barnard et 
al., 1971 ; Baldwin et al., 1972; Suominen et al., 1977; MacDougall et al., 1977; Tibbits et 
al., 1978; Bylund et al., 1977) and by the developmental stage of the organism (Battaglia 
& Meschia, 1978; Wittels & Bressler, 1965; Warshaw & Terry, 1970). The contribution of 
carbohydrates is decreased during fasting in man and increased after glucose feeding 
(Wahren, 1977). During fasting the contribution of fatty acids, branched-chain amino 
acids and ketone bodies increases (Zierler, 1976; Adibi, 1976; Owen, 1971). The contri-
bution of carbohydrates becomes higher with increasing intensity of the exercise (Wahren, 
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1977; Essen, 1978). 
Patterns of glycogen utilization changed with different types of exercise in the two 
human muscle fiber types (Essen, 1978). With continuous moderate exercise a more pro-
nounced depletion of glycogen occurred in type I than in type II fibers, whereas the op-
posite was found with continuous intense exercise. During intermittent exercise (15 sec 
severe exercise, 15 sec rest, etc for 60 min) the depletion was similar in the two fiber 
types. The glycogen utilization was similar during continuous moderate and intermittent 
exercise, but much higher during continuous intense exercise. Glycogen consumption can 
reach a very high rate during short bursts of isometric contractions, during which it can 
even become ten times higher than during heavy dynamic exercise (Wahren et al., 1978). 
The supply of FFA to the muscle increases during exercise by an increased blood 
flow through the muscle and by an increased lipolysis of adipose tissue triglycerides, 
which leads to high FFA concentration in the blood. Plasma FFA concentration is also 
elevated during starvation (Masoro, 1977). A higher rate of fatty acid oxidation leads to 
accumulation of citrate in the muscle fiber, which inhibits glycolysis presumably through 
the phosphofructokinase reaction. Subsequent accumulation of glucose-6-phosphate 
inhibits glycogenolysis and phosphorylation of glucose. This results in a lower utilization 
of muscle glycogen and blood glucose (Rennie et al., 1976; Rennie & Holloszy, 1977; 
Essén, 1978). 
In contrast to skeletal muscle, the continuously working heart muscle preferentially 
oxidizes fatty acids. Besides fatty acids cardiac muscle also oxidizes ketone bodies during 
fasting (Neely & Morgan, 1974). 
Differences in the relative contribution of energy reserves in various species may 
exist. They may be caused by variation in the intake of nutrients, differences in the 
characteristics and location of the muscle fiber types and by a different weight ratio 
between muscular tissue and other tissues, particularly liver. 
1.3. Carnitine 
Although carnitine was first isolated from meat extract at the beginning of this cen-
tury and its chemical structure, 3-hydroxy-4-(trimethylamino)butyric acid, was establish-
ed by synthesis in 1927, its physiological role was only begun to be understood in the 
early fifties (see Fraenkel & Friedman, 1957). The observation that carnitine is identical 
with vitamin By, a growth factor of the meal worm Tenebria molliter (Carter et al., 
1952), stimulated research on the involvement of carnitine in metabolism. Soon there-
after it was discovered that carnitine can be acetylated by acetyl-CoA in liver extracts 
(Friedman & Fraenkel, 1955) and that fatty acid oxidation by liver slices and homoge-
nates was stimulated by carnitine (Fritz, 1955). These data were combined in the model 
for acyl-transfer over the mitochondrial inner membrane (Bremer, 1962; Fritz & Yue, 
1963; compare section 1.2.2). After that many studies on carnitine and fatty acid meta-
bolism have been reported (see also sections 3.4 and 4.4). 
Fat accumulation in camitine-deficient larvae of Tenebria molliter indicated that 
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fatty acid metabolism was impaired, but the accumulation of uric acid crystals in the in-
testine of these larvae pointed to a disturbance of nitrogen metabolism (Chang & Fraen-
kel, 1954). Until now, no attention was given to the role of carnitine in amino acid meta-
bolism. In our investigation the effect of carnitine on leucine oxidation was studied (sec-
tions 8.3,9.4). 
1.3.1. Carnitine content of tissues and plasma 
Carnitine is present in the body in free and esterified form. Esterified carnitine in-
cludes short-chain acyl carnitines, mainly acetyl-carnitine (acid-soluble) and long-chain 
acyl-camitines (acid-insoluble). In many earlier assays free carnitine was determined or 
perchloric-acid extracts were used for determination. In these cases only a part of the 
carnitine pool was measured. 
Within an organism the carnitine level varies markedly in different tissues. It was 
known for a long time that striated muscle contains large amounts of carnitine (Fraenkel 
& Friedman, 1957). High carnitine concentrations are also found in male sex organs 
(Marquis, 1964; Böhmer et al., 1978a). Data on the carnitine content of kidney and 
adrenals of the rat vary (Broekhuysen et al., 1965; Pearson & Tubbs, 1967; Brooks & 
Mcintosh, 1975). Other tissues of the rat contain a low amount of carnitine (0.1-0.3μπιοΙ 
per g wet weight) (Brooks & Mcintosh, 1975). The concentration of carnitine in blood 
plasma is low (Table 1.6). 
A large difference exists in the amount of carnitine in striated muscle of various 
mammalian species (Table 1.6). Skeletal and heart muscle of ruminants have a high carni­
tine concentration, whereas those of rodents, except guinea pig, have relatively low carni­
tine levels. 
Carnitine concentrations in plasma and tissues can vary with nutritional and hormonal 
states and with development. During fasting carnitine concentration increases rapidly in 
rat liver (McGarry et al., 1975; Brass & Hoppel, 1978) and slowly in rat skeletal and heart 
muscle (Brass & Hoppel, 1978). Brass & Hoppel indicated that this increase is not due to 
an enhanced uptake or synthesis of carnitine, but to a decrease of the mass of the tissues. 
In man, serum levels of free carnitine decrease during fasting, but total carnitine remains 
constant (FrohUch, 1978). Carnitine levels in blood plasma of rat and lamb fetus are 
lower than in adult animals (Seccombe et al., 1978; Hahn et al., 1977). In newborns of 
man carnitine concentration of blood plasma is half that in adults (Hahn et al., 1977), but 
in newborn rats plasma carnitine reached already the adult level (Robles-Valdes et al., 
1976; Seccombe et al., 1978). At birth the amount of carnitine in rat liver strongly in­
creases (Robles-Valdes et al., 1976). During the first few weeks after birth this increase 
disappears, but carnitine concentration in the heart increases (Robles-Valdes et al., 
1976). In human adipose tissue carnitine concentration also increases during the first 
week after birth (Schmidt-Sommerfeld et al., 1978), but no data are available on mus­
cular tissues (cf. section 2.7). 
Pregnant women have a very low carnitine concentration in plasma (17 ± 3 μΜ) at 
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Table 1.6. Carnitine content of muscular tissue and blood plasma in mammalian species. 
Skeletal Heart Blood plasma References 
muscle 
Species (μιηο1ρβΓ§ (/¿mol per g (μΜ) 
Mouse 
Rat 
Hamster 
Guinea pig 
Beef 
Sheep (Merino) 
Sheep (Suffolk) 
Lamb (Merino) 
Dog 
Man 
tissue) 
03-0.4 
0.6-1.0 
0.33 
-
3.9 
8.4-12.9 
2.3 
4.8 
-
2.0-2.9 
tissue) 
0.8-1.1 
0.5-1.4 
0.83 
2.6 
1.2 
3.5 
-
-
1.0-1.5 
0.3 - 0.7 
33-51 
40-87 
13 
-
-
-
-
-
-
41-57 
(U) 
(3-9) 
(1) 
(10) 
OD 
(11,12) 
(12) 
(12) 
(13,14) 
(15-18) 
Data were obtained from 1. Borum et al. (1978); 2. Cederblad & Lindstedt (1972); 3. 
Cederblad & Lindstedt (1976); 4. Brooks & Mcintosh (1975); 5. Brass & Hoppel (1978); 
6. Borum et al. (1977); 7. Rebouche (1977); 8. Pearson & Tubbs (1967); 9. IdeU-Wenger 
et al. (1978); 10. Challoner & Proís (1972); 11. Erfle et al. (1970); 12. SnossweU & Hen-
derson (1970); 13. Schwartz et al. (1973); 14. Shug étal. (1978); 15. Hart et al. (1978); 
16. Ikeador & Lake (1978); 17. Cederblad, G. (1976); 18. section 2.7. 
the time of delivery (Hahn et al., 1977). Carnitine concentrations in plasma and tissues 
can also be affected by hemodialysis and by various diseases as liver cirrhosis and Du-
chenne dystrophy (Böhmer et al., 1974,1978; Rudman et al., 1977; see section 2.7). 
1.3.2. Carnitine transport and turnover 
The amount of carnitine in the body is influenced by the nutritional intake, synthesis 
and excretion (Mitchell, 1978). Conversion and degradation of carnitine are limited (Bre-
mer, 1977). Carnitine is dissolved in the blood plasma and can be lost upon dialysis 
(Böhmer et al., 1974, 1978). Although more than 95% of the carnitine passed through 
the glomerulus is reabsorbed daily by an active transport process in rat kidney (Huth et 
al., 1978), still approximately 7% of the body content of carnitine is excreted daily in the 
nourished rat (Cederblad & Lindstedt, 1976; Brooks & Mcintosh, 1975). In man this 
value is 3-5 % (Maebashi et al., 1976; Mitchell, 1978). These values decrease upon fasting, 
both in rat and man (Brass & Hoppel, 1978; Fröhlich et al., 1978) and also when a vege-
tarian diet with a low carnitine content is used (Mitchell, 1978). Carnitine of the mamma-
lian body can be replenished by nutritional intake and by synthesis in the liver (cf. sec-
tion 1.3.3). Carnitine is transported from the liver into the bloodstream as free carnitine 
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and acetyl-carnitine. In the nourished state, free carnitine is 65 - 80 % of the total carnitine 
in plasma, but during starvation the relative amount of esterified carnitine in the plasma 
increases (Fröhlich et al., 1978; Seccombe et al., 1978; Brass & Hoppel, 1978). Carnitine 
exchange with the blood proceeds rapidly in liver, spleen and kidney, but slower in heart 
and skeletal muscle (Brooks & Mcintosh, 1975). 
Since carnitine levels are higher in the tissues than in plasma, a concentrating me-
chanism must be present. The involvement of a transport mechanism in the plasma mem-
brane was demonstrated in rat liver cells (Christiansen & Bremer, 1976), cultured human 
heart cells (Böhmer et al., 1977; Moisted et al., 1977), rat skeletal muscle (Rebouche, 
1977; Willner et al., 1978) and rat kidney slices (Huth et al., 1978). Differences in the 
carnitine concentrations of various tissues may reflect different kinetic properties of these 
transport mechanisms. Both carnitine and its precursor 4-aminobutyrobetame (cf. section 
1.3.3) can be transported. In liver cells 4-aminobutyrobetame has a ten times lower Km 
than carnitine towards the transport system, whereas muscular tissues show a similar 
(Rebouche, 1977; Masted et al., 1978) or a higher Km (Willner et al., 1978) for the pre-
cursor. The Km for carnitine transport is 5 μΜ in human heart cells (Moisted, 1977) and 
0.5 mM in liver cells of the rat (Christiansen & Bremer, 1976). Willner et al. (1978) sug­
gested that a lower K
m
 for carnitine would exist in red muscle (250 μΜ) than in white 
muscle (600 μΜ), but their value on white muscle is ten times higher than that found by 
Rebouche (1977). Carnitine transport was inhibited by dinitrophenol and anoxia in liver, 
skeletal muscle and kidney, but not in heart cells. The carnitine transport mechanism is 
another than that of amino acids, since amino acids did not compete with carnitine. 
Na K+ATPase appears not to be involved, since ouabain has no effect on the transport 
of carnitine (Christiansen & Bremer, 1976; Rebouche, 1977;M^lsted et al., 1977). 
1.3.3. Biosynthesis of carnitine 
In contrast to the meal worm, mammalians are able to synthesize carnitine. The 
mechanism of carnitine synthesis in man is unknown, but a pathway is proposed mainly 
based on experiments with the rat (Fig.1.9). The carbon-chain and quaternary nitrogen 
atom of carnitine are derived from lysine and the methyl groups from methionine via the 
S-adenylmethionine system. The 6-N-trimethyl-L-lysme is not directly formed from free 
lysine, but protein-bound lysine residues are methylated (Paik & Kim, 1975). After degra­
dation of these proteins (LaBadie et al., 1976) 6-N-trimethyl-L-lysme can be converted to 
4-butyrobetame in all rat tissues (Cox & Hoppel, 1974; Haigler & Broquist, 1974). The 
hydroxylation of 4-butyrobetaine to carnitine appears to be restricted to the liver and 
testis of the rat (Cox & Hoppel, 1974; Haigler & Broquist, 1974). Hydroxylation of 
6-N-trimethyl-L-lysine and 4-butyrobetaine involves a 2-oxoglutarate-dependent mito­
chondrial dioxygenase (Hülse et al., 1978). In vivo experiments with rats also indicate 
that the liver is the only important organ in the conversion of 4-butyrobetame to carni-
tine (Böhmer, 1974). Once carnitine is formed it is rapidly transported to other organs 
(Böhmer, 1974). Recently Scarlato et al. (1978) found carnitine in a mixed culture of 
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Fig.l .9. Schematic presentation of the synthesis of carnitine in rat liver. 
human myoblasts and fibroblasts. These authors suggested that the ability of one of these 
cell types to synthesize carnitine could be an expression of the embryonic function of 
these cells. 
1.3.4. Role of carnitine in metabolism 
Carnitine plays a role in the interconversion of cytoplasmic and mitochondrial co-
enzyme A esters and in the maintenance of a pool of free coenzyme A. By promoting the 
translocation of the activated acyl-groups across the mitochondrial inner membrane it 
enables the mitochondrion to oxidize long-chain fatty acids (section 1.2.2). 
Short-chain acyl-CoA transferase activities were observed in mitochondria (Fritz et 
al., 1963) and also in rat liver peroxisomes (Markwell et al., 1973,1976). It was suggested 
that carnitine might be involved in the transport of the products of peroxisomal /3-oxi-
dation (Lazarow & DeDuve, 1976; Bremer, 1978) and branched-chain amino acid decarb-
oxylation (Bieber & Choi, 1977). This has still to be verified (cf. sections 4.4 and 8.4). 
Carnitine may play a role in the transport of the intramitochondrially formed acetyl-
groups into the cytoplasm, where they can be used for fatty acid synthesis (Bremer, 
1962; Bressler & Brendel, 1966). It may also act in cooperation with acyl-CoA carnitine 
transferases to form an acyl-group buffering system, by which coenzyme A regeneration 
is ascertained, and acyl-groups are preserved in active form (Childress et al., 1966; 
Pearson & Tubbs, 1967; Snosswell &. Henderson, 1970). 
Carnitine is also involved in carbohydrate utilization in flight muscle of blowflies. 
This muscle contains a high concentration of carnitine, but cannot oxidize fatty acids 
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(Childress et al., 1966). During the onset of flight the acetyl-carnitine level in these 
muscles increased 4-fold, but after 1 min of flight the level decreased and attained a 
steady state at a concentration twice that in the muscle at rest. An acetyl-buffering role 
for carnitine in carbohydrate metabolism was also suggested from experiments on white 
frog muscle (Akonyl et al., 1975). 
1.4. Disturbances in energy production in human skeletal muscle 
Several types of disturbances in the muscular energy production have been reported. 
Disorders in glycolysis or glycogenolysis lead to glycogen storage (Howell, 1978). Mito-
chondrial energy production can be impaired by inefficient ATP production (loose 
coupling') and by deficiencies in the electron transport chain and the pyruvate dehydro-
genase complex (see Bookelman, 1978). Muscular energy production may also be im-
paired by a defect in the fatty acid oxidation route and possibly by a (subsequent) ele-
vated level of long-chain acyl-CoA esters (cf. chapters 3 and 6). Deficiencies in the oxida-
tion of branched-chain amino acids may lead to severe acidosis. Some aspects of disorders 
in fatty acid and branched-chain amino acid oxidation are summarized below. 
1.4.1. Disorders in fatty acid oxidation 
A disorder of fatty acid oxidation is based on a biochemical criterion and is defined 
by a deficiency in the fatty acid oxidation pathway or the lack of one of the cofactors 
involved in this pathway. It is not equivalent to a lipid storage myopathy, which is based 
on a histochemical criterion and is defined by accumulation of lipids in the muscle fibers. 
Disorders in fatty acid oxidation may be accompanied by lipid accumulation, e.g. in car-
nitine deficiency, but this accumulation can also be absent, e.g. in several cases of carni-
tine palmitoyl transferase deficiency. On the other hand lipid storage in muscle can also 
be associated with other metabolic defects as pyruvate decarboxylase deficiency (Blass et 
al., 1971) and von Gierkes disease (glycogen storage disease type I) (Yamaguchi et al., 
1978). No cause is known in several other reported cases of lipid storage. These cases in-
volve a storage only or predominantly in type I muscle fibers (Coleman et al., 1967; Price 
et al., 1967; Culotta et al., 1974; McLeod et al., 1975; Sengers et al., 1976), in both 
muscle fiber types (Salmon et al., 1971; Jerusalem et al., 1975) and more generalized 
lipid storage myopathies (Charanin et al., 1975; Shy et al., 1966). 
Since 1973 about thirty patients with a disorder in fatty acid catabolism have been 
reported. Most of them suffered from carnitine deficiency (Engel & Angelini, 1973), ten 
of them from carnitine palmitoyl transferase deficiency (DiMauro & DiMauro, 1973) and 
one from butyryl-CoA dehydrogenase deficiency (Tanaka et al., 1977). The patients with 
carnitine deficiency in muscle are summarized in Table 1.7. They do not belong to one 
homogeneous group. The cases described by Engel & Angelini (1973), Markesbeny et al. 
(1974), Angelini (1976). Isaacs et al. (1976), Scarlato et al. (1977; 1978, case 1) and 
Bradley (1969; 1978, case 5) show muscle weakness and lipid accumulation in muscle 
especially in type I muscle fibers, and sometimes a moderately decreased plasma concen-
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Table 1.7. General characteristics of the reported cases of carnitine deficiency. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Karpatietal.(1975) m 3 y r + + + + - - + + - - + - D D 
Boudin et al. (1976) f 7 y r + + 4 - - + + + - + - + D x 
Engel et al. (1977) m 22 mn + + + + + + + + + + - + D x 
Cornelio et al. (1977) case 1 f 16 yr + + + - _ - - - f + _ _ + D x 
Cornelio et al. (1977) case 2 m 3 . 5 y r + + + - - + + - - - - + D D 
Cornelio et al. (1977) sister of 2 f 5 y r + + - - - - + - - - - + x x 
ComeHo et al. (1977) case 3 f I 4 y r + + + - - - - - - - - + D D 
Scarlato et al. (1977; 1978 case 2) m 3 y r + + + + + + + + - + - + D D 
Koskietal. (1978) f 3 y r + + - - + - - - - - - _ D N 
Smyth et al. (1975) m 5 . 5 y r + + -+ - _ _ _ + - - _ _ D x 
Hart et al. (1978) m 2 3 n m + + - - - - - + + - - + D N 
VanDijke et al. (1975) f I 8 m n + + - - - - - - - - - - D N 
Engel & Angelini (1973) f 1 9 y r + + - - - - - + - - + - D D 
Markesberry et al. (1974) f 3 8 y r + + - - - - - - - - - - D N 
AngeUni et al. (1976) f 7 y r + + - - - - - - - - - - D N 
Isaacs et al. (1976) m l 9 y r + + - - _ - - _ - + _ _ D N 
Scarlato et al. (1978) case 1 m 3 5 y r + + - - - - - - - + - - D D 
Bradley et al. (1978) case 5 f 2 3 y r + + - - - - - - - + - - D D 
1: Sex; 2: Age of onset; 3: Muscular weakness; 4: Lipid filled vacuoles in type I muscle fibers; 5: Acute vomiting; 6: Alterations in 
liver metabolism; 7: Metabolic acidosis; 8: Coma; 9: Fluctuating liver enlargement; 10: Respiratory insufficiency; 11 : Heart insuffi­
ciency; 12: Abnormal mitochondria; 13: Convulsions; 14: Death; 15: Carnitine concentration in muscle; 16: Carnitine concentration 
in plasma; 17: Muscular fat accumulation; 18: Liver fat accumulation; 19: Heart fat accumulation. 
Symbols mean: m: male; f : female; yr: year;mn: month;+: stated;- : not stated; x: not determined; D; decreased; N: normal. 
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tration of carnitine. It is suggested that carnitine uptake in the muscle is impaired in these 
patients (Angelini, 1976a). 
The cases of carnitine deficiency reported by Karpati et al. (1975), Boudin et al. 
(1976), Engel et al. (1977), Cornelio et al. (1977, 3 cases) and Scarlato (1978, case 2) 
have in addition severe metabolic affections. Lipid accumulation is also found in other 
tissues, as heart, liver and kidney. Nearly all patients of this second group of carnitine de­
ficiency died. Two young patients (VanDyke et al., 1975; Hart et al., 1978) may repre­
sent a third group. They show an involvement of both skeletal and heart muscles. One of 
them died by heart insufficiency. 
The cases described by Smith et al. (1975) and Koski et al. (1978) are not sufficient­
ly documented for adequate classification. A patient with partial carnitine deficiency in 
muscle, described by Whitaker et al. (1978), shows such evident liver disturbances, that it 
seems probable that carnitine deficiency in muscle is secondary to liver disease. Second­
ary carnitine deficiency in muscle is also observed in patients with liver cirrhosis (Rudman 
et al., 1977) and in patients with leaky muscle fibers, such as in Duchenne muscle dys­
trophy (Borum et al., 1977). 
Carnitine palmitoyl transferase (CPT) deficiency was always reported in connection 
with recurrent myoglobinuria, muscle pain (cramps) and myalgias. The deficiency is often 
partial and can involve CPT-I, CPT-II or both carnitine palmitoyl transferases. Attacks 
were nearly always reported to occur during prolonged exercise after fasting, after a high-
fat diet or during cold weather. Muscle weakness was limited to a few cases. The cases 
reported are summarized in Table 1.8, where various other characteristics are given. Even 
in a patient with frequent attacks, the attacks could be completely prohibited by a carbo­
hydrate rich diet given in frequent small doses (Reza et al., 1978). 
A 4 year-old girl, who had severe episodes of hypoglycaemia, leading to lethargy or 
even coma, seemed to be deficient in butyryl-CoA dehydrogenase (short-chain acyl-CoA 
dehydrogenase) (Tanaka et al., 1977). Although this suggestion was only based on analy­
sis of plasma metabolites, it seems probable that in such a case muscle would also be in­
volved. Short-chain acyl-CoA dehydrogenase can be inhibited together with branched-
chain acyl-CoA dehydrogenase by metabolites of hypoglycin or its analogues (see section 
1.4.2). 
Deficiencies in fatty acid oxidation are unknown in animals, except for the physiolo­
gical carnitine deficiency in the meal worm Tenebria molliter and the absence of any 
fatty acid oxidation in some other insects (Childress et al., 1966). Brownell & Engel 
(1978) induced a lipid storage myopathy in rats by feeding them brominated vegetable 
oil, but their conclusion that this lipid storage is due to impaired 0-oxidation of medium­
and short-chain fatty acyl residues is only based on the measurement of 1 ^СО^ produc­
tion from [ l^C] fatty acids, and should be reevaluated (cf. section 3.4). 
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Table 1.8. Survey of cases of carnitine palmitoyl transferase deficiency. All patients suffered on recurrent myoglobinuria, muscle pain 
and myalgias. 
Age/Sex 
yrs 
Engeletal. (1970) case 1 
Engel et al. (1970) case 2 
Bank et al. (1975) easel 
Bank et al. (1975) case 2 
Cummingetal. (1976) 
Heiman ÄNadler (1977) 
Reza et al. (1977) case 1 
Reza et al. (1977) case 2 
Reza et al. (1977) case 3 
Layzeretal.(1977) 
Hostetleretal.(1978) 
Carroll et al. (1978) 
Schölte et al. (1978) 
Brownell et al. (1978) 
Bertormietal.(1978) 
18/f 
18/f 
20/m 
33/m 
21/m 
16/m 
20/m 
24/m 
17/f 
16/m 
28/m 
21/m 
20/m 
23/m 
?/m 
Onset Fasting Elevated 
yrs induced plasma 
ketosis triglycerides 
4 -5 
4 -5 
13 
20 
12 
14 
14 
13 
2 
12 
21 
3 
18 
20 
51 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
χ 
χ 
No 
No 
Yes 
Yes 
No 
No 
No 
No 
No 
X 
No 
No 
No 
X 
X 
Excess lipid Carnitine palmitoyl 
in biopsy transferase activity 
( % of controls) 
Yes 
Yes 
No 
No 
Variabel 
No 
Yes 
No 
Yes 
X 
Yes 
X 
No 
Yes 
Yes 
X 
X 
12 
5 
6 
20 
5 
0 
0 
25 
46 
< 1 0 
6-16 
20 
10-15 
x: not determined. 
Ν H, 
(CHjliCHCH^ÇN-ÇOOH 
LEUCINC 
il о 
(CH,),CHCH,-C-COOH 
a-KETOISOCAPROIC ACIO 
co, (Τ) ^Щмлле srajp URINE DISEASC •сл ^ 
tCH,), CHCH,-COOH I tCHjlj CHCHj-CO-S-CoA 
ISOVALEUlC ACID ISOVALEBYL C«A 
(CHjJjClOHJCHjÇOOH ( ? ) 
jS-HTDROKTlSOVALERlC AGO 
t 
ISOVALERIC ACIDEMIA and UCPA INHIBITION 
(CH )1C(OHJCHjC0-S-CoAt:.Vi(CH3)2C-CK-ÇO-S-CoA---*(CH3)2C-CH-Ç0-NHCHjC00H 
^-MTDBOITISOVALÎftTL CöA -^METHTLCROTONTL CoA H-Q -^CTHTLCBOTOHYLOLTClHE 
( T ) иним /2-М£ТНП.СМ)Т0ЫП. CoA 
сля оггшзе cericiENcr 
• ' Ç H , 
HOOC-CHi-C»CH-ÇO-S-C<iA 
-^UETHYLGLUTACONTL CoA 
Fig.1.10. Schematic presentation of metabolic disorders in branched-chain amino acid 
oxidation. Arabic figures represent 1. 2-oxoisocaproate dehydrogenase; 2. iso-
valeryl-CoA dehydrogenase; 3. 3-methyl-CoA carboxylase, (modified from 
Tanaka et al., 1976). 
1.4.2. Deficiencies in branched-chain amino acid oxidation 
As will be outlined in section 9.4 skeletal muscle may be more involved in the oxida-
tion of branched-chain amino acids than previously was suggested (Shinnick & Harper, 
1976). Especially in man, in which the ratio between muscle to liver weight is much 
higher than in rat, a deficient branched-chain amino acid oxidation may contribute to 
accumulation of large quantities of intermediates and to acidosis. Inborn errors in leucine 
metabolism are shown in Fig. 1.10. In maple syrup urine disease valine and isoleucine 
catabolism is also affected. The isovaleryl-CoA dehydrogenase can be inhibited by a 
metabolite of hypoglycine: methylene cyclopropyl acetyl-CoA (MCPA-CoA). This 
inhibition also affects the short-chain acyl-CoA dehydrogenase and is known as the 
cause of the 'vomiting disease' of Jamaica (cf. Sherratt & Osmundsen, 1976) and similar 
syndromes (Lawson & Chalmers, 1978). 
Recently, a deficiency of lipoamide dehydrogenase was reported (Robinson et al., 
1977), which affected the branched-chain 2-oxo acid dehydrogenase as well as pyruvate 
and 2-oxoglutarate dehydrogenases. 
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1.5. Aim of our investigation 
In the foregoing survey it was outlined that muscle has an important contribution to 
the metabolism of the whole body. This is particularly the case in man, in which the total 
mass of striated muscle is 15 - 20 times larger than that of liver. At the start of our inves­
tigation insight in the metabolism of human skeletal muscle was available only from (a) 
physiological experiments, mainly by determination of arterial-venous differences of sub­
strates and products, oxygen consumption and heat production; (b) histochemical investi­
gation of human muscle biopsies, and (c) biochemical studies on muscular tissues of ani­
mals and some patients. 
Our biochemical study was aimed at increasing our understanding of energy produc­
tion by skeletal muscle. We determined the rate and capacity of fatty acid oxidation by 
normal human striated muscle and compared these data with those for rat muscle. Sec­
ondly, we investigated for rat muscle how and to what extent branched-chain amino acids 
can be oxidized in muscular tissue under normal conditions. 
To realize our first aim it was necessary to develop sensitive and accurate assays of 
fatty acid oxidation and carnitine content in muscle, and to choose suitable parameters 
for muscular fatty acid oxidation (chapters 2 and 5). After a critical comparison of the 
radiochemical and Polarographie assays of fatty acid oxidation with rat muscle mitochon­
dria (chapter 3), the occurrence of Д-oxidation intermediates during palmitate oxidation 
was investigated (chapter 4). The assays developed on rat muscle were checked for their 
applicability to homogenates and mitochondria from human muscle biopsies (chapter 5). 
A radiochemical assay was adapted to a microscale. With this microassay we examined 
whether there are differences in fatty acid oxidation rates between various types of 
striated muscle in man (chapter 5). Investigations were performed on human and rat heart 
to see to what extent capacity and regulation of fatty acid oxidation are comparable 
(chapter 6). 
To evaluate the degree to which branched-chain amino acids can be used for energy 
production in striated muscle, it was necessary to develop an adequate assay for the ox­
idation of these amino acids, and to examine which factors influence their oxidation rates 
(chapter 7). When it appeared that carnitine enhanced the oxidation rate of leucine, the 
mechanism of this stimulation was examined (chapter 8). The localization of the branched-
chain oxo acid dehydrogenase complex and the effect of the metabolic state of the mito­
chondrion on leucine oxidation were investigated in order to make a more reliable esti­
mation of the capacity of muscle to oxidize branched-chain amino acids (chapter 9). 
In our study homogenates and mitochondria of muscle were used to limit the com­
plexity of the system. These studies may therefore be considered as a basis for further in­
vestigations, in which intact cells will be used and a distinction will be made between dif­
ferent muscle fiber types. 
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CHAPTER 2 
GENERAL METHODS AND MATERIALS 
2.1. Materials 
The specific reagents used in this study are listed together with the suppliers. 
Carnitine acetyltransferase (EC 2.3.1.7), catalase (EC 1.11.1.6), lactate dehydroge­
nase (EC 1.1.1.27), myokinase (EC 2.7.4.3), pyruvate kinase (EC 2.7.1.40), cytochrome с 
(horse heart), coenzyme A, acetyl-CoA, valinomycine and FCCP (carbonyl cyanide p-tri-
fluoromethoxyphenyl hydrazone): Boehringer, Mannheim, FRG. 
Amino acid oxidase (type Г ), 2-oxoisocaproic acid, thiamine pyrophosphate, palmi-
toyl-CoA and rotenone: Sigma, St. Louis, USA. 
L-Camitine: Grand Island Biol. Сотр., New York, USA. 
Isovaleryl-CoA: PL-Biochemicals, Milwaukee, USA. 
Tryptamine, dinitrophenol, silicagel G for thin-lay er plates and bovine serum albu­
min: Merck, Darmstadt, FRG. 
Silicagel: Mallinckrodt, St. Louis, USA. 
[1-14C]- and [U-14C]fatty acids, L-[U-14C]malate, [l-14C]acetyl-CoA and 1-14C-
and U-14C-labeled L-leucine: the Radiochemical Centre, Amersham. 
[16-l4C]palmitate, [side-chain 2-^4C]tryptamine and L-[l-14C]valine: New England 
Nuclear, Dreieichenhain, FRG. 
Diethyleneglycol succinate on 60 - 80 mesh Gas-Chrom P: Applied Science Laborato­
ries, State CoUege, Pa, USA. 
Acetyl-L-camitine, propionyl-L-camitine and isovaleryl-L-camitine were synthesized 
according to Solberg& Bremer (1970), palmitoyl-L-carnitine after Ziegleret al. (1967). 
[14C]2-oxoisocaproate was prepared from L-['4C]leucine according to the method 
of Meister (1957). 
Sodium tetrathionate was synthesized from sodium thiosulphate after Schlessinger 
(1962). 
Fatty acid-free albumin was prepared according to Chen (1967) and dialyzed (Lopes-
Cardozo & Van den Bergh, 1972). 
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2.2. Source of muscular tissue 
Animals 
Male random bred Wistar rats (160 - 240 g) were used, one rat per experiment. After 
fasting for 18 - 24 hr the rats were killed by decapitation. Musculi quadriceps femoralis 
and/or the heart were removed and immediately cooled in ice-cold buffer consisting of 
0.25 M sucrose, 2 mM EDTA, 10 mM Tris-HCl (pH 7.4) and 50 units/ml heparin (SETH-
buffer). 
Human muscle biopsies 
Several types of striated muscular tissue were used to study the normal metabolism 
of fatty acids by human muscle. Biopsies of m. pectoralis were obtained from breast 
carcinoma patients (30 - 78 years old). The material was transferred into ice-cold SETH-
buffer within 15 min after breast amputation. Depending on the surgical handling, mus­
cular tissue had been anoxic for 10 - 50 min. When the muscular tissue was cooled in ice-
cold buffer, its bright red color returned quickly. Transport of these biopsies to the labo­
ratory usually took 1 - 2 h. The time of transport had no effect on the quality of the sub­
sequently isolated mitochondria. 
The other kinds of muscular tissue were prepared for homogenization within 10 -
20 min after biopsy. Biopsies of m. abductor longus and m. gluteus were obtained from 
patients undergoing orthopedic corrections (11 - 15 and 20 - 75 years old, respectively), 
those from m. quadriceps from cases of accidental trauma (52 - 89 years old). These 
biopsies were placed in a known volume of ice-cold SETH-buffer within 5 min. Heart 
muscle tissue was obtained from patients with tetralogy of Fallot (6 - 24 years old). The 
muscular tissue removed during insertion of an artificial valve was initially placed in 0.9 % 
NaCl solution at room temperature, and after 10 - 15 min in ice-cold SETH-buffer. Mus­
cular biopsies from patients with muscular weakness, taken for diagnostic purpose, were 
placed immediately in ice-cold SETH-buffer. 
2.3. Preparation of homogenates and mitochondria 
All procedures were performed at 0° С After removal of fat and connective tissue 
the muscular tissue was minced with a pair of scissors and homogenized in 10 volumes 
(w/v) of 10 mM Tris-HCl (pH 7.4) containing 0.25 M sucrose, 2 mM EDTA and 50 units/ 
ml heparin. Homogenization was performed with a teflon-glass Potter-Elvejhem homo-
genizer using two or three pestles with different diameter (the intervening space was 0.20 
and 0.12 mm respectively, for human tissue, and 0.35, 0.20 and 0.12 mm respectively, 
for rat tissue). After two centrifugations for 5 min at 600xg, the supernatant was filtered 
through nylon gauze (0.13 mm diameter) and termed the homogenate. 
Mitochondria were prepared from this homogenate by centrifugation at 7000xg for 
10 min. A solution of 100 mM KCl, 50 mM Tris-HCl (pH 7.4), 1 mM MgC^, 0.2 mM 
EDTA and 0.2 mM ATP was used for washing and final suspension. During washing the 
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F ig.2.1. Metabolic steady states in mitochondria. 
These states are identified by changes in the rate of oxygen consumption and in 
the degree of reduction of the pyridine nucleotides. The five metabolic states, 
which were characterized by Chance & Williams (1955), are indicated with 
arabic numerals. Data were obtained with rat liver mitochondria and L-glutamate 
as substrate (from Hackenbrock et al., 1966). 
mitochondria were stabilized by 0.5%fatty acid-free dialyzed albumin. The yield was 
1 - 1.5 mg mitochondrial protein per gram fresh weight of rat skeletal muscle. The yield 
would have been 1.3-2 times higher, if the mitochondria would have been prepared by 
centrifugation at 14000xg, but such preparations contain considerably more impurities 
(Ernster & Nordenbrand, 1967). 
2.4. Quality control of the mitochondria 
Since the bulk of muscular tissue consists of myofibrils, mitochondria constitute a 
relatively smaller part of total tissue mass than in other organs. The muscular tissue also 
has to be treated more vigorously to isolate mitochondria, since the latter are mainly 
situated between the myofibrils. Since mitochondria are rather labile organelles, many 
authors have tried to avoid mechanical force by the use of proteolytic enzymes, partic­
ularly Nagarse. De Jong & Hülsmann (1970) and Pande & Blanchaer (1970) have shown 
that Nagarse destroyed the activity of palmitoyl-CoA synthetase, which is situated on the 
outer surface of the mitochondria. Hence, we decided to use only mechanical force. 
The rates, at which intact mitochondria oxidize substrates, depend on the availability 
of oxygen and ADP. The metabolic states defined by Chance & Williams (1956) are sum-
marized in Fig.2.1. The ratio between the rates in state 3 and state 4(after ADP depletion) 
is generally considered to be a good parameter of mitochondrial intactness and is termed 
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Fig.2.2. Respiratory control index (RCI) and ADP/O ratio of rat mitochondria. 
These parameters were determined in Dow's medium (Dow, 1969) with a Clark 
oxygen electrode at 250C. Incubation occurred in a final volume of 1.25 ml with 
0.43 mg mitochondrial protein of rat skeletal muscle. As substrate served 11 mM 
L-glutamate. Oxidation was stimulated by additions of 324 nmol ADP. Figures 
in the graph represent oxidation rates expressed in natom oxygen.min'^.mg.pro-
tein"'. Respiratory control index was calculated from the ratio between the oxy-
gen consumption stimulated by ADP (state 3) and that after depletion of ADP 
(state 4). ADP/O ratio was caluclated from the ratio between the amount of 
ADP which was phosphorylated during a state 3 period and the oxygen con-
sumption which accompanied this phosphorylation. 
the respiratory control index (RCI). 
Fig.2.2. shows a graph representing the measurement of the respiratory control index 
with an oxygen polarograph (Estabrook, 1967). Since a known and limited amount of 
ADP is added in such experiments, the ratio between the consumption of ADP and oxy-
gen can be calculated. This ADP/O ratio is a second parameter of mitochondrial quality. 
Values of respiratory control indexes and ADP/O ratios are summarized in Tables 2.1 and 
2.2. These values are comparable to those observed by other investigators, which used 
only mechanical homogenization (Ernster & Nordenbrand, 1967; Peter, 1968; Max et 
al., 1972), but are somewhat lower than those from muscle mitochondria, prepared by 
treatment with proteolytic enzymes (Makinen & Lee, 1968;Bullock, 1973;Palmer et al., 
1978). 
Examination of the mitochondrial pellets by electron microscopy (Fig.2.3) revealed 
that the mitochondrial preparations are contaminated with material, which probably ori-
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Table 2.1. Respiratory control of rat muscle mitochondria. 
Substrate 
2-Oxoglutarate (21 mM) 
L-Glutamate(llmM) 
Pyruvate (11 mM) + 
L-malate (9 mM) 
Succinate (11 mM) + 
rotenone (4 μΜ) 
Palmitoyl-L-camitine 
Nrof 
expts. 
8 
9 
5 
5 
3 
(20 μΜ) + L-malate (0.5 mM) 
Oxygen consumption 
State 3 
280 ± 30 
270 ±30 
180 ±52 
300 ±80 
151 ±23 
State 4 
69 ±20 
54 ±14 
59 ±6 
147 ±15 
46 ± 2 
RCI value 
5.7 ±1.5 
5.4 ±1.5 
4.3 ±1.0 
2.0 ± 0.2 
3.3 ±0.6 
ADP/O ratio 
2.6 
2.6 - 2.8 
2.3-2.6 
1.4 
2.3 - 2.6 
Respiratory control index of rat skeletal muscle was determined in Dow's medium (Dow, 
1969) at 25° С with a Clark oxygen electrode. The incubation medium contained 0.30 -
0.35 mg/ml mitochondrial protein. Respiration in state 3 was determined after addition 
of ADP. Oxygen consumption in state 4 was determined after depletion of ADP. The 
ADP concentration was assayed spectrophotometrically using lactate dehydrogenase and 
myokinase (Bergmeyer, 1974). Oxygen consumption is expressed in natom oxygen per 
min per mg protein. Values are the means with SD for the stated numberof experiments. 
Table 2.2. Respiratory control of human muscle mitochondria. 
M. adductor longus (1) 
11 mM L-glutamate 
11 mM pyruvate + 9 mM 
L-malate 
M. pectoralis (2) 
11 mM L-glutamate 
20 μΜ palmitoyl-L-camitine 
10 mM 0-hydroxybutyrate 
Heart (2) 
11 mM L-glutamate 
20 μΜ palmitoyl-L-carnitine 
11 mM succinate +4 μΜ 
rotenone 
Oxygen consumption 
State 3 
125 
99 
109-140 
84-112 
102 
161-225 
163 
211 
State 4 
37 
39 
27-41 
28-38 
27 
28-40 
40 
80 
RCI 
3.42 
2.54 
2.7-5.2 
2.2-4.0 
3.9 
5.6-5.7 
4.0 
2.64 
ADP/O ratio 
2.81 
2.56 
2.0 - 2.4 
1.7-2.9 
2.8 
2.6-3.0 
2.6-3.0 
1.8 
Respiratory control index in human muscle mitochondria was determined at 25° С as 
described in Table 2.1. Oxygen consumption is expressed in natom oxygen per min per 
mg. protein. Oxidation of palmitoyl-L-camitine and 0-hydroxybutyrate was measured in 
the presence of 0.5 mM L-malate. 
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Fig.2.3. Electronmicroscopic pictures of rat skeletal muscle mitochondria. 
Figs, a and b show two pictures of the same mitochondrial pellet. Part of the 
pellet consisted of purified mitochondria (a), but the top of the pellet contained 
contaminating material (b). The major part of the mitochondria appears to be 
intact. 
ginates from myofibrils, sarcotubular membranes and/or submitochondrial particles. 
Since the material may contain ATPase activity (Ernster & Nordenbrand, 1967), there is 
continuous formation of small amounts of ADP. This leads to a marked difference in the 
oxygen consumption prior to ADP addition (state 4b) and that after ADP depletion (state 
4) (Fig.2.2). Decrease of the RCI value by contamination with ATPase activity may ex-
plain the difference between our RCI values and those obtained with mitochondria iso-
lated after proteolytic treatment. When we would derive the respiratory control ratio 
from the extent of the stimulation of respiration by ADP (state 4 b - state 3 transition), 
values ranging from 10 to 20 would be obtained. 
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Additional evidence was obtained, which indicates the intactness of the mitochon­
dria. Palmitate oxidation appears to be completely dependent on the presence of carni­
tine (section 3.3). Also the effect of carnitine on the oxidation of leucine (section 8.3) in­
dicates that the mitochondria are functionally intact. 
2.5. Assay of cytochrome с oxidase 
Cytochrome с oxidase activity of freezed and thawed preparations was determined 
according to Smith (1955) with slight modifications. Mitochondrial membranes were 
broken before the assay by freezing and thawing at least 3 times. Fresh mitochondria 
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were diluted with 0.25 M sucrose before they were frozen and stored at -20oC. Homoge-
nates were stored undiluted at -20oC. 
Reduction of cytochrome c. To 30 ml 90 μΜ horse heart cytochrome с in 50 mM potas­
sium phosphate (pH 7.4) 50 μΐ 1.2 M sodium dithionite was added. Nitrogen gas, which 
had been passed through water, was bubbled through the solution for 1.5 h to remove SO2. 
Reduction was checked by determination of the optical density at 550 and 565 nm. The 
ratio between these values had to be 12 or more. After addition of potassium fenicyanide 
to a sample of the solution, the optical density of the completely oxidized sample had to 
be 0.630. 
Assay. Oxidation of cytochrome с was assayed in a Zeiss PMQ II spectrophotometer in a 
cuvette-holder, the temperature of which was maintained at 250C. The optical density at 
550 nm was recorded on a Kipp BD 11 recorder. A 25 - 50 μΐ (χ μΐ) specimen of homoge-
nate or diluted mitochondrial suspension was added to 2.5 ml 90 μΜ reduced cytochrome 
с in 50 mM potassium phosphate. After rapid and vigorous shaking, the decrease in optical 
density was recorded for 3 - 8 min (O.D.t j and O.D. t2). Finally all cytochrome с was oxi­
dized by the addition of a few grains of potassium ferricyanide. The latter value repre­
sents the optical density at infinite time (O.D.-). 
Calculation. Since cytochrome с is oxidized at a first order rate, the first order velocity 
constant к is calculated from the formula 
k
 =
 In (O-D-ta - 0-D-) - In (O-D-t. - O.D~). x mm-ljnH 
ml specimen t 2 - 1 1 2500 + χ 
The activity of cytochrome с oxidase is calculated from the equation V/ml specimen 
=k.[S], in which V/ml is the velocity in μιηοΐ cytochrome с min"'.(ml specimen)"^, к is 
the first order velocity constant and [S] is set at 90 μΜ cytochrome с 
Results and discussion. The activity appeared to be linear with the amount of mitochon­
drial or homogenate protein present. The kinetics of the assay are rather unusual for en­
zyme assays. The reaction not only proceeds with a first order velocity, but the value of 
the first order rate constant also depends on the total concentration of cytochrome с (re­
duced plus oxidized) (Smith & Conrad, 1956). The higher the total concentration of 
cytochrome c, the lower the value of the first order velocity constant (Fig 2.4). 
Cytochrome с oxidase activity appeared to depend on the conditions of mitochondrial 
storage and on the rupture of the mitochondrial membranes. Rupture of the membranes 
increased the activity of cytochrome с oxidase by yielding a better exposure of the mito­
chondrial inner membrane. Activity increased upon freezing and thawing in 0.25 M sucrose, 
but became constant after this had been repeated 3 times. When the mitochondria were 
frozen and thawed in 100 mM KCl containing 50 mM Tris-HCl (pH 7.4) and 0.2 mM 
EDTA, the activity of cytochrome с oxidase decreased. This could be prevented by add­
ition of 0.5 % albumin, but the activity still decreased during storage at -20oC. The best 
results were obtained with 0.25 M sucrose. The cytochrome с oxidase activity of rat 
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Fig.2.4. Kinetics of cytochrome с oxidase. 
Activity of cytochrome с oxidase was determined spectrophotometrically by 
measuring the decrease of reduced cytochrome с at 550 nm. Assay occurred 
with 0.16 mg protein of rat skeletal muscle homogenate in 50 mM potassium 
phosphate (pH 7.4) at 250C as described under 2.5. Various concentrations of 
cytochrome с (total of reduced and oxidized cytochrome c) were used. With all 
cytochrome с concentrations first order kinetics were observed. The first order 
velocity constant decreased with increasing concentrations of cytochrome с 
skeletal muscle mitochondria was stable for several months, when the mitochondria were 
stored at -20oC after tenfold dilution with 0.25 M sucrose. The activity of human skeletal 
muscle mitochondria was stable for 5 days at -20oC, but decreased slightly thereafter. 
Specific activities of cytochrome с oxidase in mitochondrial preparations of human 
and rat muscle and heart are summarized in Table 2.3. A higher specific activity was 
measured in rat skeletal muscle mitochondria than in those of man. However, conclusions 
are hazardous, since horse heart cytochrome с was used in the assay. Human liver mito­
chondria show a lower cytochrome с oxidase activity with horse heart cytochrome с 
than with human cytochrome с (Borza & Benga, 1975). It is difficult to compare our data 
for the activity of cytochrome с oxidase with those reported in the literature. Most 
authors measured oxygen consumption during oxidation of cytochrome c, but the presence 
of endogenous substrates and the oxygen binding protein myoglobin make this assay un-
suited for studies of skeletal muscle homogenates. Comparison with spectrophotometric 
determinations of cytochrome с oxidase activity by other workers is hampered by the 
different conditions under which it was measured. Our values on human and rat mito­
si 
Table 2.3. Cytochrome с oxidase and monoamine oxidase activities in mitochondrial pre­
parations of man and rat. 
Cytochrome с oxidase 
(μιηοΐ cyt.cmin . 
mg protein"!) 
Monoamine oxidase 
(nmol tryptamin.min'l. 
mg protein"^) 
MAN m. pectoralis 
m. gluteus 
heart 
RAT m. quadriceps 
heart 
1.0 ±0.3 (19) 
1.0 ± 0.2 (7) 
2.5 ±1.1 (7) 
5.6 ±1.2 (49) 
6.2 ± 0.9 (5) 
0.44 ±0.13 (7) 
0.49 ± 0.08 (27) 
Activities of cytochrome с oxidase and monoamine oxidase were determined as described 
in 2.5 and 2.6, respectively. Cytochrome с oxidase was determined by measuring the rate 
of horse heart cytochrome с oxidation with mitochondria, which were 3 times frozen and 
thawed after tenfold dilution with 0.25 M sucrose. Monoamine oxidase was measured on 
freshly-isolated mitochondria. Values represent means with SD of the number of experi­
ments indicated within parentheses. 
chondria are of the same order of magnitude as those of Willems (1978) and Bookelman 
(1978), who used similar assay conditions. 
2.6. Assay of monoamine oxidase 
Assay of monoamine oxidase, a marker enzyme of mitochondria! outer membrane, 
was carried out according to the method of Wurtman &. Axelrod (1963) with some modi­
fications. 
Assay. Mitochondrial suspension (25 ml 3 mg/ml) was added to 200 μΐ 0.5 M potassium 
phosphate (pH 7.9) in a centrifuge tube, and preincubated at 37° С for 2 min. Reaction 
at 37° С was started by addition of 100 μϊ 83 juM [14C]tryptamine (1 μα/μιηοΐ) in 0.5 M 
potassium phosphate. After 20 min the reaction was stopped by addition of 0.2 ml 2 M 
HCl, and 6 ml toluene was added. After mixing with a pasteur pipette, the tube was cen-
trifuged and 4 ml of the toluene phase was transferred to a scintillation vial. Radioactivity 
was determined with 10 ml 0.4% Omnifluor in toluene in a liquid scintillation counter. 
Results and discussion. A stock solution of 83 μΜ [ ! 4C]tryptamme in 0.5 M potassium 
phosphate could be used for 1 - 2 months, when stored in the dark at 4 0C under nitrogen. 
The assay appears to be linear with time for at least 20 min and with the protein content 
in the range 0.02 - 0.40 mg. Preliminary experiments indicated that it was necessary to in­
crease the substrate concentration from 8.3 to 25 μΜ tryptamine. Such an adaptation was 
also recommended by Himms-Hagen & Irwin (1976). The assay was not influenced by the 
phosphate concentration of the buffer between 0.2 and 0.8 M. A pH of 7.9 appeared to 
be well suited for both rat and human skeletal muscle (cf. Arora & Meltzer, 1977a,b). 
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Monoamine oxidase activity was always measured within 5 h after preparation of the 
mitochondria or homogenates. When the preparation was kept at 0° C, the enzyme was 
stable during this period. After 18 h at 0° С its activity had decreased by 20 - 25%. By 
freezing at -20° С the activity of monoamine oxidase was considerably diminished in 
both homogenates and mitochondrial suspensions. 
Specific activities of monoamine oxidase in mitochondria of human and rat skeletal 
muscle are shown in Table 2.3. The value for rat mitochondria is in accordance with those 
reported by Rifenberick et al. (1973) and Himms-Hagen & Irwin (1976). 
2.7. Assay of carnitine 
Immediately after biopsy muscular tissue was placed in a known volume of ice-cold 
buffer to prevent any loss of carnitine. The buffer consisted of 0.25 M sucrose, 10 mM 
Tris-HCl (pH 7.4), 2 mM EDTA and 50 units/ml heparin. The tissue was homogenized in 
this buffer within 30 min. Carnitine leakage from skeletal muscle was rather slow, but 
human and rat heart lost carnitine more rapidly. Carnitine content of muscular tissue was 
determined according to a modification of the method of McGarry & Foster (1976) for 
plasma. Acyl-camitines were hydrolyzed before carnitine assay. 
Hydrolysis : In a centrifuge tube 500 μΐ homogenate and 200 μΐ 0.4 M potassium hy­
droxide were mixed and incubated for 1 h at 37° С Next, 300 μΐ 0.6 M perchloric acid 
was added, and after standing for 10 min in ice, the tube was centrifuged. Then 500 jtil 
supernatant was transferred and neutralized in the presence of 25 μΐ phenolred (I % in 
ethanol) with a known volume of 2 M potassium hydroxide. After standing in ice for 30 
min, the tube was centrifuged and the supernatant was used for carnitine assay. 
Assay : The following solutions were transferred to a centrifuge tube : 100μ1 medium 
containing 400 mM Tris-HCl (pH 7.3), 2 mM sodium tetrathionate and4 mM EDTA, 50 μΐ 
0.2 mM acetyl-CoA, 50 μΐ [l-14C]acetyl-CoA (0.27 μπιοΐ/ιηΐ, Ιμα/ιηΐ) and 100 μΐ deprote-
inized and neutralized tissue extract. Incubation was started by addition of 25 μΐ camitine-
acetyltransferase (40 units/ml) and was performed for 20 min at 37° С The reaction was 
terminated by addition of 0.3 ml Dowex Xl-10(Cr)-solution (200400 mesh, 0.8 g dry 
weight/ 3 ml aq. bidest) and subsequent addition of 0.7 ml 120 mM Tris-HCl (pH 7.3). 
After vigorous mixing, the tubes were cooled in ice for 30 min, during which period they 
were mixed at 10 min intervals. Thereafter the tubes were centrifuged and radioactivity 
of 0.5 ml supernatant was determined with 10 ml Aquasol in a liquid scintillation counter. 
Blanks and standard amounts of L-camitine were simultaneously assayed. 
Results and discussion 
Sodium tetrathionate was prepared from sodium thiosulphate according to Schles-
singer (1962). It was stored in a desiccator in the dark. Its color had to be white. A com­
mercial, yellow preparation did not appear usable for the assay. The pH of the assay is 
critical. Higher values will favour hydrolysis of acetyl-CoA, whereas at lower pH values 
binding of acetyl-CoA to the Dowex resin will be incomplete, both leading to high blank 
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values. Since divalent cations might interfere with the activity of the acetyl-carnitine trans­
ferase (Bergmeyer, 1974), EDTA was added to the assay medium. Possible interference of 
Tris (Christiansen & Bremer, 1978) in the carnitine assay was eliminated by simultaneous­
ly assaying at a range of L-camitine concentrations. TTie assay of standards showed good 
linearity from 2.5 to 15 nmol L-camitine (higher amounts not tested); this linearity was 
not abolished by the presence of homogenate. 
Concentrations of carnitine in human and rat skeletal muscle, are given in Table 2.4. 
Carnitine values for adult human muscle are comparable to those reported by other au­
thors (Cederblad et al., 1974; Bank et al., 1975; Borum et al., 1977; Hart et al., 1978). 
Carnitine concentrations were about equal in different types of skeletal muscle of man. 
Cederblad et al. (1974) reported slight differences in the carnitine levels in rectus abdo­
minis muscle and leg muscle of man. Age and sex may also have an effect on muscle car­
nitine levels. Unfortunately, sex and age of control subjects were omitted from most of 
the published reports. Cederblad (1974) reported differences in the carnitine concentra­
tion of muscles of male and female subjects, but found no correlation between carnitine 
content and age. We could not establish age- or sex-related differences (Table 2.4). Only 3 
biopsies from children younger than 3 years showed a relatively low carnitine concentra­
tion. Borum et al. (1977) also reported low carnitine values in 2 children of 1 month and 
3 years old, but Ikeador & Lake (1978) found adult values in skeletal muscle biopsies 
from 3 children of 9 month to 1 year old. 
The low carnitine concentration in muscle of a patient with Duchenne dystrophy is 
due to leakage of the muscle cells, and was also found by Borum et al. (1977). As a conse­
quence the ability to oxidize fatty acids is markedly decreased in this disease. The carnitine 
concentration found in rat skeletal muscle is comparable to values reported previously 
(Broekhuysen et al., 1965; Marquis & Fritz, 1965; Pearson & Tubbs, 1967; Brooks & 
Mcintosh, 1975) and is only about one fourth of the concentration in human skeletal 
muscle. 
2.8. Protein determination 
Protein concentration in the homogenates and the mitochondrial suspensions was de­
termined according to Lowry et al. (1951) with bovine serum albumin as a standard. 
Ten μΐ samples (containing 25-100 μ% protein) are diluted to 400μΐ with 0.9 % sodium 
chloride and mixed with 2 ml of an alkaline copper reagent, consisting of 50 ml 2 % Ыа2СОз 
in 0.1 M NaOH and 1 ml 0.5 % CUSO4.5 H2O in 1 1 sodium citrate. After lOmin 200μΐ 
1 N Folin-Ciocalteu phenol reagent is added and mixed rapidly. After 30 min the optical 
density of the solution is measured at 750 nm in a Zeiss PMQ II spectrophotometer. 
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Table 2.4. Carnitine content of human and rat skeletal muscle. 
Sex Age Number of Mean ± SD Range Disease 
biopsies 
MAN 
(Controls) 
(Patients) 
RAT 
M. pectoralis 
M. abductor longus 
M. gluteus 
M. quadriceps 
M. quadriceps 
M. quadriceps 
M. quadriceps 
M. quadriceps 
M. soleus 
M. deltoideus 
M. quadriceps 
M. soleus 
M. quadriceps 
f 
m/f 
m/f 
m/f 
f 
m 
m 
m/f 
m 
m 
m 
m 
m 
31-79yr 
l l - 1 5 y r 
20 - 73 yr 
52-89yr 
8 days 
21 months-
2 years 
6-14yr 
14-89yr 
10-49yr 
13 yr 
2yr 
46 yr 
2-3 months 
(19) 
( 2 ) 
OD 
( 2 ) 
( О 
( 2) 
( 3 ) 
( 9 ) 
( 4 ) 
( i) 
( i) 
( О 
( 6 ) 
3.0 ±0.6 
2.5 ± 0.2 
2.8 ± 0.7 
2.5 ± 0.3 
1.25 
0.94-1.21 
2.6 ±1.1 
2.7 ± 0.7 
2.411.0 
1.64 
0.27 
4.29 
0.69 ± 0.22 
(2.1 
(2.4 
(2.0 
(2.1 
(1.4 
(1.5 
(1.0 
(0.4 
-3.9) 
•2.7) 
•3.8) 
•2.8) 
•3.5) 
•3.4) 
•3.2) 
•1.0) 
breast carcinoma 
orthopedic correction 
orthopedic correction 
accidental trauma 
non-ketonic hyperglycemia 
Leigh / unknown 
Neuromuscular disease without 
. evident involvement of carbohy­
drate or fat metabolism 
Duchenne dystrophy 
Dubin & Johnson hyperbiluribi-
nemia 
Healthy 
Carnitine concentrations of human and rat skeletal muscle were determined as described in 2.7. Concentrations are given in μιτιοί L-
<л carnitine per g fresh weight tissue. 
CHAPTER 3 
PALMITATE OXIDATION BY RAT SKELETAL MUSCLE MITOCHONDRIA 
COMPARISON OF POLAROGRAPHIC AND RADIOCHEMICAL EXPERIMENTS 
3.1. Introduction 
It is now generally accepted that fatty acids are quantitatively the most important 
substrate for oxidation in skeletal muscle in various metabolic states (Felig, 1976). Sever-
al studies on the oxidation of fatty acids in mitochondria or homogenates of skeletal 
muscle were performed by determining the production of 14C02 from 14C-labeled fatty 
acids (Lin et al., 1970; Kark et al., 1971; Rifenberick & Max, 1974; Mole et al., 1971 ; 
Baldwin et al., 1972). However, in none of these studies it is evaluated to what extent 
production of 14C02 reflects oxidation of fatty acids. Only Beatty et al. (1972) have re-
ported a difference between oxygen consumption during palmita te oxidation and ^ C 0 2 
production from [14C]palmitate in rhesus monkey muscle homogenates. 
Endogenous fatty acids may interfere in the assay of ^4C02 in homogenates by 
causing a decrease of the specific activity of the added [l4C]pa]mitate. Determination of 
14C02 production from [l4C]-labeled fatty acids would only reflect oxidation when the 
fatty acid is completely oxidized to CO2 and no label-dilution occurs during the oxida-
tion route. By means of polarography it was shown that the palmitate molecule is indeed 
totally degraded by rabbit muscle mitochondria (Pande, 1971). However, in Polarographie 
experiments only limited amounts of palmitate can be added for oxidation. Stanley & 
Tubbs (1975) observed that during oxidation of fatty acids in rat liver mitochondria ac-
cumulation of intermediates occurs, which are only oxidized after depletion of the ori-
ginal substrate. If non-limiting substrate concentrations are used, palmitate may be only 
partially degraded. Since many investigators prefer to use higher concentrations during 
fatty acid oxidation by homogenates in order to overcome label-dilution by endogenous 
fatty acids, determination of ^4C02 production from *4C-labeled fatty acids may lead to 
erroneous interpretations. 
In the present study we have compared oxygen consumption during palmitate oxi-
dation by rat muscle mitochondria with the production of ' 4C02 from 14C-labeled pal-
mitate. Since a large discrepancy was observed between the rates of palmitate oxidation 
calculated from Polarographie and radiochemical experiments, the fate of the [' C]-
atoms during the oxidation of [ 14C]palmitate was determined quantitatively. A more 
accurate determination of fatty acid oxidation was obtained by assaying simultaneously 
the production of 14C02 and perchloric acid-soluble products. 
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3.2. Materials and methods 
Male random bred albino Wistar rats (160 - 240 g) were used, one rat per experiment. 
After fasting for 18 - 24 h the rats were killed by decapitation. Musculi quadriceps femo-
ralis were isolated and handled as described in section 2.2. Mitochondria were prepared 
as described in section 2.3 and were concluded to be intact from their RCI values and 
ADP/O ratios (section 2.4). 
Palmitate oxidation was measured polarographically with a Clark oxygen electrode 
in a 1.25 ml cell at 370C. The output was recorded by a Kipp BD 5 micrograph. The 
medium contained 25 mM sucrose, 30 mM KCl, 75 mM Tris-HCl (pH 7.4), 10 mM pot­
assium phosphate, 5 mM MgC^, 1 mM EDTA, 5 mM ATP, 1 mM NAD+ , 25 μΜ cyto­
chrome c, 0.1 mM coenzyme A, 0.5 mM L-malate and 2 mM L-camitine. Palmitate bound 
to dialyzed, fatty acid-free albumin was used as a substrate. 
Oxidation of [14C]palmitate was assayed in the same medium using 0.2 mM L-cami­
tine and 120 μΜ [14C]palmitate complexed to dialyzed, fatty acid-free albumin (molar 
ratio 5:1). Specific activity usually was 1.5 дСі/дтоІ. Incubation was carried out in a 
final volume of 1.0 ml containing 150 - 200 μg mitochondrial protein. After 5-10 min 
preincubation at 370C the reaction was started by the addition of [14C]palmitate. The 
oxidation was stopped by adding 0.2 ml 3 M perchloric acid and followed by another 
incubation for 90 min. 1 4 C02 produced was bound to 0.2 ml ethanolamine-ethylene-
glycol (1:2, by vol). The acid incubation mixture was then centrifuged, and 400 μΐ was 
assayed for radioactivity by liquid scintillation counting in Aquasol. Radioactivity of 
'
4 C 0 2 was counted with 0.4% Omnifluorin toluene:methanol(2:l,by vol). 
Oxidation of malate was assayed in the same way as that of [^CJpalmitate, using 0.5 
mM L-[U-14C]malate (specific activity 0.15 μΠ/μπιοΙ) as substrate. After exactly 10 min 
preincubation in the presence of [U-'4C]malate, unlabeled palmitate complexed to albu­
min was added. 14C02 production was then linear for at least 30 min. Values obtained 
were corrected for 1 4 C02 production during the preincubation period. 
In parallel experiments perchloric acid-soluble products were determined after termi­
nation of the reaction by placing the vials in ice. An aliquot of 950 μΐ of the incubation 
mixture was immediately transferred to a centrifuge tube containing 475 μΐ 3 M per­
chloric acid. The tube was placed in ice for 10 -15 min to permit precipitation and evapo­
ration of ' 4 C 0 2 , whereupon it was centrifuged. The pellet was washed once with 0.1 M 
perchloric acid, after which it was hydrolyzed with 0.4 M potassium hydroxide at 370C 
and assayed for radioactivity to calculate overall recovery. Both supernatant fractions 
were collected and neutralized with potassium hydroxide, phenolred serving as indicator. 
After centrifugation part of the supernatant was evaporated to diyness with methanol. 
The residue was dissolved in a small volume of ethanol:water (1:1, by vol) prior to elec­
trophoresis. Electrophoresis was performed in acetic acid / formic acid / water (19:19: 
1000, by vol, pH 2.5) on Whatman 3 MM paper for 1 h at 45 V/cm. After autoradiograph­
ic detection of the labeled compounds, the spots were cut out and eluted with 5 ml 0.1 
M sodium hydroxide under vigorous shaking for 45 min. Radioactivity was measured with 
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10 ml Aquasol in a liquid scintillation counter. The identity of the labeled compounds 
was ascertained by thin-layer chromatography on cellulose in diethylether / formic acid / 
water (7:2:1, by vol). Recovery of the total extraction procedure was 91 ± 3%with 
[U-14C]palmitate and 100 ± 2% with [U-14C]malate. Recovery after electrophoresis and 
elutionwas98-100%. 
Protein and cytochrome с oxidase activity were determined as described in sections 
2.8 and 2.5, respectively. 
3 3 . Results 
3.3.1. Mitochondrial quality and metabolic state 
The isolated mitochondria show satisfactory respiratory control index values and P/O 
ratios (section 2.4). Respiratory control index values stayed constant for at least 2.5 h, 
when the mitochondria were kept cold. After 30 min at 370C the values decreased from 
5.0 to 3.1 with 2-oxoglutarate as substrate; after 60 min the mitochondria were totally 
uncoupled. Palmitate concentrations used in this study were too low to uncouple rat liver 
mitochondria (Lopes-Cardozo & Van den Bergh, 1972). Rat muscle mitochondria also ap­
peared to be coupled during oxidation of 100 μΜ palmitate in a medium similar to the 
one we used (Groot & Hülsmann, 1973). 
Although no ADP was added to the incubation system, there was a rapid generation 
of ADP from ATP upon incubation of the mitochondria. This resulted in a concentration 
of 0.7 - 1.1 mM ADP at the moment of palmitate addition. The ADP-level remained con-
stant during a ЗО-тіп incubation period. Therefore, all further experiments were started 
under state 3 conditions. As palmitoyl-CoA may inhibit the adenylate translocator (Pande 
& Blanchaer, 1971; Shug et al., 1971), the metabolic state may shift to between state 3 
and state 4 during palmitate oxidation. In our study such inhibition was only observed 
when high palmitoyl-CoA concentrations were used (see section 3.3.2). 
3.3.2. Polarographie determination of palmitate oxidation 
During oxidation of palmitate, oxygen consumption was linear with the concentra­
tion of mitochondrial protein, if at least 0.1 mg protein per ml was used. Since the palmi-
tate/albumin ratio affects fatty acid activation in heart homogenates (Oram et al., 1975) 
and production of acetyl-CoA in liver mitochondria (Lopes-Cardozo & Van den Bergh, 
1974), we have investigated its effect on the overall fatty acid oxidation process. With 
palmitate/albumin ratios ranging from 2 to 8 we observed identical rates of oxygen con­
sumption, indicating that reactions affected by this molar ratio are not rate-limiting for 
palmitate oxidation by rat skeletal muscle mitochondria. The rate of oxygen consump­
tion became linear with time within 1 - 3 min, when high concentrations of coenzyme A 
(25 - 100 μΜ) were used for palmitate activation. With 2 μΜ coenzyme A it took 5-10 
min before oxygen consumption became linear and identical to that obtained with higher 
coenzyme A concentrations. The lag period was considerably longer, when less than 0.1 
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Fig. 3.1. Substrate dependence of fatty acid oxidation by mitochondria of rat skeletal 
muscle. 
Oxygen consumption during palmitate oxidation was determined in the pres­
ence of 0.1 mM coenzyme A, 0.5 mM L-malate and 2 mM L-camitine, as de­
scribed in 3.2. Palmitate was complexed to albumin in a molar ratio 8:1 ( · - · ) 
or 5:1 (• - •). Other substrates were palmitoyl-L-camitine (o - o) and palmito-
yl-coenzyme A + 0.2 mM L-camitine (a - G). Data represent means of 4 - 8 ex­
periments. 
mg/ml mitochondrial protein was used. These observations suggest that the lag period was 
needed to reach a non-rate-limiting concentration of palmitoyl-CoA. After this lag period 
the rate of oxygen consumption with palmitate was identical with that of palmitoyl-CoA 
and palmitoyl-L-camitine at concentrations up to 30 μΜ (Fig. 3.1). At palmitoyl-CoA 
concentrations above 30 μΜ the oxidation rates strongly decreased. Addition of 50 μΜ 
palmitoyl-Co A also inhibited the oxidation of pyruvate (Fig. 3.2). Since this inhibition 
could be partly eliminated by addition of the uncoupling agent FCCP, palmitoyl-CoA ap­
peared to inhibit the adenylate transloca tor (Pande & Blanchaer, 1971). Inhibition was 
less at high concentrations of palmitate. 
At 120 μΜ palmitate the oxygen consumption was 10-15% less at palmitate/albumin 
ratios of 7 - 8, whereas no decrease was observed at molar ratios of 2 - 5, presumably 
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Fig.3.2. Inhibition of pyruvate oxidation by palmitoyl-coenzyme A. 
Oxygen consumption was determined as described in section 3.2 in a 1.25 ml 
cell containing 0.31 mg mitochondrial protein. Values below the graph repre­
sent oxygen consumption rates expressed as natom oxygen per min. 
Fig. 3.3. Effect of the presence of palmitate on pyruvate oxidation. 
Oxygen consumption was measured as described in section 3.2 in a cell con­
taining 0.41 mg mitochondrial protein. Palmitate was complexed to albumin in 
a molar ratio of 8:1. Values below the graph represent oxidation rates express­
ed as natom oxygen per min. 
since the concentration of free palmitate or palmitoyl-CoA was greatly diminished by the 
added albumin. Addition of 0.5 mM pyruvate or 2-oxoglutarate to mitochondria oxidizing 
120 μΜ palmitate (molar ratio palmitate/albumin 8:1) stimulated oxygen consumption 
to the rate, which was also observed when pyruvate or 2-oxoglutarate was oxidized with­
out palmitate (Fig. 3.3). From these observations it can be concluded that during oxida­
tion of 120 μΜ palmitate state 3 conditions were preserved and that the lower oxygen 
consumption by 120 μΜ palmitate (molar ratio 8:1) was not caused by inhibition of the 
adenylate translocator. The palmitate/albumin ratio only affected extramitochondrial 
processes. Therefore, the observed decrease of oxidation may reflect inhibition of carnitine 
palmitoyltransferase, which can be caused by a slightly elevated concentration of palmitoyl-
CoA (Wood et al., 1977), whereas higher palmitoyl-CoA concentrations also affect the 
adenylate translocator. The different effects of palmitoyl-CoA may be correlated with the 
differences in the ratio palmitoyl-CoA/protein. 
In order to obtain maximal palmitate oxidation L-c am itine and citric acid cycle inter­
mediates must be added (Lin et al., 1970). Using 10 and 120μΜ palmitate maximal rates 
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Effect of carnitine and malate on the oxidation of palmitate by mitochondria 
of rat skeletal muscle. 
Oxygen consumption was determined as described in section 3.2. Substrates 
were 10 μΜ palmitate (o - o) and 120 μΜ palmitate ( · - · ) both complexed to 
albumin in a molar ratio 8:1. The effect of L-camitine was studied in the pres­
ence of 0.5 mM L-malate; that of L-malate in the presence of 2 mM L-camiti­
ne. Values are the means of 4 experiments. 
of oxygen consumption were reached at 0.3 - 0.4 mM L-malate and at 0.1 - 0.2 mM L-
camitine (Fig. 3.4). Therefore, 0.5 mM L-malate and 2 mM L-camitine were usually ap­
plied. Under these conditions it was possible to determine the oxygen consumption per 
nmol added palmitate at low palmitate concentrations (2 - 4 μΜ). A value of 40 - 46 
natom oxygen per nmol palmitate was obtained (Fig. 3.5), indicating that palmitate was 
totally degraded to CO2. The oxidation rates of palmitate and palmitoyl-L-camitine ap­
peared to be equal, but lower than that of pyruvate. Oxidation rates under optimal con­
ditions were expressed with respect to mg protein and to the activity of the mitochondrial 
marker enzymes cytochrome oxidase and monoamine oxidase (Table 3.1). 
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mitochondria 
0.5 m M L-malate 
2 mM L-carnitine 
43.5> 
2.6 nmol palmitate 
18.6 
100 natom 
oxygen 
I 1 
2 min 
45.5\ 
13.7 
12 nmol palmitate 
I 
natom oxygen consumed 11Θ _ 
nmol palmitate consumed 2.6 
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Fig. 3.5. Relation between oxygen and palmitate consumption in rat muscle mitochon­
dria. 
Oxygen consumption was determined as described in section 3.2 in a 1.25 ml 
cell containing 0.31 mg mitochondrial protein. The values below the graph rep­
resent rates of oxygen consumption expressed in natom oxygen per min. 
Table 3.1. Oxidation rates of palmitate and pyruvate in relation to mitochondrial marker 
enzymes. 
Substrate Nr.of 
expts. (mg protein) 
Oxygen consumption 
(μτηοΐ cytochrome (jumol tryptami-
c min'lyl ne min'l)"! 
Palmitoyl-L-camitine 5 246 ± 53 44 ± 9 
Palmitate 10 228 ± 55 39 ± 9 
Pyruvate 5 361 ± 122 61 ±25 
0.49 ±0.12 
0.46 ±0.11 
0.75 ± 0.25 
Oxidation rates and enzyme activities in mitochondria of rat skeletal muscle were deter­
mined as described in section 3.2. Substrate concentrations were 10μΜ palmitoyl-L-car-
nitine, 10 μΜ palmitate complexed to albumin in a molar ratio 5:1 and 11 mM pyruvate. 
Oxygen consumption is expressed as natom oxygen per min. Values are the means with 
SD for the stated number of experiments. 
62 
nmolLcJ palmi tate oxidized 
to I c j labeled products 
min"1 · mg protein" 1 
-ι 1 Η 
1 0 2 0 
L-malate ( m M ) 
Fig. 3.6. Effect of L-malate on the oxidation of [14C]palmitate. 
Oxidation of [l-'^CJpalmitate and [U-^CJpalmitate, complexed to albumin in 
a molar ratio 5:1, was determined as described in section 3.2. The palmitate con­
centration was 120 μΜ. Symbols represent ^ C 0 2 production from [1-^CJpal-
mitate (* - *) and [U-14C]palmitate ( · - · ) , and the sum of 1 4 C02 and [ 1 4C]-
labeled perchloric acid-soluble products from [l-'4C]palmitate (Δ - Δ) and 
[U-14C]palmitate(o-o). 
3.3.3. Oxidation of [l^CJpalmitate 
The time course of ' 4 C 0 2 release during oxidation of [^CJpalmitate showed an 
initial lag period of about 5 min. Thereafter ^ С С ^ production was linear for at least 
25 min. Its subsequent decrease is presumably caused by deterioration of the mitochon­
dria. We calculated 14C02 production from [ ' 4C]palmitate from the linear part of the 
time course, usually from 10 to 30 min after addition of palmitate. Linearity between 
1 4 C02 production from [14C]palmitate and mitochondrial protein was observed when 
the system contained 0.12 - 0.60 mg protein per ml. 1 4 C02 production from [14C]palmi-
tate depends only slightly on the substrate concentration between 30 and 180 μΜ palmi­
tate (Table 3.2). With 180 μΜ palmitate , 4 C02 production showed a longer lag period, 
up to 20 min, than at lower concentrations. Such a prolonged lag period may be the re­
sult of an elevated palmitoyl-CoA concentration (Wood et al., 1977). Since at low palmi­
tate concentrations the ' 4 C 0 2 production is only linear for a short period of time due to 
substrate depletion, a concentration of 120 μΜ was used in further studies. 
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Table 3.2. [^C]palmitate oxidation by mitochondria of rat skeletal muscle. 
Palmitate concentration Oxidation rate 
(μΜ) [l-14C]palmitate [U-14C]palmitate 
30 1.4 ±0.3 0.5 ±0.2 
60 1.0 ±0.3 0.5 ±0.2 
90 1.0 ±0.3 0.5 ±0.1 
120 1.1+0.2 0.6 ±0.1 
180 0.8 ±0.2 0.4 + 0.3 
14C02 production from ['^CJpalmitate, complexed to albumin in a molar ratio of 5:1, 
was determined in the presence of 0.5 mM L-malate as described in section 3.2. Specific 
activity of [l-l4C]palmitate and [U-'^CJpalmitate was 0.5 дСі/ттоІ. Values are given 
as means with SD for 4 experiments and expressed as nmol [ l4C]palmitate oxidized to 
14C02 per min per mg protein. 
Though addition of malate is necessary for palmitate oxidation, a decrease in ^ C 0 2 
production was observed when concentrations of L-malate above 0.1 mM were used (Fig. 
3.6). Since the carbon atoms in [14C]acetyl-CoA, deriving from [14C]palmitate must go 
around the citric acid cycle at least once before they can be released as 1 4 C02, a notable 
exchange of labeled intermediates might occur with unlabeled malate. This was confirmed 
by determining the production of [14C]-labeled perchloric acid-soluble compounds from 
[l4C]-palmitate. Since long-chain acyl-CoA and acyl-camitine esters are insoluble in per­
chloric acid solution, all soluble [14C]-labeled products represent oxidation products of 
palmitate. The sum of ^4C02 and [l4C]-labeled perchloric acid-soluble products showed 
a simUar dependence on malate concentration as the oxygen consumption in Polarograph­
ie experiments (Fig. 3.6). 
1 4 C02 production from [l-14C]palmitate appeared to be twice as large as that from 
[U-14C]palmitate, when both substrates were used at equal specific activities (Table 3.2). 
This is in contrast to the observation of Mole et al. (1971) on rat muscle homogenates. 
However, since they used 750 μΜ palmitate, comparison is hardly possible. The differ­
ence in 1 4 C02 production could be attributed to a different label-dilution during the cit­
ric acid cycle, since the [1-14C]- and [2-14C]-carbon atoms of acetyl-CoA are processed 
differently in the citric acid cycle. One would still expect then that the sum of 1 4 C02 
and [14C]-labeled perchloric acid soluble products from [l-14C]palmitate and [U-14C]-
palmitate would be about equal. However, these totals differed even more than the rates 
of 1 4 C02 production. The higher value of the sum for [l-14C]pa]mitate is due in nearly 
equal amounts to increases in 1 4 C02 production and in [ ' 4C]-labeled perchloric acid-
soluble products. Thus it appears that the carboxyl-terminal carbon atoms of the palmi­
tate molecule were removed oxidatively in preference to the other carbon atoms and that 
intermediates of the ^-oxidation accumulated. Since the difference in oxidation products 
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from [l-^CJpalmitate and [U-14C]palimtate increased twofold when the concentration 
of L-camitine was increased from 0.2 to 2.0 mM, these intermediates may accumulate as 
camitine-esters. This accumulation was not due to leakage from the mitochondria, since 
these were morphologically and functionally intact. [l-14C]palmitate oxidation was not 
higher than [U-^C]palmitate oxidation after addition of disrupted mitochondria. Nei­
ther did addition of the 20 OOOxg supernatant, obtained from the homogenate, change the 
rates of oxidation of [l-14C]palmitate and [U-14C]palmitate by mitochondria. 
Evidence for a partial degradation of the palmitate molecule was also obtained from 
the comparison of the ' 4 C02 production with the oxygen consumption during palmitate 
oxidation. If palmitate was totally degraded, we would expect a production of 16 nmol 
CO2 during consumption of 46 natom oxygen. ^ 4C02 production from [^4C]palmitate 
will be affected through label-dilution by the added malate, but in case of total degrada­
tion of the palmitate molecule we would expect a production of ' 4 C02 from malate cor­
responding to this label-dilution. Therefore, ' 4 C 0 2 production was determined in parallel 
experiments containing [U-14C]palmitate plus unlabeled L-malate and unlabeled palmi­
tate plus L-[U-14C]malate. The total 1 4 C02 production from both combinations of sub­
strates amounted to 2.34 nmol 1 4 C02 per min per mg protein, while 190 natom oxygen 
per min per mg protein was consumed. The ratio between these values indicates that pal­
mitate was not totally degraded. This might be due in part to the accumulation of inter­
mediates during /3-oxidation. Furthermore, since 1 4 C02 production from L-[U-14C]-
malate represented only 77 ± 6 % (mean ± S.E.M., 8 experiments) of the [14C]-carbon 
in [14C]-labeled perchloric acid-soluble products accumulating from [U-14C]palmitate, 
incomplete oxidation must also occur after the production of acetyl-CoA from palmi­
tate. 
Incomplete oxidation during the citric acid cycle could be demonstrated by analysis 
of the [14C]-labeled perchloric acid-soluble products from [14C]palmitate (Table 3.3). 
Accumulation of succinate, malate and especially 2-oxoglutarate was observed. Fumarate, 
citrate and carnitine esters accumulated only to a minor degree, whereas no accumulation 
of /3-hydroxybutyrate and acetoacetate was observed. During palmitate oxidation most 
intramitochondrial coenzyme A is converted to acyl-CoA, hence accumulation of 2-oxo­
glutarate might occur by competition between /3-oxidation and the 2-oxoglutarate-dehy-
drogenase complex for coenzyme A. However, addition of 0.5 mM 2-oxoglutarate to 
mitochondria oxidizing 120 μΜ palmitate increased oxygen consumption from 200 to 
322 natom oxygen per min per mg protein. Therefore, the accumulation of 2-oxogluta­
rate was not caused by a rate-limiting effect of palmitate oxidation on the 2-oxoglutarate-
dehydrogenase complex. 
The short-chain acylcamitines were separated by thin-layer chromatography on Sili-
cagel G with chloroform/methanol/water/conc. ammonia/formic acid (55/50/10/7.5/2.5, 
by vol) as described by Solberg and Bremer (1970). With [16-14C]palmitate at least 5 
camitine-esters were observed. About 30 % of the radioactivity was found in acetyl-car­
nitine. The other camitine-esters represent various /3-oxidation intermediates of short-
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Table 3.3. [14C]-labeled oxidation products from [U-14C]palmitate. 
Compound natom 14C per mg protein 
Citrate 
2-Oxoglutarate 
Succinate 
Fumarate 
L-Malate 
Short-chain acyl carnitine esters 
CO2 
Perchloric acid-insoluble oxidation products 
8± 17 
448 ±149 
188± 46 
65+ 28 
204± 93 
96 ± 66 
217± 47 
442 ±138 
Oxidation of [U-l4C]palmitate by mitochondria of rat skeletal muscle took place in the 
presence of 0.5 mM L-malate, 0.2 mM L-carnitine and 0.1 mM coenzyme A as described 
in section 3.2. Oxidation was started by addition of 120μΜ [U-'4C]palmitate and termi­
nated after 30 min with perchloric acid. ['4C]-labeled perchloric acid-soluble products 
were analyzed by paper electrophoresis in acetic acid / formic acid / water (19:19:1000, 
by vol., pH 2.5) as described in section 3.2. The amount of ^C-labeled perchloric acid-
insoluble oxidation products was calculated from the difference in production of the sum 
of 1 4 C02 and 14C-labeled perchloric acid-soluble products from [1-14C]- and [U-14C]-
palmitate. Data represent the means with SD of 5 experiments. 
chain length. Analysis of perchloric-acid insoluble oxidation products showed formation 
of mainly camitine-esters of /3-oxidation intermediates, and to a minor extent coenzyme 
A esters. Also free acids were observed, which might have been formed by hydrolysis of 
these intermediates during the incubation. Preliminary experiments demonstrated a dis­
tribution of radioactivity over compounds of various chain length (cf. section 4.3). 
3.4. Discussion 
In this study the rate of fatty acid oxidation by rat skeletal muscle was determined 
both polarographically and radiochemically. The mitochondria were shown to be func­
tionally intact, and it was indicated that all experiments were performed under state 3 
conditions, except those in which high palmitoyl-CoA concentrations were used. The 
minimal concentrations of palmitate, palmitoyl-CoA or palmitoyl-L-camitine, which give 
maximal oxidation rate, closely agree with those obtained for palmitoyl-CoA with rabbit 
skeletal muscle mitochondria (Pande, 1971) and for palmitate with human skeletal mus­
cle mitochondria (section 5.3). So, it appears that muscle mitochondria of various ver­
tebrate species oxidize palmitate maximally at the same minimal substrate concentra­
tions. 
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From Polarographie experiments it can be concluded how many atoms oxygen are 
consumed per molecule fatty acid. Since a limited amount of oxygen can be consumed 
during such experiments, only low palmitate concentrations can be used. Pande (1971) 
showed that 43.2 atoms oxygen are consumed per molecule palmitoyl-ester by rabbit 
skeletal muscle mitochondria. These mitochondria were prepared by Nagarse treatment, 
during which the palmitate activiting system is lost (Pande & Blanchaer, 1970). With 
functionally intact mitochondria of rat skeletal muscle we also found a consumption of 
40 - 46 atoms oxygen per molecule palmitate. In radiochemical experiments the palmitate 
concentrations required for measuring the oxidation rate are higher than those used in 
Polarographie experiments. In such experiments partial degradation of the palmitate 
molecule was observed, due to accumulation of inteimediates. Such accumulation may 
occur at three stages of the fatty acid oxidation route: (1) formation of ^-oxidation inter­
mediates, (2) conversion of the final products of 0-oxidation into ketone bodies or acetyl-
carnitine, (3) accumulation of intermediates during the citric acid cycle. 
The increased formation of 1 4 C02 and 14C-labeled perchloric acid-soluble products 
from [l-14C]palmitate, compared to that from [U-l4C]-palmitate, indicates that accumu­
lation of intermediates occurs during /3-oxidation. Palmitate oxidation strongly decreases 
the intramitochondrial coenzyme A concentrations (Hansford & Johnson, 1975; Hans­
ford, 1977). This may lead to partial conversion of coenzyme A ester intermediates from 
|8-oxidation into camitine-esters, which may be transported out of the mitochondrion. 
The involvement of camitine-esters was recently demonstrated in rat liver mitochondria, 
which oxidized palmitate in state 4 in the presence of fluorocitrate, but not in state 3 
(Lopes-Cardozo et al., 1978). In our study carnitine-esters appeared also to be produced 
during state 3 oxidation in muscle mitochondria. Stanley & Tubbs (1975) observed only a 
slight accumulation of saturated coenzyme-Α intermediates of ß-oxidation during state 3 
oxidation of palmitate. The accumulation of/3-oxidation intermediates observed in this 
study was much larger. The involvement of camitine-esters might be of special interest for 
muscle tissue, in which the physiological carnitine concentration is much higher than in 
other tissues (Brooks & Mcintosh, 1975). Since the accumulated intermediates were not 
further oxidized until the original substrate was depleted (Stanley & Tubbs, 1975), it 
would be of interest to know whether these carnitine inteimediates are only formed to re-
lease part of the intramitochondrial coenzyme A pool needed for continuation of the ox-
idation, or whether they also play a role in regulation. 
Formation of ketone bodies was not observed. This would have been expected, since 
during state 3 conditions the citric acid cycle has a higher capacity than the ß-oxidation in 
muscle (Pande, 1971; Hansford & Johnson, 1975). Accumulation of acetyl-carnitine will 
therefore also be small. During passage of the citric acid cycle several intermediates accu-
mulate, especially 2-oxogIutarate. Accumulation of citrate, which was reported to occur 
as a major component during palmitate oxidation by rat liver mitochondria (LaNoue et 
al., 1973), was sUght in skeletal muscle mitochondria, presumably since these mitochondria 
lack a citrate-transporting system (De Haan et al., 1973). Since malate is added during 
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palmitate oxidation, the malate/2-oxoglutarate exchange may shortcircuit the citric acid 
cycle, by which 2-oxoglutarate accumulates. The driving force for the exchange might be 
the high malate level outside the mitochondrion (La Noue et al., 1973) and/or a decreased 
activity of the 2-oxoglutarate dehydrogenase complex. Since no inhibition of 2-oxogluta­
rate oxidation by palmitate was observed, accumulation of 2-oxoglutarate must primarily 
occur by dicarboxylate exchange, due to the high malate gradient across the mitochon­
drial membrane. 
Accumulation of intermediates during oxidation of ['4C]-labeled fatty acids causes a 
severe underestimation of fatty acid oxidation, when this is calculated from ^ С С ^ prod­
uction alone. Since Polarographie determination of fatty acid oxidation is restricted to 
mitochondrial preparations, the assay of ^ CO2 production from labeled fatty acids is 
commonly used for homogenates and tissue preparations of muscle. Determination of the 
sum of ''*C02 production and ['4C]-labeled perchloric acid-soluble products is however 
a more accurate and sensitive method for assay of ^-oxidation activity. This method will 
be valuable when the fatty acid oxidation capacity of different types of muscle is com­
pared and in the diagnosis of disorders of fatty acid metabolism of human skeletal muscle. 
3.5. Summary 
Oxidation of palmitate by rat skeletal muscle mitochondria was determined polaro-
graphically and radiochemically under state 3 conditions. Maximal oxidation rate is reach­
ed at 4 μΜ palmitate, palmitoyl-CoA or paJmitoyl-L-camitine. At palmitoyl-CoA concen­
trations higher than 30 μΜ oxidation is inhibited. 
At limiting substrate concentrations, as used in Polarographie experiments palmitate 
is totally degraded to CO2. At higher concentrations the palmitate molecule is only par­
tially degraded, due to the accumulation of intermediates. 
Citric cycle intermediates, especially 2-oxoglutarate, accumulate during oxidation of 
palmitate in the presence of malate. It is suggested that this accumulation is stimulated by 
dicarboxylate exchange. 
The rate of formation of l 4 C02 a n ^ [^C]4abeled perchloric acid-soluble products 
from [l-14C]pa]mitate is higher than that from [U-14C]palmitate. This difference, which 
is enhanced by higher carnitine concentrations indicates incomplete oxidation during the 
0-oxidation in state 3. 
The simultaneous determination of ' 4 C 0 2 production and [ ' 4C]-labeled perchloric 
acid-soluble products appears to be a more accurate and sensitive method for measuring 
[l4C]fatty acid oxidation than that of ^4C02 production alone. 
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CHAPTER 4 
ACCUMULATION OF B-OXIDATION INTERMEDIATES DURING PALMITATE 
OXIDATION BY RAT SKELETAL MUSCLE MITOCHONDRIA 
4.1. Introduction 
During palmitate oxidation by rat skeletal muscle there is accumulation of acid-solu-
ble products, mainly citric acid cycle intermediates (section 3.3; cf. section 6.3). [1-14C]-
palmitate produces a larger amount of ^C-labeled acid-soluble products than [U-14C]-
palmitate, suggesting that incomplete oxidation of the palmitate molecule, and hence ac-
cumulation of /3-oxidation intermediates or related compounds occurs. Accumulation of 
/3-oxidation intermediates (coenzyme A esters) was demonstrated during palmitate ox-
idation by rat liver mitochondria (Stanley & Tubbs, 1974; 1975). Camitine-esters of these 
intermediates were observed after oxidation of palmitate with carnitine and fluorocitrate 
in the absence of ADP (Lopes-Cardozo et al., 1978). 
Since skeletal muscle contains a relatively high carnitine concentration, the accumu-
lation of camitine-esters of j3-oxidation intermediates may occur under physiological con-
ditions. Therefore, we investigated whether carnitine influenced the dependence of the 
formation of 14C02 and 14C-labeled acid-soluble products on the label-position of [14C]-
palmitate, but without the use of inhibitors. We excluded that this dependence was due 
to the composition of the incubation system. In addition we examined whether short-
chain acyl-camitines were formed, and to what extent the amount of radioactivity in the 
various fractions of the acid-insoluble material depended on the label-position of [ ' ^C]-
palmitate. Finally, we compared the production of 14C02 and 14C-labeled acid-soluble 
products from [^CJpalmitate, labeled at different positions for mitochondria of rat mus-
cle and liver. 
4.2. Materials and methods 
Male albino Wistar rats (180-240 g) were used, one rat per experiment. The animals 
had been fasted for 18 - 24 h before they were killed. Skeletal muscle mitochondria were 
prepared as described in section 2.3. Liver mitochondria were prepared in a similar way, 
but a solution of 0.25 M sucrose, 2 mM EDTA and 10 mM Tris-HCl (pH 7.4) was used for 
homogenization of the tissue and for washings and final suspension of the mitochondria. 
Oxidation rates of palmitate were usually measured in lOmM potassium phosphate, 
75 mM Tris-HCl (pH 7.4), 25 mM sucrose, 35 mM KCl, 1 mM EDTA and 5 mM MgC^ 
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(system 1), supplemented with 5 mM ATP, 1 mM NAD+ , 25 μΜ cytochrome с, 0.1 тМ 
coenzyme А, 0.5 mM L-malate and various concentrations of L-camitine (0.2 - 2 mM). In 
comparative studies two other systems were used. System 2 contained 72 mM KCl, 50 
mM MOPS (pH 7.4), 5 mM K2HPO4,1 mM EGTA and 5 mM MgC^. System 3 contained 
225 mM mannitol, 10 mM HEPES (pH 7.4), 1 mM EGTA and 7 mM potassium phosphate. 
Systems 2 and 3 were supplemented with equal concentrations of coenzymes and cofac-
tors as system 1. As substrate 120 μΜ [14C]palmitate, complexed to albumin in 5 : 1 
molar ratio, was used (spec. act. 1 - 3 μΟ/μπιοΙ). Further details of the assay of 1 4 C02 
and 14C-labeled acid-soluble products are given in section 3.2. 
Perchloric acid-insoluble products were extracted according to Bligh & Dyer (1959). 
The compounds in the chloroform phase were separated on silicagel G thin-layer plates, 
which were developed in two solvent systems (Lopes-Cardozo et al., 1978): (I) petroleum 
(b.p. 40 - 60oC) : diethylether : formic acid (60 : 40 : 2, by vol), and after drying the 
plates in (II) chloroform : methanol : 0.1 M sodium acetate (50 : 40 : 10). Neutral lipids 
were eluted and separated on a second silicagel G thin-layer plate in benzene : ethylacetate 
: diethylether : acetic acid (80 : 10 : 10 ; 0.7, by vol). 
Free fatty acids were extracted according to Dole (1960). Small amounts of phos­
pholipids were removed by treating the collected heptane phases with silicagel (Mallinck-
rodt, 1 g per 40 ml heptane). Fatty acids were methylated with borium trifluoride in 
methanol according to Morrison & Smith (1964). Methylated fatty acids were determined 
by gas chromatography on a 2 mm χ 183 cm column of 15% diethyleneglycol succinate 
on 60 - 80 mesh Gas-Chrom Ρ at 130° С 
Perchloric acid-soluble products were separated by electrophoresis at pH 2.5 as de­
scribed in section 3.2. The positively-charged material was eluted with 50 % (v/v) methanol 
and separated on silicagel G plates with methanol : chloroform : water : cone, ammonia : 
formic acid (55 : 50 : 10 : 7.5 : 2.5, by vol) (Solberg & Bremer, 1970). 
43. Results 
4.3.1. Effect of the incubation system 
The incubation system, in which palmitate oxidation was measured (cf. chapters 3, 5 
and 6), contains a large amount of Tris-buffer. Since the pK value of Tris (pK 8.1) is close 
to the pH value of the incubation medium (pH 7.4), the composition of the incubation 
sytem could possibly influence mitochondrial properties. Hence, we investigated whether 
the difference in formation of oxidation products from [1-14C]- and [U-14C]palmitate 
(cf. section 3.3) was due to the composition of the incubation system, or that it generally 
occurs with skeletal muscle mitochondria. Two different mitochondrial preparations of 
identical muscles of one rat were used. One batch was prepared as in previous experi­
ments (section 2.3). The second batch was made in a similar way, except that homogen-
ization, washings and final suspension were performed in 220 mM mannitol, 70 mM su­
crose and 5 mM MOPS (pH 7.4), a buffer system used by several other investigators 
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Fig. 4.1. Effect of incubation medium and preparation of the muscle mitochondria on the 
oxidation of [ 1 4C]palmitate, labeled at different positions. 
Production of ^ C 0 2 (open) and '^C-labeled perchloric acid-soluble products 
(dashed) from [14c]palmitate, labeled at different positions, was measured in 
three different media and with two mitochondrial preparations from one rat. 
Mitochondria were prepared as described in section 4.2. and indicated with 
roman numerals. I, mitochondria as used in other experiments; II, mitochondria 
prepared in mannitol-sucrose-MOPS-buffer. Arabic numerals at the top refer to 
the various incubation media, which are described in section 4.2. Oxidation rates 
are expressed in nmol [ ^C]palmitate oxidized to ^ C 0 2 and ^C-labeled acid-
soluble products per min per mg protein. Data represent the means of two expe­
riments. 
(Palmer et al., 1978; Idell-Wenger et al., 1978). 
Palmitate oxidation rates were measured in three different incubation systems. These 
media contained equal amounts of coenzymes and cofactors, but the buffer and the main 
osmotically active compounds were varied. System 1 was the same as in previous studies 
(chapter 3). The other systems, given in section 4.2, were used for studies of fatty acid 
oxidation by several other investigators (e.g. Tomec & Hoppel, 1975; Bremer & Osmund-
sen, 1978). The production of ' ^ C 0 2 and ^C-labeled perchloric acid-soluble products 
from [1- 1 4 C]-, [U- ' 4 C]- and [16-1 4C]palmitate under these various conditions are given 
in Fig 4.1. Although there are differences in the relative proportion, which is represented 
by ' ^ € 0 2 , and small variances in the oxidation rates, the general pattern of product 
formation is similar under all these conditions. Product formation from [l-14C]palmitate 
exceeds that from [U-14C]palmitate by 9 - 48 ^ , that from [U-14C]palmitate is 35 - 64 % 
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Fig. 4.2. Effect of carnitine on product formation from [ ' 4C]palniitate labeled at differ­
ent positions. Production of 14(Γθ2 and l4C-labeled perchloric acid-soluble 
products was measured as described in section 4.2. · - · [l-14c]palimtate;o - о 
[U-14c]palmitate ; A - A [ 16-14c]palmitate. 
Mgher than that from [16-14C]palmitate. Therefore, it can be concluded that the de­
pendence of oxidation products from [14C]palmitate on the label position is not only re­
lated to the preparation or the incubation system of the mitochondria. 
43.2. Involvement of carnitine 
Without addition of carnitine, palmitate is only slowly oxidized by rat skeletal mus­
cle mitochondria. Addition of 0.2 mM L-camitine stimulates the formation of labeled 
products from [l-l4C]palmitate to a larger extent than that from [U-14C]palmitate, which 
in tum gives more degradation products than [16-14C]palmitate (Fig 4.2). Addition of 
higher concentrations of carnitine did not change the ratio between product formation 
from [16-14C]- and [U-l4C]pa]mitate, but stimulated the product formation from 
[l-14C]palmitate relatively more. 
43.3. Comparison of the perchloric acid-insoluble fractions 
In order to investigate to what extent the amount of radioactivity in the 
various fractions of the acid-insoluble material depends on the label-position 
during [l4C]palmitate oxidation, the perchloric acid-insoluble material was extracted ac­
cording to Bligh & Dyer (1959) and separated by silicagel thin-layer chromatography. 
Free fatty acids represented 95 - 98%of the 14C-radioactivity of the neutral lipids, tri­
glycerides contained less than 2%. 
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Palmitoyl-camitme (Rp 0.50) runs between lecithin (Rp 0.58) and lysolecithin (Rp 
0.43) in the system used. Separation of carnitine esters and all phospholipids could not be 
obtained in several systems. Since part of the carnitine esters may represent acyl-camitines 
with a chain length of 8 - 14 carbon atoms and hydroxy acyl-camitines (Bremer & 
Wojtczak, 1972; Lopes-Cardozo et al., 1978), the carnitine esters may partly overlap the 
spot of lysolecithin. No radioactivity was detected in the lecithin fraction. Although 
mitochondria lack the capacity for de novo synthesis of the major phospholipids (Van 
den Bosch, 1974), exchange of acyl-moieties of phospholipids by de- and re-acylation 
cannot be completely excluded. A small amount of labeled lysolecithin may still be pres­
ent in the carnitine ester fraction. 
Acyl-CoA esters presumably accumulate at the interphase of the Bligh & Dyer two-
phase system. These very polar compounds represented 5-20% of the perchloric acid-in­
soluble material, but their composition was not further investigated. 
The radioactivity of the other perchloric acid-insoluble fractions was determined af­
ter oxidation of palmitate labeled at different positions. An inverse relationship towards 
label-position was observed in fatty acids and acylcamitines in comparison to that in 
^ С С ^ and 14C-labeled acid-soluble products (Table 4.1). When 0.2 mM L-camitine was 
used, fatty acids represented 60 - 80 % of the 14C-labeled perchloric acid-insoluble mate­
rial. With 2 mM L-camitine they amounted to 30 - 40 % , and carnitine esters to 50 - 65 % 
of the radioactivity. With 0.2 mM L-camitine the dependence on the label-position of the 
added palmitate could only be established in the oxidation products and the fatty acids. 
At the higher carnitine concentration (2 mM) the ratio between oxidation products from 
[1-14C]- and [U-14C]pa]mitate was relatively larger than at low carnitine concentration 
(0.2 mM) (cf. Fig. 4.2). 
Gas chromatographic analysis of the free fatty acids, extracted according to Dole 
(1960) before and after oxidation of unlabeled palmitate by rat skeletal muscle mito­
chondria, showed a clear but variable increase of the saturated fatty acids with a chain 
length of 8 - 14 carbon atoms. In a representative experiment with 0.5 mM L-camitine 
the increase of saturated С ¡4-, Cj2- and CjQ-fatty acids after a 30 min-period of palmi-
tate oxidation (120 nmol palmitate degraded per mg protein) amounted to 18, 5.5 and 
1.1 nmol per mg protein, respectivily. Studies with the more sensitive radio-gas-chromato-
graphy and with [14C]palmitate molecules labeled in various other positions are necessary 
for a proper quantification of the conversion of palmitate to ß-oxidation intermediates. 
4.3.4. Short-chain acyl intermediates of/3-oxidation 
During oxidation of [ 14C]pa]mitate by rat skeletal muscle mitochondria several la-
beled acid-soluble compounds accumulated. Some of these appeared to be positively 
charged at pH 2.5, judging from their electrophoretic behavior (cf. section 3.3). These 
compounds could be clearly demonstrated with 2.0 mM carnitine, whereas only a small 
amount of acetyl-carnitine was observed with 0.2 mM carnitine. Fig. 4.3 shows a thin-
layer chromatogram of these compounds from a representative experiment, in which 
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Table 4 .1 . Effect of label-position of [14C]palmitate on the distribution of radioactivity. 
Carnitine Fraction 
concentr. 
0.2 mM Oxidation products 
Fatty acids (Dole) 
Fatty acids (Bligh 
& Dyer) 
Acyl-camitines 
2.0 mM Oxidation products 
Fatty acids (Dole) 
Fatty acids (Bligh 
& Dyer) 
Acyl-camitines 
Number 
of expts. 
4 
3 
2 
2 
4 
2 
4 
4 
Ratio in amount of radioactivity 
[1-14C]/[16-14C] 
1.80 ±0.15 
0.72 ± 0.08 
0.85 ± 0.05 
1.10±0.15 
2.29 ± 0.24 
0.71 ±0.03 
0.77 ± 0.09 
0.88 ± 0.03 
[U-14C]/[16-14C] 
1.41 ±0.25 
0.74 ± 0.07 
0.78 ± 0.01 
1.08 ±0.25 
1.49 ±0.11 
0.79 ± 0.09 
0.75 ±0.07 
0.90 ± 0.05 
Rat skeletal muscle mitochondria (0.15 - 0.33 mg protein/ml) were incubated with [' C]-
palmitate for 30 min as described in section 4.2. [ l - ^ C ] - , [U-14C]- and [16-1 ^ p a l m i -
tate with indentical specific activities were used. After incubation the fatty acids were ex-
tracted by the method of Dole (see section 4.2). In parallel incubations oxidation was 
terminated by addition of perchloric acid (final concentration 1 M). Oxidation products 
represent the sum of ^ 4C02 and l4C-labeled perchloric acid-soluble products, deter-
mined as described in section 4.2 and 3.2. The perchloric acid-soluble compounds were 
washed once with 0.1 M perchloric acid, after which they were extracted according to 
Bligh & Dyer and separated on silicagel thin-layer plates (section 4.2). The results are 
given as the ratio of the radioactivities found in each fraction after oxidation of palmitate 
labeled at different positions. Values represent the means with SD for the number of 
experiments indicated 
[1-14C]-, [U-14C]- and [16-l4C]palmitate oxidation had occurred in the presence of 2.0 
mM L-camitine. With [l-14C]palmitate only acetyl-carnitine was observed. With [U-14C]-
and [16-l4C]palmitate 3 or 4 additional radioactive spots were found, which represent 
camitine-esters with varying chain length, and are probably short-chain intermediates of 
0-oxidation. Acyl-camitines with more than 6 carbon atoms have nearly equal Rp values 
in the chromatographic system used (cf. Seim & Strack, 1977). Palmitoyl-camitine can-
not be present in the labeled spot with the highest Rp value, since palmitoyl-camitine is 
insoluble in perchloric acid, and no labeled spots except acetyl-carnitine were found with 
[l-14C]palmitate. 
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Fig. 4.3. Thin-layer chromatogram of perchloric acid-soluble camitine-esters formed 
during palmitate oxidation by rat skeletal muscle mitochondria. 
Perchloric acid-soluble products were extracted after 30 min oxidation of [' C]-
palmitate, labeled at different positions, in the presence of 2 mM L-camitine. 
Incubation of mitochondria occurred in system 1 described in section 4.2. After 
electrophoresis at pH 2.5, positively charged compounds were eluted and sepa­
rated on silicagel G thin-layer plates with methanol : chloroform : water : cone. 
ammonia : formic acid (55:50:10:7.5:2.5, by vol). The spots were tentatively 
identified as carnitine esters. The amount of radioactivity (in dpm) present in 
the spots is indicated. 
4.3.5. Comparison of the effect of label-position on ['^ CJpalmitate degradation by liver 
and skeletal muscle mitochondria 
In order to compare our results with those of Stanley & Tubbs (1974, 1975) and 
Lopes-Cardozo et al. (1978) on rat liver mitochondria, we determined the rate of product 
formation from ['^CJpalmitate, labeled át different positions by rat skeletal muscle and 
liver mitochondria, without inhibitors present. 
Under our assay conditions liver mitochondria showed maximal rates of oxygen con-
sumption during palmitate oxidation. Determination of the ADP concentration in the 
incubation medium during oxidation revealed that a constant level of ADP (about 1 mM) 
was formed, presumably mainly by the action of damaged mitochondria. Therefore, the 
metabolic state under which liver and skeletal muscle mitochondria (cf. section 3.3.1) 
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Table 4.2. Effect of label-position on the formation of labeled products from [14C]palmi-
tate. 
Number Ratio products fonned from [l4C1palmitate 
of expts. [1-14C]/[U-14C] [16-14C]/[U-14C] 
measured measured expected expected vs. 
measured 
Liver 6 1.31 ±0.21 0.87 ±0.09 0.94 ±0.04 0 . 1 < P < 0 . 2 
Skeletal muscle 7 1.44 ± 0.16 0.76 ± 0.08 0.91 ± 0.03 0.001 < Ρ < 
0.002 
Liver vs. muscle 0.2 < Ρ 0.02 < Ρ < 
0.05 
The production of 1 4 C02 and 14C-labeled acid-soluble products from [,4C]palniitate 
was determined in system 1 with 2 mM L-camitine, as described in section 4.2. Ratios of 
products fonned with palmitate labeled in different positions are given. On the basis of 
the ratio of the products formed from [1-14C]- and [U-^CJpalmitate, the ratio expected 
for the products fonned from [16-14C]- and [U-^Cjpalmitate, when only Cj^interme-
diates would be formed, was calculated. By means of Student's t-test we checked whether 
the measured and expected ratios were equal, and whether the effects of label-position 
were similar in liver and skeletal muscle. 
oxidized palmitate appeared to be comparable with an ADP/ATP ratio of about 0.25. 
When the rates of product formation from [ l4C]palmitate labeled at different posi­
tions were compared, the ratio of the products formed from [1-14C]- and [U-14C]palmi-
tate was nearly equal, but that for [16- 1 4 C]- and [U-14C]palmitate was markedly less for 
skeletal muscle than for liver mitochondria (Table 4.2). This was not due to a difference 
in amount of protein present during oxidation with skeletal muscle (0.15 - 0.33 mg pro­
tein per ml) and liver mitochondria (0.30 - 0.65 mg protein per ml), since three- and 
sixfold dilution of the suspension of liver mitochondria did not decrease the ratio be­
tween the products formed from [16-14C]- and [U-14C]palmitate (data not shown). The 
nearly equal ratio between labeled products from [1-14C]- and [U-14C]palmitate suggests 
that the accumulation of Cj4 intermediates is similar in mitochondria of both tissues. 
From the ratio between the products fonned from [1-14C]- and [U-14C]palmitate it 
could be calculated that the ratio between products from [16-14C]- and [U-14C]palinitate 
would be 0.94 and 0.91 with liver and skeletal muscle mitochondria, if only C ^ inter­
mediates would accumulate. The difference between the measured and the expected ratio 
between labeled products from [16-14C]- and [U-14C]palmitate suggests that the accumu­
lation of Cg -C¡2intermediates may be more prominent with skeletal muscle than with 
liver mitochondria. 
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4.4. Discussion 
The observed differences in formation of 14C02 and ' 4C-labeled acid-soluble prod-
ucts from [1-14C]-, [U-14C]- and [16-14C]palmitate can be explained by two different 
mechanisms. The difference may be caused by futile cycling, such as is known in glucose 
metabolism (Katz & Rognstad, 1978). Although the /J-oxidation enzymes have the capac-
ity for chain elongation (Whereat, 1971) it does not seem probable that part of the en-
zymes of ^-oxidation are involved in chain shortening, whereas another part would be in-
volved in chain elongation. 
The dependence of the formation of 14C02 and 14C-labeled acid-soluble products 
on the label-position is more probably caused by the escape of intermediates from the 
postulated multienzyme complex of ^-oxidation enzymes. After a 30-min incubation 
period the difference in these products between [l-'4C]-and [16-^4C]palmitate amounts 
to 30 - 60 nmol per mg protein with rat skeletal muscle mitochondria. Only 2.3 nmol 
coenzyme A and 2.1 nmol carnitine per mg protein are present in heart mitochondria 
(Idell-Wenger et al., 1978). Therefore, the resulting intermediates are probably transport-
ed out of the mitochondrion as carnitine esters, since neither acyl-CoA nor fatty acids can 
penetrate the mitochondrial inner membrane. 
The occurrence of camitine-esters of ß-oxidation intermediates was demonstrated 
during palmitate oxidation by rat liver mitochondria in the presence of fluorocitrate 
(Lopes-Cardozo et al., 1978). Our observation that the amount of [ '4C]acyl-camitines 
was higher with [16-'4C]palmitate than with [U-'4C]palmitate and [l-^4C]palmitate in-
dicates the involvement of carnitine esters in muscle. Lopes-Cardozo et al. (1978) suggest-
ed that long chain intermediates (coenzyme A esters) penetrating with their hydrocarbon 
tail into the lipid bilayer of the mitochondrial membrane during passage through the 0-
oxidation pathway, would escape by lateral diffusion in the plane of the mitochondrial 
membrane. Within skeletal muscle mitochondria these intermediates could be converted 
into carnitine esters, after which they could leave the mitochondrion by exchange with 
carnitine (cf. section 1.2.2). 
Since outside the mitochondrion coenzyme A and carnitine esters are in equilibrium 
through the action of carnitine palmitoyl transferase I, the accumulation of carnitine 
esters depends on the ratio between coenzyme A and carnitine (cf. Oram et al., 1975; 
Idell-Wenger et al., 1978). At 2 mM carnitine carnitine esters represented a large fraction 
of the intermediates, but at low carnitine concentration (0.2 mM) the dependence of the 
14C-labeled acid-insoluble products on the label-position in [14C]palmitate could only be 
established in the free fatty acids. The camitine-esters, which are converted to coenzyme 
A esters, are probably rapidly hydrolyzed in our system (Fig 4.4). Indications for the oc-
currence of ß-oxidation intermediates were also obtained with human skeletal muscle (cf. 
section 5.3) and with heart muscle of man and rat (cf. section 6.3). Since the cytoplasm 
of muscle contains a large amount of carnitine and little coenzyme A (Idell-Wenger et al., 
1978), carnitine intermediates may be of physiological importance. 
Accumulation of intermediates was observed in skeletal muscle and liver mitochon-
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Fig. 4.4. Accumulation of /3-oxidation intermediates during palmitate oxidation by rat 
skeletal muscle mitochondria. 
dna at maximal rates of palmitate oxidation under our experimental conditions. Al­
though the Cj4 intermediates dominate in mitochondria of both tissues, the amount of 
saturated Cg - С j 2 intermediates was larger for skeletal than for liver mitochondria. Main­
ly Сj4 and Cj2 intermediates were observed during palmitate oxidation by liver mito­
chondria in the absence of ADP (Lopes-Cardozo et al., 1978) These authors found an 
equal degradation of [1-14C]- and [U-14C]palmitate at maximal oxidation rates, suggest­
ing that no intermediates are produced. However, they used a 10 - 20 times higher con­
centration of mitochondrial protein in their incubations than we did in our experiments. 
Since the accumulation of/3-oxidation intermediates in liver mitochondria depends on the 
amount of mitochondria in the incubation system (Stanley & Tubbs, 1975), the occur­
rence of intermediates might be more pronounced in our studies. 
It was recently demonstrated that peroxisomes have an active /3-oxidation system 
(Lazarow & DeDuve, 1976). This system has a maximal capacity towards acyl-CoA esters 
with a chain length of 12 to 18 carbon atoms and little or no activity towards C5 and C4 
acyl-CoA esters (Osumi & Hashimoto, 1978). The presence of a short-chain carnitine acyl 
transferase in peroxisomes (Markwell et al., 1973, 1976) has led to the suggestion that 
fatty acids can be degraded by the peroxisomes to C4- and Cg-residues, whereafter they 
can be further oxidized in the mitochondrion (cf. Bremer, 1978). Therefore, it might be 
argued that (3-oxidation intermediates in liver mitochondrial preparations are not released 
from mitochondria, but from peroxisomes. Peroxisomes were demonstrated in many 
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tissues (Masters & Holmes, 1977), including heart, tongue and diaphragm muscle of rat 
(Hand, 1974). Since unstained muscle peroxisomes are indistinguishable from dilated cis-
temae of the sarcoplasmic reticulum, they may contaminate our mitochondrial prepara-
tion. However, it seems unlikely that the large discrepancy observed between formation 
of 14C02 and 14C-labeled acid-soluble products from [1-14C]- and [16-14C]palmitate 
with our mitochondrial preparation (fraction 600-7000xg) would only be caused by 
peroxisomal ß-oxidation. 
4.5. Summary 
Production of 14C02 and l4C-labeled acid-soluble products by rat skeletal muscle 
mitochondria depended on the label-position in [14C]palmitate. At maximal rate of pal-
mitate oxidation the total amount of ^4C02 and '4C-labeled acid-soluble products from 
[1-14C]- and [16-14C]palmitate were 144 and 77 Ζ , respectively, ofthat from [U-14C]-
palmitate, indicating accumulation of/3-oxidation intermediates. This accumulation was 
not related to the composition of the incubation system. 
Analysis of the labeled perchloric acid-insoluble material obtained after incubation 
with [14C]palmitate labeled at different positions showed that /3-oxidation intermediates 
were mainly present as free fatty acids and carnitine-esters. Gas-chromatographic separa­
tion of the free fatty acids showed the formation of saturated Cg - C J 4 fatty acids. When 
2.0 mM L-camitine was used, short-chain acyl-camitines could be identified. 
Muscle and liver mitochondria of the rat formed a similar amount of intermediates 
with a chain length of 14 carbon atoms, but the accumulation of Cg - Cj2 intermediates 
was larger for muscle mitochondria. 
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CHAPTERS 
OXIDATION OF LONG-CHADM-FAITY ACIDS BY HUMAN SKELETAL MUSCLE 
5.1. Introduction 
Fatty acids are an important fuel for human type I muscle fibers and heart, especially 
during starvation and exercise (Felig, 1976; Neely & Morgan, 1974; Angelini, 1976). In 
recent years several defects in the metabolism of fatty acids associated with muscular 
diseases have been reported (Engel & Angelini, 1973; DiMauro & DiMauro, 1973). For 
biochemical studies in lipid myopathies a sensitive assay for the fatty acid oxidation route 
is needed. Since it is difficult to obtain enough mitochondria from human muscle biopsies 
for Polarographie studies, estimation of the conversion of [14C]fatty acids to 1 4 C02 by 
homogenates is a common assay of fatty acid oxidation (Engel & Angelini, 1973; Bylund 
et al., 1975; Lin et al., 1970; Kark et al., 1971; Mole et al., 1971; Baldwin et al., 1972; 
Rifenberick & Max, 1974). However, the ' CO2 production expressed on the basis of 
non-collagen protein proved to be very variable (Kark et al., 1973). We tried to reduce 
this variability by expressing ^ C 0 2 production from [l4C]palmitate in relation to the 
activities of mitochondrial marker enzymes. During this investigation the rate of ' 4 C 0 2 
production by human skeletal muscle mitochondria did not appear to reflect oxygen 
consumption during palmitate oxidation. We have, therefore, devised a more sensitive and 
accurate assay of long-chain fatty acid oxidation. The results obtained with this radio­
chemical assay are in good agreement with those of Polarographie experiments. The 
variability of palmitate oxidation by human muscle preparations appeared to be rather 
small when oxidation rates were expressed relative to cytochrome с oxidase activity. 
5.2. Materials and methods 
Human striated muscle was obtained and handled as described in section 2.2. Homo­
genates (600xg supematants) and mitochondria were prepared as described in section 2.3. 
The mitochondria appear to be intact as judged by their RCI values and ADP/O ratios 
(section 2.4). 
Palmitate oxidation was measured polarographically with a Clark oxygen electrode in 
a 1.25 ml cell at 370C; the output was recorded by a Kipp BD 5 micrograph. The medium 
contained 25 mM sucrose, 30 mM KCl, 75 mM Tris-HCl (pH 7.4), 10 mM potassium phos­
phate, 5 mM MgCl2, 1 mM EDTA, 5 mM ATP, 1 mM NAD+ , 25 μΜ cytochrome c, 0.1 
mM coenzyme A, 0.5 mM L-malate and 2 mM L-camitine. Palmitate bound to dialyzed 
fatty acid-free albumin was used as substrate. 
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Oxidation of [14C]palmitate was assayed in the same medium containing 0.5 mM L-
camitineand the substrate complexed to dialyzed fatty acid-free albumin (molar ratio 
5:1). Except where otherwise indicated, [ 1 ^CJpalmitate concentration was 90 and 120μΜ 
for mitochondria and homogenate assays, respectively. Specific activity was 1.5 μΟί/μπιοΙ 
approximately. Incubation was carried out in a final volume of 1.0 ml containing 150 -
200 ¿ig mitochondrial protein or 200 jul homogenate. After 5 - 1 0 min preincubation at 
370C the reaction was started by the addition of [^CJpalmitate. The oxidation was 
stopped by adding 0.2 ml 3 M perchloric acid and followed by incubation for 75 min at 
0oC. 14C02 produced was trapped in 0.2 ml ethanolamine/ethyleneglycol(l/2, by vol). 
The acid incubation mixture was centrifuged, and 400 μΐ supernatant was assayed for 
radioactivity by liquid scintillation counting in 10 ml Aquasol. ' 4 C 0 2 was measured in 
0.4 % Omnifluor in toluene/methanol (2/1, by vol). 
Assays of protein, cytochrome с oxidase and monoamine oxidase are described in 
sections 2.8, 2.5 and 2.6, respectively. 
5.3. Results 
5.3.1. '¿*C02 production from [l-'^Jpalmitate 
In neuromuscular disease the mitochondrial content of muscle can vary considerably 
(DiMauro et al., 1974). Therefore, 14C02 production from [l-,4C]palmitate was express-
ed relative to protein content as well as to the activities of cytochrome с oxidase and mo­
noamine oxidase (Table 5.1). In control tissue, oxidation rates of palmitate by homogena-
tes of various types of muscle showed an equal relationship to protein and to these mito­
chondrial marker enzymes. In patients with neuromuscular disease the oxidation rates rel­
ative to protein and cytochrome с oxidase were about the same as in the control tissues, 
but the activity of monoamine oxidase was frequently reduced. Relative standard devi­
ations of the ^ CO2 production were equally large (30 - 50%) for the three parameters. 
In further investigations oxidation rates were expressed per unit cytochrome с oxidase 
or per mg protein. 
In human muscle homogenates as well as mitochondria 1 4 C02 production from 
[l-14C]palmitate appeared to be markedly dependent on palmitate concentration (Table 
5.2) and on the ratio between palmitate and albumin (Table 5.3). These observations are 
in contrast to those on mouse muscle homogenates (Lin et al., 1970) and on rat skeletal 
muscle homogenates and mitochondria (cf. section 3.3). In rat, ' 4 C 0 2 production was 
constant at palmitate concentrations from 30 to 120 μΜ and at palmitate/albumin ratios 
ranging from 2 to 8. 1 4 C02 production from [U-14C]palmitate was about half that from 
[l-14C]palmitate in human skeletal muscle preparations (data not shown), as also was ob­
served in rat muscle homogenates and mitochondria (Brownell & Engel, 1978; section 
3.3). 
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Table 5.1. 1 4 C02 production from [l-14C]palmitate by human muscle homogenates. 
'
4 C 0 2 production in nmol.min"1 
mg protein 1 (Mmol cyt.c. 
mm"l)"l 
(Mmol tryptamine. 
min"l)*l 
M. pectoralis 
M. gluteus 
Heart 
0.026 ±0.011 (15) 0.48 ±0.19 (16) 0.83 ± 0.35 (6) 
0.035 ±0.023 (17) 0.44 ±0.23 (17) 0.84 ±0.41 (5) 
0.214 ± 0.064 ( 4) 0.53 ± 0.13 ( 4) 0.90 ± 0.35 (4) 
Neuromuscular 
patients 
M. quadriceps 0.047 ± 0.030 ( 5) 0.48 ± 0.20 ( 5) 1.38 ±0.93(3) 
Duchenne dystrophy 
M. quadriceps 0.031 0.57 4.49 
14C02 production from [l-l4C]palmitate by homogenates of m. pectoralis (breast carci­
noma patients), m. gluteus (orthopedic patients) and heart muscle (tetraplegia of Fallot) 
was determined as described in section 5.2 in the presence of 0.5 mM L-malate, 0.5 mM 
L-camitine, 0.1 mM coenzyme A and 5 mM ATP. Palmitate (120μΜ) was complexed to 
albumin in 8:1 molar ratio. Values represent means with SD for the number of experi­
ments indicated between parentheses. 
Table 5.2. Concentration dependence of ' 4 C 0 2 production from [l-14C]palmitate by 
homogenates and mitochondria of human skeletal muscle. 
Palmitate 
concentration 
30 
60 
90 
120 
180 
(MM) 
Mitochondria 
M. pectoralis 
0.20 ± 0.05 
0.40 ± 0.04 
0.53 ±0.16 
0.48 ± 0.08 
-
Homogenates 
M. pectoralis 
— 
0.24 ± 0.06 
0.40 ±0.11 
0.67 ±0.26 
0.53 ± 0.30 
M. gluteus 
— 
0.21-0.22 
0.44 - 0.48 
0.70-0.82 
0.91 
14C02 production from [l-'4C]palmitate was determined as described in section 5.2 in 
the presence of 0.5 mM L-malate, 0.5 mM L-camitine, 0.1 mM coenzyme A and 5 mM 
ATP. Palmitate was complexed to albumin in a molar ratio of 8:1. Values are expressed 
in nmol [l-l4C]palmitate oxidized to 14C02.mm"l. (Mmol cyt.c.min"!)-!. Values of m. 
pectoralis represent means with SD of 4 experiments, those of m. gluteus homogenates 
were obtained from 2 experiments. 
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Table 5.3. Effect of palmitate/albumm ratio on the production of I 4 C02 from [1-14C]-
palmitate by human skeletal muscle. 
Palmitate/albumm ratio 
8:1 5:1 
Mitochondria M. pectoralis 0.57 ± 0.34 ( 7) 0.09 ± 0.08 (6) 
M. gluteus 0.42 ± 0.24 ( 5) 0.14 ±0.08 (6) 
Homogenates M. pectoralis 0.50 ± 0.18(19) 0.07 ±0.04 (5) 
M. gluteus 0.44 ±0.23 (17) 0.05 ±0.06(3) 
l^COj production from [l-'^CJpalmitate
 w a s
 determined as described in section 5.2 in 
the presence of 0.5 mM L-malate, 0.5 mM L-camitine, 0.1 mM coenzyme A and 5 mM 
ATP. Palmitate was complexed to albumin in a molar ratio 8:1 or 5:1. For mitochondria 
90 juM palmitate was used, for homogenates 120 μΜ. Values are expressed in nmol 
[1-I4c]palmitate oxidized to l^CC^.min'l.Gumol cyt.c.min-l)-l and represent means 
with SD for the number of experiments indicated between parentheses. 
5.3.2. Oxygen consumption during palmitate oxidation 
With 10 μΜ palmitate serving as substrate, maximal oxygen consumption in mito­
chondria of m. pectoralis occurred at a L-camitine concentration of at least 0.3 mM. 
When palmitate complexed to albumin in a 8:1 molar ratio was used, the rate of oxygen 
consumption by m. pectoralis mitochondria appeared to be maximal at 4 - 50 μΜ palmitate. 
With mitochondria of m. gluteus, m. soleus and m. quadriceps maximal oxygen consump­
tion was observed at palmitate concentrations of 4 μΜ or more, while above 50 μΜ palmi­
tate the rate of oxygen consumption markedly decreased (Table 5.4). When palmitate was 
complexed to albumin in a 5:1 molar ratio the rate of oxygen consumption was con­
stant from 10-90 μΜ palmitate. The different oxidation rates may be explained by dif­
ferent concentrations of free palmitoyl-CoA. When palmitate is complexed to albumin in 
a 8:1 molar ratio, the albumin molecule is overloaded with fatty acids. Free palmitoyl-
CoA might then inhibit the adenylate translocator (Pande & Blanchaer, 1971 ; Shug et al., 
1971). At a molar ratio 5:1 no inhibition would occur, since palmitoyl-CoA would be 
bound to albumin. 
When the rate of 1 4 C02 production from [l-14C]pa]mitate by mitochondria and 
their oxygen consumption during palmitate oxidation were compared, two discrepancies 
were observed. In experiments in which mitochondria oxidized limited amounts of pal­
mitate, the ratio between oxygen consumption and palmitate consumption (Fig.5.1) was 
29 ± 7 natom oxygen per nmol palmitate (mean with SD, 10 experiments) instead of the 
theoretical value of 46. This indicates an incomplete degradation of the palmitate mole­
cule. With a consumption of 29 natom oxygen per nmol palmitate an oxidation rate of 
about 3 nmol palmitatejnin^.^mol cyt.cmin-l)-! would be expected. The 1 4 C 0 2 
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mitochondria 
0 5 mM L-malate 
2 mM L-carnitine I i' 
362N 
2.6 η mol palmitate 
5 2 nmol palmitate 
132 
31.7N 
13ΧΓ 
100 natom 
oxi gen 
4 mm 
31.8^ 
Fig.5.1. Oxygen consumption during oxidation of limited amounts of palmitate by 
human skeletal muscle. 
Palmitate oxidation by human m. pectoralis mitochondria was polarographically 
assayed in the presence of 0.5 mM L-malate, 2 mM L-camitine, 0.1 mM coen­
zyme A and 5 mM ATP in a 1.25 ml cell containing 0.44 mg mitochondrial pro­
tein. Palmitate/albumin ratio was 8:1. After consumption of fatty acids associ­
ated with the mitochondrial preparation, limited amounts of palmitate were 
added. The ratio between the oxygen consumption (in natom) and the amount 
of palmitate (in nmol) was calculated. Values beyond the graph represent natom 
oxygen.min'l. In this experiment ratios of 39.4 and 33.7 were calculated after 
the addition of 2.6 and 5.2 nmol palmitate, respectively. 
production from [l-'^C]palmitate, however, was 0.57 and 0.14 nmol ^ C 0 2 . m m * ' . 
(дто і суt.с-min"I)"1, respectively, at palmitate/albumin ratiosof 8:1 and 5:1. An under­
estimation of palmitate oxidation from 1 4 C 0 2 production may be due to label-dilution 
by citric acid cycle intermediates, which must be added to the assay system for activation 
of the citric acid cycle. Incomplete oxidation and label-dilution might also explain why 
the rate of 1 4 C 0 2 production from [l- 1 4C]palmitate was about twice that from [U-^4C]-
palmitate in both homogenates and mitochondria of human skeletal muscle. 
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Table 5.4. Concentration dependence of palmitate oxidation by mitochondria of human 
musculus pectoralis. 
Palmitate 
concentration 
2 
4 
10 
60 
10 
90 
Molar 
ratio 
8:1 
8:1 
8:1 
8:1 
5:1 
5:1 
Number of 
experiments 
8 
8 
8 
5 
14 
4 
Oxygen consumption (natom O.mùrl) 
mg protein"1 
90 ±26 
103 ± 39 
99 ±36 
49 ± 7 
106 ±37 
109 ±35 
(Mmolcyt.cmm"1)"1 
78±14 
89 ±25 
86 ±25 
45 ±11 
92 ±21 
95 ±10 
Palmitate oxidation was polarographically assayed in the presence of 0.5 mM L-malate, 
2.0 mM L-camitine, 0.1 mM coenzyme A and 5 mM ATP in a 1.25 ml cell containing 
200 - 400 Mg mitochondrial protein, as described in section 5.2. Palmitate was complexed 
to albumin in molar ratios 8:1 or 5:1. Values represent means with SD for the stated 
number of experiments. 
Table 5.5. Comparison of Polarographie and radiochemical determination of palmitate 
oxidation by mitochondria of human muscle. 
Palmitate oxidation rate 
[ 1 •14C]pa]mitate [U-14C]palmitate Polarography 
Heart 
M. pectoralis 
M. quadriceps 
M. gluteus 
(3) 
(4) 
(1) 
(1) 
2.5 ± 0.3 
2.9 ± 0.3 
3.4 
3.9 
2.1 ±0.4 
2.0 ± 0.2 
2.8 
3.1 
2.3 ±0.1 
2.2 ±0.2 
2.9 
2.6 
Palmitate oxidation was determined in the presence of 0.5 mM L-malate, 0.5 mM L-cami-
tine, 0.1 mM coenzyme A and 5 mM ATP. Palmitate complexed to albumin in a molar 
ratio 5:1 was used at a concentration of 90 juM. Values of the radioactive experiments are 
expressed in nmol [14C]palmitate oxidized to 14C02 and 14C-labeled perchloric acid-
soluble products.mm"l.(¿ímol cyt.c.min"!)·!; those of the Polarographie experiments as 
1/46 χ natom oxygen.min-l.Onmol cyt.c.min-l)-l. The values are means with SD for the 
number of experiments given between parentheses. 
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A further discrepancy was noticed between ' 4 C 0 2 production and Polarographie 
results. Conversion of [14C]palmitate to 1 4 C02 was enhanced (Tables 5.2 and 5.3) 
under conditions which diminished oxygen consumption (Table 5.4), viz. a high concen­
tration of pahnitate and a high palmitate/albumin ratio. It can be concluded that 1 4 C02 
production from 14C-labeled fatty acids is an unreliable indicator of fatty acid oxidation. 
5.3.3. Degradation rate of long-chain fatty acids 
All oxidation products of long-chain fatty acids, produced via acetyl-CoA, are soluble 
in perchloric acid, with the exception of CO2 which can be assayed by the conventional 
radiochemical technique. Since long-chain fatty acids and their coenzyme A and carnitine 
esters are insoluble in perchloric acid, the total production of ^COj and ^C-labeled 
perchloric acid-soluble products from [l4C]fatty acids reflects the overall rate of fatty 
acid activity and /5-oxidation. At substrate concentrations of 30 - 90 μΜ the rate of mito­
chondrial oxidation of labeled palmitate to 14C02 and l4C-labeled perchloric acid-soluble 
products was unchanged. In homogenates a similar oxidation rate was observed at sub­
strate concentrations of 30-120 μΜ palmitate. In addition, no differences were observed 
in the oxidation rate with palmitate/albumin ratios of 8:1 and 5:1. 
The rate of degradation of [14C]palmitate to 1 4 C02 and 14C-labeled perchloric acid-
soluble products was compared with the oxygen consumption during palmitate oxidation 
(Table 5.5) and with the production of 1 4 C02. Oxidation rates estimated from 1 4 C02 
production (Table 5.3) were only 2 - 20 % of those estimated from the total degradation 
products. If we assume complete oxidation of the palmitate molecule, the oxidation rates 
derived from Polarographie experiments were somewhat less than those measured with 
[l-l4C]palmitate, but closely agreed with those found with [U-l4C]pa]mitate. The over-
estimation of palmitate oxidation with [l-14C]palmitate can be mainly attributed to in­
complete degradation during 0-oxidation. A similar accumulation of /3-oxidation inter­
mediates was observed in mitochondria of rat skeletal muscle (sections 3.3 and 4.3). 
Oxidation rates in human m. pectoralis mitochondria at 90 μΜ substrate concentra­
tion were 77 ± 4% with [l-14C]stearate and 103 ± 7 Ζ with [l-14C]oleate of the rate with 
[l-'4C]palmitate (means with SD, 5 experiments). It must be kept in mind that measure­
ment of the oxidation of these [l-14C]fatty acids only reflects the flux through fatty acid 
activation, its translocation and the first cycle of ß-oxidation, and not the flux through 
the whole /3-oxidation pathway. 14C02 production from [l-14C]palmitate and [1-14C]-
oleate appeared also to be similar with skeletal muscle homogenates of man (Engel & 
Angelini, 1973) and rat (Mole et al., 1971). 
The rates of fatty acid oxidation calculated from the sum of 14C02 and l4C-labeled 
acid-soluble products (Table 5.6) showed smaller standard deviations than those obtained 
from 14C02 production (Tables 5.1 - 5.3). In human tissues the degradation rates of 
[1-14C]- and [U-l4C]palmitate in relation to cytochrome с oxidase activity were observed 
to be 10-30 Ζ less in homogenates than in the corresponding mitochondria (Table 5.6). No 
differences were observed in the rates of palmitate oxidation by homogenates and mito-
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Table 5.6. Comparison of the rates of palmitate oxidation in homogenates and mitochon­
dria of human and rat muscle. 
Number 
of 
[l-14C]palmitate 
Heart 
M. pectoraUs 
M. quadriceps 
[U-14C]palmitate 
Heart 
M. pectoraUs 
M. quadriceps 
Rat m. quadriceps 
expts. 
3 
7 
1 
3 
7 
1 
3 
Rate of palmitate oxidation 
Mitochondria 
2.5 ±0.3 
2.9 ± 0.4 
3.4 
2.1 ±0.4 
2.2 ±0.3 
2.8 
0.40 ±0.01 
Homogenates 
1.94 ±0.17 
2.36 ± 0.60 
2.45 
1.54 ±0.14 
1.79 ±0.61 
1.94 
0.40 ± 0.03 
Ratio homogenate/ 
mitochondria 
0.77 ±0.13 
0.82 ±0.15 
0.72 
0.72 ±0.11 
0.81 ±0.21 
0.69 
1.0 ±0.1 
Palmitate oxidation was assayed in the presence of 0.5 mM L-malate, 0.5 mM L-camitine, 
0.1 mM coenzyme A and 5 mM ATP. Palmitate was complexed to albumin in a molar 
ratio 5:1. Substrate concentration was 120 μΜ palmitate for homogenates, 90 μΜ for 
mitochondria. In all experiments homogenates and mitochondria from a single biopsy 
specimen were compared. Values are expressed in nmol palmitate oxidized to ^^COj and 
'
4C-labeled perchloric acid-soluble products per min ρετμπιοί cyt.c.min" . 
chondria of rat skeletal muscle (Table 5.6). Human muscle tissue often contains many fat 
deposits, which might change the specific activity of the added palmitate. However, since 
we observed equal rates in the production of total 1 4 C02 and 14C-labeled perchloric acid-
soluble products in human muscle homogenates at palmitate concentrations ranging from 
30 to 120 μΜ, label-dilution by endogenous fatty acids can be excluded. Damaged mito­
chondria in the homogenates may still contain cytochrome с oxidase activity, but they 
have an impaired 0-oxidation capacity. Since the damaged organelles are removed during 
isolation of the mitochondria, the degradation rate of palmitate based on cytochrome с 
oxidase activity is often higher in mitochondria than in homogenates. 
Measurement of long-chain fatty acid oxidation was adapted to a volume of 50 μΐ, 
containing 10 μΐ homogenate. Technical data of this microassay are given in the legend of 
Fig.5.2. ParaUel incubation in 1.0 ml and 50 μΐ volumes showed identical values of palmi­
tate oxidation per mg homogenate protein. Table 5.7 shows ['4C]palmitate oxidation 
rates in various types of human muscle, obtained by this microassay. They are of the 
same order of magnitude for all types of skeletal muscle. The ratio between [1-14C]- and 
[lM4C]palmitate oxidation does not markedly differ in the various biopsies. 
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00 Table 5.7. Palmitate oxidation in homogenates of human and rat striated muscle. 
Palmitate oxidation rate Ratio [1-14C]/[U-14C] 
[l-14C]pa]mitate [U-14C]palmitate[l-14C]palmitate [U-14C]palmitate mean ± SD range 
per mg protein регдтоі cytochrome cmin in-1 
M. quadriceps ' ) 
M. soleus · ) 
M. gastrocnemius1) 
M. deltoideus ' ) 
M. gluteus 2 ) 
M. pectoralis 3 ) 
Heart 4 ) 
0.15 + 0.05(6) 0.12 ±0.04 (5) 1.62 ±0.70 (6) 1.32 ±0.57 (5) 
0.28 + 0.09(3) 0.22 ±0.07(3) 1.66 ±0.40(3) 1.32 ±0.31(3) 
0.27 0.22 1.23 1.31 
0.10 0.09 2.15 1.93 
0.20 ±0.09 (4) 0.17 ±0.08 (4) 1.42 ±0.36 (4) 1.00 ±0.24 (4) 
0.13 ±0.03 (8) 0.09 ±0.02 (8) 2.36 ±0.60 (7) 1.79 ±0.61 (7) 
1.06 ±0.16 (6) 0.80 ±0.13 (6) 1.76 ±0.39 (5) 1.38 ±0.34 (5) 
1.13 + 0.08(5) (1.06 - 1.26) 
1.27 ±0.01(3) (1.26 - 1.28) 
1.23 (1.23) 
1.31 (1.31) 
1.44 + 0.17(3) (1.31-1.63) 
1.35 ±0.10 (7) (1.16-1.48) 
1.33 ±0.08 (6) (1.19-1.41) 
M. quadriceps s ) 
ophthalmoplegia plus 0.10 
ophthalmoplegia plus 039 
Rat m. quadriceps 0.42 ± 0.08 (4) 
0.08 4.1 
2.7 
3.25 1.25 
0.35±0.05(4) 0.59±0.10(4) 0.51±0.11(4) 1.15 ± 0.02 (4) (1.13 - 1.18) 
Palmitate oxidation by homogenates (600xg supernatant) of human and rat muscle was determined as described under Fig. 5.2. 
Muscle biopsies were obtained from ·) neurological patients without apparent defect in carbohydrate or fat metabolism; 2 ) ortho­
pedic patients (corrective surgery); 3 ) breast carcinoma patients; 4 ) patients with tetralogy of Fallot; s ) neurological patients with 
metabolic abnormalities. Palmitate oxidation is expressed in nmol [ ' 4C]palmitate oxidized to 1 4 C02 and 14C-labeled perchloric 
acid-soluble products. Values represent means with SD of the number of experiments indicated between parentheses. 
Fig. 5.2. Microassay of [^CJpalmitate oxidation. 
Incubation was carried out in an Eppendorf centrifuge cup (A, 1.5 ml volume), 
which was placed in a counting vial (B) containing 2 ml aq. dest. to mmimalize 
evaporation. The final volume was 50 μΐ containing 10 /il human skeletal mus­
cle homogenate (10 % w/v, 600xg supernatant). 
Assay medium and incubation conditions were equal to those described in sec­
tion 5.2. " C O 2 w a s trapped in ethanolamine:ethyleneglycol in another Eppen­
dorf cup (C), the upper part of which was cut off. The reaction was terminated 
by injecting 0.2 ml 3 M perchloric acid through the rubber enclosure into the 
incubation cup. This relatively large volume of acid was necessary to stop the 
reaction immediately. After a second incubation period of 75 min at 40C the 
reaction cup was centrifuged in a Koolspin microcentrifuge at 20 OOOxg for 2-3 
min. Radioactivity was determined in 150 μΐ of the supernatant with 10 ml 
Aquasol in a liquid scintillation counter. Parallel experiments without homoge­
nate were used as blanks. 
5.4. Discussion 
Polarographic determination of fatty acid oxidation in muscle homogenates is severe­
ly hampered by the presence of endogenous substrates and the oxygen binding protein 
myoglobin. Therefore a radiochemical assay of the CO2 production from fatty acids is 
commonly used (Engel & Angelini, 1973; Lin et al., 1970; Kark et al., 1971; Mole et al., 
1971; Baldwin et al., 1972; Rifenberick & Max, 1974; Whittaker et al., 1978). We ob­
served a large variability, however, when the 1 4 C02 production rates from [l-14C]palmi-
tate were related to protein or to the mitochondrial marker enzymes cytochrome с oxi­
dase and monoamine oxidase. 1 4 C02 production from [U-14C]pa]mitate by teased mus­
cle fibres showed less variability (Bylund et al., 1975), but the assay requires rather large 
biopsies and a high, unphysiological palmitate concentration (2.5 mM). 
In the present study we also observed large discrepancies between the rates of palmi­
tate oxidation estimated from ^4C02 production from [^4C]palmitate and from oxygen 
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consumption. Label-dilution and incomplete oxidation during the citric acid cycle can be 
overcome by determining the sum of 1 4 C02 and 14C-labeled perchloric acid-soluble 
products from [U-^C]long-chain fatty acids. The oxidation rates thus obtained closely 
agree with those from the Polarographie experiments. Inhibition of oxygen consumption, 
with continuing palmitate degradation, occurs only at high concentrations of palmitate 
complexed to albumin (molar ratio 8:1). In that case the reducing equivalents produced 
by /3-oxidation are probably transferred to NAD , which is added to the incubation mix­
ture. 
Expression of fatty acid oxidation relative to the cytochrome с oxidase activity ap­
pears to be advantageous, since it eliminates erroneous interpretation caused by a de­
creased number of mitochondria in the muscle biopsy specimen. In human skeletal mus­
cle homogenates cytochrome с oxidase reflects rather well the amount of mitochondrial 
protein. In purified mitochondria of m. pectoralis and leg muscle cytochrome с oxidase 
activities per mg protein of 1.01 ± 0.28 (mean + SD, η = 19) and 1.00 ± 0.19 (n = 7) were 
found. Cytochrome с oxidase appears to be a good reference enzyme, since its activity 
increases parallel to palmitate oxidation in normal muscle during exercise (Baldwin et al., 
1972; Bylund et al., 1977; Salminen et al., 1977). The sum of 1 4 C02 and 14C-labeled 
perchloric acid-soluble products, expressed per unit cytochrome с oxidase activity, is 
relatively constant in homogenates and mitochondria of human muscle (relative standard 
deviations 12 - 25%). Hence, the assay of these products may be valuable in the screening 
of patients with neuromuscular disease for their capacity to oxidize long-chain fatty 
acids. Since the assay is also more sensitive than that of 1 4 C02 production, fatty acid 
oxidation can be determined in smaller volumes (with 10 μΐ of homogenate), and suffi­
cient muscle tissue would be obtained with needle biopsies. 
As it was remarked in section 2.5 it is hazardous to compare fatty acid oxidation by 
human and rat skeletal muscle mitochondria on a cytochrome с oxidase basis. The rate of 
fatty acid oxidation per mg protein was about 2.5 times higher in rat than in human 
skeletal muscle mitochondria (cf. section 3.4). A similar difference was observed by Maki-
nen & Lee (1968) when using palmitoyl-camitine as substrate. Measurements of the rate 
of fatty acid oxidation by human skeletal muscle are rare. Those published (Makinen & 
Lee, 1968; Engel & Angelini, 1973; Whittaker et al., 1977) do not make a difference be­
tween type, age and sex of the muscle. Our data show that palmitate oxidation is of the 
same order of magnitude within different muscle groups. No clear sex differences ap­
pear to exist. Since the assay of fatty acid oxidation could be adapted to smaller vol­
umes, sufficient muscle tissue might be obtained from needle biopsies. This would make 
possible a systematic investigation with biopsies. 
5.5. Summary 
Rates of oxidation of palmitate by mitochondria and homogenates of human skeletal 
muscle and heart were determined, and expressed relative to protein content and to the 
activities of cytochrome с oxidase and monoamine oxidase. 
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Production of 1 4 C 0 2 from [14C]palinitate varied considerably and depended on pal-
mitate concentration, label-position and the palmitate/albumin ratio in the sytem. Only 
2-20% of the palmitate oxidation rate, calculated from the rate of oxygen consumption, 
was reflected in the rate of 1 4 C02 production. 
The sum of l^CC^ and of ^C-labeled perchloric acid-soluble products from [^4C]-
palmitate appeared to be a more accurate index of the palmitate oxidation rate, since this 
sum closely agreed with the rate obtained by Polarographie estimation. 
Palmitate oxidation rates related to the activity of cytochrome с oxidase were in the 
same order of magnitude in homogenates of different types of striated muscle of man. 
This radiochemical assay, adapted to a small volume, can be applied in screening muscle 
of patients with a neuromuscular disease for the capacity to oxidize long-chain fatty 
acids. 
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CHAPTER 6 
PALMITATE OXIDATION BY HUMAN AND RAT HEART 
6.1. Introduction 
Fatty acids play an important role in heart muscle. They form an important part of 
the membrane lipids, they provide a substrate for energy production, and they act as bio­
chemical modulators of a number of essential enzymes and as carrier molecules for Ca"1""^  
ions. Since fatty acids are the main energy source of heart muscle (Neely & Morgan, 
1974), changes in fatty acid oxidation will affect cardiac function. Interest in fatty acid 
oxidation in the heart muscle was stimulated by the observation that the concentrations 
of acyl-CoA and acyl-camitine esters rapidly increased during ischemia of the heart (Shug 
et al., 1975; Whitmer et al., 1978; Shug et al., 1978). Although the in vivo effects of these 
compounds are still uncertain, in vitro they are known to be involved in the regulation of 
mitochondrial activity (Pande & Blanchaer, 1971; Shrago, 1978; Wood, 1978). Insight in 
the metabolism of fatty acids in heart muscle was mainly obtained from animal studies. 
Since we had the opportunity of measuring fatty acid oxidation rates in human heart 
biopsies, we were able to evaluate how palmitate oxidation by homogenates and mito­
chondria of human heart muscle compares with that by rat heart muscle preparations. 
6.2. Materials and methods 
Human heart muscle was obtained from patients with tetralogy of Fallot (6 - 24 years 
old). Although these patients have a right ventricular hypertrophy, they show no evidence 
of cardiac failure or mitochondrial dysfunction (Lentz et al., 1978; Peters et al., 1977). 
The muscular tissue removed for the insertion of an artificial valve was handled as de­
scribed in section 2.2. Rat hearts were obtained from male random bred albino Wistar 
rats (180 - 240 g), which had been fasted for 18 h (section 2.2). Homogenates and mito­
chondria were prepared as described in section 2.3. 
Palmitate oxidation was determined polarographically and radiochemically at 37° С 
in 25 mM sucrose, 30 mM KCl, 75 mM Tris-HCl (pH 7.4), 10mM potassium phosphate, 
5 mM MgCl2, 1 mM EDTA, 5 mM ATP, 0.5 mM ADP, 1 mM NAD+, 25 μΜ cytochrome 
c, 0.1 mM coenzyme A, 0.5 mM L-malate and 0.5 mM L-camitine. 90 μΜ palmitate, 
bound to albumin in 5:1 molar ratio, was used as substrate. Details of the measurements 
are described in section 3.3. 
The assay methods for protein and cytochrome с oxidase activity are described in 
sections 2.8 and 2.5. 
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6.3. Results 
The ADP/O ratio of the heart muscle mitochondria measured with an oxygen polaro-
graph ranged from 2.8 to 3.0. The respiratory control index was 5.5 or higher with 2-oxo-
glutarate or L-glutamate as substrate. Oxygen uptake at 90 μΜ palmitate in the presence 
of 0.5 mM L-malate and 0.5 mM L-carnitine amouted to 240 - 245 natom oxygen.min"'.-
mg.protein"! at 37° for human heart mitochondria. Oxygen uptake was linear for 25 min 
and was 10 - 20 % higher at 10 μΜ palmitate. Palmitate oxidation by human heart muscle 
mitochondria appeared to be completely camitine-dependent, as it was also observed for 
other species (Neely & Morgan, 1974). 
During oxidation of long-chain fatty acids not only CO2 is produced, but also citric 
acid cycle intermediates and acetyl-carnitine may accumulate. These products are soluble 
in perchloric acid, whereas long-chain fatty acids and their coenzyme A- and camitine-
esters are insoluble. Therefore we estimated the rate of palmitate oxidation from the total 
production of 1 4 C02 and ^C-labeled perchloric acid-soluble products as described for 
skeletal muscle (sections 3.3 and 5.3). Comparison of this value with the rate of oxygen 
uptake during oxidation of palmitate, showed that 50 and 42 atoms oxygen appear to be 
consumed per molecule palmitate for [U-14C]- and [l-14C]palmitate, respectively. These 
values suggest that the palmitate molecule is completely degraded or that other unlabeled 
substrates are oxidized in addition to incomplete degradation of the palmitate molecules. 
The results given below clearly disprove the first suggestion. Therefore endogenous sub­
strates are additionally oxidized (cf. section 5.3). 
When human heart muscle mitochondria were incubated with 90 μΜ [U-14C] palmi­
tate for 25 min, about 16 % of the added substrate was converted to CO2 and perchloric 
acid-soluble products. ' 4 C 0 2 represented only 3 ± 2% of the ^4C-labeled degradation 
products (Table 6.1). The main perchloric acid-soluble products were 2-oxoglutarate and 
acetyl-carnitine. Short-chain acyl-carnitines (C4 - Cg) were also produced, and to a lesser 
extent citrate, succinate and malate. Formation of ketone bodies was not observed, When 
[l-14C]palmitate was used, 1 4 C02 represented only 5 + 3% (mean with SD, 5 experi­
ments) of the labeled degradation products for human heart muscle mitochondria. Prod­
uction of ' 4 C 0 2 was relatively much larger for rat heart mitochondria where 1 4 C02 rep­
resented 24 ± 5 7c, of the labeled carbon atoms in the degradation products of [l-14C]pal-
mitate and 16 ± 4 % from those of [U-14C]palmitate (mean with SD, 5 experiments). 
The oxidation rates of [1-'4C]- and [U-'4C]palmitate were calculated relative to the 
protein content and to the cytochrome с oxidase activity (Table 6.2). On protein basis no 
differences were observed between human and rat heart muscle preparations. The rates 
expressed relative to the mitochondrial marker enzyme cytochrome с oxidase did not 
differ between homogenates and mitochondria, but differed between human and rat heart 
muscle. This difference appeared to be due to the different specific activities of cyto­
chrome с oxidase in both species (Table 2.3). The specific activity of cytochrome с oxid­
ase is higher in heart muscle mitochondria than in skeletal muscle mitochondria of man, 
but it is about the same in heart and skeletal muscle mitochondria of the rat. 
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Table 6.1. Products formed during oxidation of [U-14C]palmitate by human heart muscle 
mitochondria. 
natom 1 4 C per mg protein 
Perchloric acid-soluble products 
Citrate 54 ± 32 
2Oxoglutarate 581 ±82 
Succinate 56 ± 32 
Fumarate 6 ± 11 
Malate 37 + 24 
Acetyl-carnitine 267 ± 88 
Short-chain acyl-camitines 133 ± 46 
Glutamate and aspartate 32 ± 37 
CO2 70 ± 37 
Perchloric acid-insoluble oxidation products 355 ± 45 
Human heart muscle mitochondria (1.2 - 2.0 mg/ml protein) were incubated in the pres­
ence of 0.5 mM L-malate, 0.5 mM L-carnitine and 0.1 mM coenzyme A as described in 
section 6.2. Oxidation was started by addition of 90 μΜ [U-'4C]palmitate complexed to 
albumin in a 5:1 molar ratio, and terminated after 25 min with perchloric acid. R e ­
labeled perchloric acid-soluble products were analyzed by paper electrophoresis in acetic 
acid/formic acid/water (19/19/1000, by vol.,pH 2.5) (section 3.2). Perchloric acid-soluble 
camitine-esters were desalted by preparative electrophoresis and separated by thin layer 
chromatography on Silicagel G (Solberg & Bremer, 1970, system A). The amount of Re­
labeled perchloric acid-insoluble oxidation products was calculated from the difference in 
the sum of ' 4 C 0 2 and '4C-labeled perchloric acid-soluble products from [1-14C]- and 
[U-l4C]palmitate. Data represent means with SD for 4 experiments. 
The sum of 1 4 C02 and ^C-labeled acid-soluble products from [l-14C]palmitate 
was higher than that from [U-'4C]palmitate (Table 6.2). This difference appeared to be 
due to accumulation of 0-oxidation intermediates (perchloric acid-insoluble oxidation 
products). It amounted to about half of the amount of citric acid cycle inteimediates 
(Table 6.1). Accumulation of /3-oxidation intermediates was previously found with 
mitochondria of rat liver, and ox heart (Stanley & Tubbs, 1975) and in those of rat and 
human skeletal muscle (sections 4.3 and 5.3). 
6.4. Discussion 
A maximal rate of palmitate oxidation by human heart muscle mitochondria was 
reached at the same palmitate concentration as observed for rat heart (Pande, 1971) and 
human (section 5.3) and rat skeletal muscle (section 3.3). The rate of oxygen consump­
tion per mg protein during palmitate oxidation was of the same order of magnitude as in 
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Table 6.2. Palmitate oxidation by homogenates and mitochondria of human and rat heart 
muscle. 
Oxidation rate 
/mg protein /cyt. с oxidase activity 
[1-14C] [U-14C] [1-14C] [U-14C] 
palmitate palmitate palmitate palmitate 
RAT Homogenates 1.4 ±0.2 (9) 1.2 ±0.2 (9) 0.8 ± 0.1 (9) 0.7 ±0.1 (9) 
(600xg supernatant) 
Mitochondria 5.6 ±0.7 (9) 5.1 ±0.8(9) 0.9 ±0.2 (5) 0.8 ±0.2 (5) 
MAN Homogenates 1.1 ±0.2 (6) 0.8 ± 0.1 (6) 1.8 ±0.4 (5) 1.4 ±0.3 (5) 
(600xg supernatant) 
Mitochondria 5.3 ± 1.5 (6) 4.4 ± 1.5 (6) 2.1 ± 0.2 (5) 1.8 ± 0.3 (5) 
Oxidation of [l4C]palmitate was measured in the presence of 0.5 mM L-malate, 0.5 mM 
L-camitine and 0.1 mM coenzyme A over 25 min as described in section 6.2. As substrate 
was used 90 μΜ palmitate complexed to albumin in a 5:1 molar ratio. Results are express­
ed in nmol [ 14C]palniitate oxidized to ' 4 C 0 2 and '4C-labeled perchloric acid-soluble 
products.min"' per mg protein or per Mmol cytochrome c.min"'. Values represent means 
with SD for the number of experiments indicated between parentheses. 
rat (Williams & Li, 1977; Hansford, 1978) and calf heart mitochondria (Tomec & Hoppel, 
1975). In our study we found that the production rates of the sum of 1 4 C02 and R e ­
labeled perchloric acid-soluble products from [14C]palmitate, which reflect activation, 
translocation and ß-oxidation, were about the same for rat and human heart homogenates 
and mitochondria, when expressed per mg protein. Previously we found about equal 
palmitate oxidation rates for skeletal muscle mitochondria of both species (section 5.3), 
but they were about half of the rates found for heart muscle mitochondria. 
The rate of fatty acid oxidation depends on the rates of fatty acid oxidation, /З-охі-
dation, citric acid cycle and respiratory chain. At low fatty acid concentrations the 
acetyl-CoA produced during /?-oxidation was completely oxidized by the citric acid cycle 
in rat heart muscle mitochondria (Pande, 1971). We also found this to be the case with 
human heart muscle mitochondria. At high fatty acid concentrations acetyl-carnitine ac­
cumulated in the cytoplasm, but oxygen consumption did not further increase in the per­
fused rat heart (Oram et al., 1973). A marked amount of acetyl-carnitine accumulated 
also during oxidation of 90 μΜ palmitate by human heart muscle mitochondria. These 
observations indicate that the citric acid cycle is slower than the ^-oxidation cycle under 
these conditions. 
Accumulation of C-labeled 2-oxoglutarate and relatively large amounts of succi­
nate and malate was also observed during palmitate oxidation by rat heart muscle mito-
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chondria (Christophersen & Christiansen, 1975). Although the accumulation of 2-oxoglu-
tarate might be artificially stimulated by the addition of malate (LaNoue et al., 1970), 
the relatively large amounts of citric acid cycle intermediates suggest also a limited flux 
through the citric acid cycle in human heart muscle mitochondria during oxidation of 
non-limiting amounts of palmitate. This suggestion is strengthened by the fact that Lentz 
et al. (1978) found about the same oxygen consumption during oxidation of glutamate 
and succinate by human heart muscle mitochondria, as we found during palmitate oxida­
tion. The smaller fraction of ^COj produced by human mitochondria than by rat mito­
chondria suggests that the limitation in the citric acid cycle activity is more prominent in 
human than in rat heart muscle. Citric acid cycle activity also appeared to be lower in 
skeletal muscle mitochondria of man than in those of rat (Bookelman, 1978). 
Since the flux through the citric acid cycle and the rate of oxidative phosphorylation 
are tightly coupled (LaNoue et al., 1970), oxygen supply and energy utilization may 
markedly influence fatty acid oxidation (Neely & Morgan, 1974; Whitmer et al., 1978; 
Oram et al., 1973). A high intramitochondrial NADH/NAD+ ratio and a high FADH2 
level may make the 0-oxidation rate-limiting for fatty acid oxidation and may lead to 
increased concentrations of acyl-CoA and acyl-camitine esters (Shug et al., 1975; Oram et 
al., 1973; Idell-Wenger et al., 1978). In vitro, Д-oxidation becomes rate-limiting after in­
crease of the NADH/NAD+ ratio by high palmitoyl-CoA concentration (Pande & Blan-
chaer, 1971 ; Shrago, 1978; Wood, 1978). Our observation that the oxygen consumption 
rate of human heart muscle mitochondria oxidizing 90 μΜ palmitate was 80 - 90 % ofthat 
for 10 μΜ palmitate suggests that an elevated palmitoyl-CoA concentration may slightly 
affect the adenylate translocator and the NADH/NAD+ ratio in our system. However, 
the accumulation of large amounts of acetyl-carnitine contradicts a limitation by the 
Д-oxidation cycle. 
In summary, human and rat heart muscle mitochondria show equal rates of palmitate 
oxidation, measured as the sum of 1 4 C02 and 14C-labeled acid-soluble products, but 
there may exist proportional differences in the fluxes through the /3-oxidation and the 
citric acid cycle. 
6.5. Summary 
Palmitate oxidation rates were deteimined in mitochondria and homogenates of 
human and rat heart muscle. Oxidation rates based on the sum of the production of 
'
4 C 0 2 and '^C-labeled acid-soluble products from [ ' 4C]palmitate were in good agree­
ment with those calculated from the oxygen consumption during palmitate oxidation. 
With limited amounts of substrate palmitate was completely oxidized to CO2, but with 
non-limiting palmitate concentrations acetyl-carnitine and citric acid cycle intermediates 
accumulated. When about 16% of the added palmitate was oxidized by human heart 
muscle mitochondria, CO2 represented only 3 - 5 % of the oxidation products. With rat 
heart muscle mitochondria the latter value was 16 - 24%. Palmitate oxidation rates per 
mg protein were about equal for human and rat heart muscle. Palmitate oxidation rates by 
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homogenates and mitochondria were about equal, when expressed on the basis of cyto­
chrome с oxidase activity for each species, but they differed between rat and man. It is 
concluded that the capacity of /}-oxidation exceeds that of the citric acid cycle in both 
human and rat heart muscle mitochondria, but proportional differences between both 
species may exist in the fluxes through the /3-oxidation and the citric acid cycles. 
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CHAPTER 7 
COFACTOR REQUIREMENT FOR LEUCINE AND VALINE OXIDATION 
BY RAT SKELETAL MUSCLE 
7.1. Introduction 
Skeletal muscle is considered to be an important site of oxidation of the branched-
chain amino acids leucine, valine and isoleucine (Miller, 1962; Manchester, 1965; Odessey 
& Goldberg, 1972; Buse et al., 1975; Shinnick & Harper, 1976). The oxidation of these 
amino acids is under metabolic and hormonal control (Manchester, 1965; Buse et al., 
1972; Buse et al., 1973). They may play an important role in the energy supply of muscle 
since amino acid catabolism is accelerated during starvation (Buse et al., 1972; Adibì et 
al., 1974; Goldberg & Odessey, 1972). However, studies leading to these insights were 
performed in hemidiaphragms or intact muscle fibers. It is difficult to quantitate branched-
chain amino acid oxidation in such studies, because 14C02 production from radioactive 
substrate can be affected by the rate of transport of the substrate into the cell and by 
dilution with non-labeled substrates in the cell. Recently, oxidation of leucine in rat 
skeletal muscle homogenates was reported (Dohm et al., 1976), but the rate of CO2 prod-
uction was less than that obtained with whole muscle. 
Isovaleryl-CoA and isobutyryl-CoA are formed from leucine and valine by the first 
degradation steps, transamination and oxidative decarboxylation. These products are in 
fact branched-chain fatty acyl-CoA esters. Since branched-chain acylcamitines were iden-
tified in mitochondria of kidney and heart (Solberg & Bremer, 1970), L-camitine might 
be involved in the metabolism of branched-chain amino acids, as it is in the oxidation of 
fatty acids. We have investigated the influence of cofactors, particularly carnitine, on the 
oxidation of leucine, valine and 2-oxoisocaproate by homogenates and mitochondria of 
rat skeletal muscle. 
7.2. Materials and methods 
Male albino Wistar rats (180 - 240 g) were used, one rat per experiment. After fasting 
for 18 - 24 h the animals were killed by decapitation. Homogenates (600xg supernatant) 
and mitochondria were prepared as described in section 2.3. 
Amino acid oxidation was determined in a medium containing 10 mM potassium 
phosphate, 75 mM Tris-HCl (pH 7.4), 75 mM sucrose, 1 mM EDTA, 5 mM MgC^, 1 mM 
2-oxoglutarate, 1 mM NAD+ , 25 μΜ cytochrome с and 5 mM ADP. As substrates 2.0 mM 
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L-[l-14C]valine and 0.5 mM L-[l-14C]leucine (spec. act. lOO/iCi/minol) were used. Incu­
bation occurred in a final volume of 2.0 ml, containing 1.5 - 2.0 mg homogenate protein, 
at 370C for 90 min. 1 4 C02 was trapped in 0.2 ml ethanolamine-ethyleneglycol (1:2, by 
vol). Reactions were terminated by the addition of 0.2 ml 5 M perchloric acid. The vials 
were then shaken for 90 min at 0oC to bind all 1 4 C02. Radioactivity was determined in a 
liquid scintillation counter with 0.4 % Omnifluor in toluene-methanol (2:1, by vol). The 
time course of 14C02 production was linear for 120 min. The assay showed a linear cor­
relation between ' 4 C 0 2 production and homogenate protein (1.25 - 5 mg). 
The same medium was used for mitochondria, but final concentrations of sucrose 
and KCl were 25 mM and 35 mM, respectively. The concentration of [l-14C]-2-oxoisoca-
proate (100 дСі/ттоІ) was 0.5 mM when used as substrate. Incubation occurred in a 
final volume of 1.0 ml, containing 0.13 - 0.20 mg mitochondrial protein, at 370C for 30 
min. A linear correlation between ^4C02 production and mitochondrial protein was ob­
served when less than 0.22 mg protein/ml was used. Time course of ^4C02 production 
was linear for 40 min. 
Concentrations of L-camitine and protein were determined as described in sections 
2.7 and 2.8. 
7.3. Results 
73.1. Oxidation of leucine and valine by muscle homogenates 
The first steps in the oxidation of branched-chain amino acids are transamination and 
oxidative decarboxylation. The production of ^4C02 from [l-14C]-labeled branched-
chain amino acids reflects the overall rate of these steps. In homogenates ^4C02 prod­
uction from [l-14C]leucine and [l-14C]valine increases with increasing substrate concen­
trations (Figs. 7.1 and 7.2). ' 4 C 0 2 production from [l-l4C]leucine is nearly maximal at 
0.5 mM leucine, but that from [l-l4C]valine increases up to 2 - 3 mM valine. Concentra­
tions of 0.5 mM leucine or 2.0 mM valine were used as substrate concentration in subse­
quent experiments. Since branched-chain amino acid transaminase activity greatly ex­
ceeds that of branched-chain 2-oxo acid dehydrogenase in muscle (Shinnick & Harper, 
1976; Dohm et al., 1976), measurement of 1 4 C 0 2 production may give a good esti­
mation of the latter enzyme activity. 
2-Oxoglutarate appeared to be a good amino-acceptor of branched-chain amino acids 
(Miller, 1962; Buse et al., 1975). In the presence of 1 mM 2-oxoglutarate rat skeletal 
muscle homogenates produce 0.8 ± 0.3 nmol ^CC^Jr'-mg protein"* from [l-14C]leu-
cine and 2.7 ± 1.2 nmol ^CC^.h^jng protein"1 from [l-14C]valine (means with SD, 12 
and 9 experiments, respectively). Addition of more 2-oxoglutarate did not increase oxi­
dation. 1 4 C02 production from [l-14C]leucme is 60% lower and from [l-14C]valine 70% 
lower without 2-oxoglutarate. Pyruvate cannot replace 2-oxoglutarate for transamination. 
It even decreases 1 4 C02 production, presumably by competitive inhibition with 2-oxo· 
isocaproate and 2-oxoisovalerate for oxidative decarboxylation, or with endogenous 
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Fig. 7.1. Effect of leucine concentration on '^СС^ production from L-[l-'^C]leucme by 
homogenates of rat skeletal muscle. 
Data were obtained in the presence of 1 mM 2-oxoglutarate and 0.1 mM coen­
zyme A as described in section 7.2 and represent means of 4 experiments. 
2-oxoglutarate for transamination (Buse et al., 1975; Buse et al., 1972). Oxidation of 
branched-chain amino acids decreases with increasing pyruvate concentration. Inhibition 
of 1^C02 production is also observed when 2-oxoglutarate and pyruvate are added to­
gether. 
Thiamine pyrophosphate (0.15 mM) stimulates the oxidation of 2-oxoisocaproate 
and 2-oxoisovalèrate by human fibroblast mitochondria (Danner & Elsas, 1974). However, 
it had little or no stimulatory effect on the oxidation of leucine and valine by rat skeletal 
muscle homogenates even at 1 mM concentration (Table 7.1). The effect of thiamine py-
rophosphate was also small when oxidation was enhanced by the addition of coenzyme A 
and L-camitine (data not shown). Apparently rat skeletal muscle homogenates contain 
enough thiamine pyrophosphate for maximal activity. Therefore, thiamine pyrophosphate 
was not added in subsequent experiments. 
Addition of coenzyme A stimulates the oxidation of 0.5 mM leucine and 2 mM va-
line (Table 7.1). The effect was constant when the coenzyme A concentration was varied 
from 25 - 100 μΜ. At valine concentrations below 0.5 mM the addition of coenzyme A is 
inhibitory. L-Camitine considerably increased oxidation of leucine and valine. The en­
hancement of ' 4 C 0 2 production by L-camitine was independent of the addition of coen­
zyme A. Both with and without added coenzyme A an increase of 140 -170% was found 
for 1 4 C02 production from leucine and of 90 % for that from valine. If no L-camitine 
was added, the actual carnitine concentration in the incubation system was 15-20 μΜ 
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Fig. 7.2. Effect of valine concentration on ^ С С ^ production from L-[l-^C]valine by 
homogenates of rat skeletal muscle. 
Data were obtained in the presence of 1 mM 2-oxoglutarate and 0.1 PIM coen­
zyme A as described in section 7.2 and represent means of 4 experiments. 
after addition of homogenate, since rat muscle tissue contains 0.69 ± 0.22 mM L-carnitine 
(means with SD, 6 experiments). When the actual L-camitine levels are plotted in a Line-
weaver-Burk graph no significant stimulation of leucine or valine oxidation is observed 
below 70 μΜ L-camitine. Above this concentration ^^COj production is markedly in­
creased (Fig. 7 3 and 7.4). The apparent K
m
 for L-camitine in the 1 4 C 0 2 production 
from [l-14C]leucine is 0.34 ± 0.08 mM, and in that from [l-14C]valine 71 ± 9 μΜ (means 
with SD, 4 experiments). Since stimulation of both leucine and valine oxidation is ob­
served at the same minimal concentration of L-camitine, it is probable that low carnitine 
concentrations are removed by endogenous substrates in the homogenates. When the oxi­
dation of leucine and valine is stimulated by the addition of coenzyme A and carnitine, 
the effects of omission of 2-oxoglutarate and the presence of pyruvate are similar to those 
without such stimulation (Table 7.2). 
7.3.2. Oxidation of leucine and valine by muscle mitochondria 
The observed effects of L-camitine and coenzyme A on the oxidation rate of branched-
chain amino acids could be complicated by involvement of cytoplasmic factors. We have, 
therefore, studied oxidation of leucine and valine in rat muscle mitochondria. Oxidation 
rates of leucine, valine and 2-oxoisocaproate in mitochondria are shown in Table 7.3. The 
oxidation rate of leucine was markedly lower than that of 2-oxoisocaproate. This was also 
observed in homogenates, which produced 0.08 ± 0.02 nmol *4C02Jnm"'.mg protein"' 
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Fig. 7.3. Lineweaver-Burk plot for the L-camitine dependence of the 14(χ)2 production 
from L-[l-14C]leucme. Oxidation of 0.5 mM L-[l-14c]leucine by homogenates 
of rat skeletal muscle was assayed in the presence of 1 mM 2-oxoglutarate and 
0.1 mM coenzyme A as described in section 7.2. The carnitine concentration re­
presents the sum of endogenous and added carnitine. Values represent mean of 3 
experiments. 
Table 7.1. Cofactor dependence of leucine and valine oxidation by rat skeletal muscle 
homogenates. 
Addition 
Relative activity 
Leucine Valine 
None 
Thiamine pyrophosphate 
Coenzyme A 
L-camitine 
100 
103 (96-106) (2) 
148 ±12 (4) 
271 ±67 (5) 
Coenzyme A and L-camitine 405 ± 56 (3) 
100 
113 (105-121) (2) 
154 ±56 (5) 
197 ±40 (8) 
246 ± 128(5) 
Concentrations of added compounds were: coenzyme A, 0.1 mM; thiamine pyrophos­
phate, 1 mM; L-camitine, 2 mM for leucine oxidation and 1 mM for valine oxidation. 
Results obtained in the presence of 1 mM 2-oxoglutarate are expressed in percent of the 
rate without additions. Values represent means with SD for the number of experiments 
indicated in parentheses. Without additions ^^COj production from L-[l-14c]leucme is 
0.8 ± 0.3 and from L-[l-14c]valine 2.7 ± 1.2 nmol l4C02.h-l.mg protein-1 (12 and 9 
experiments, respectively). 
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Fig. 7.4. Lineweaver-Burk plot for the L-camitine dependence of the 14(Χ)2 production 
from L-[l-l4C]valine. Oxidation of 2.0 mM L-[1-Hc]valme by homogenates of 
rat skeletal muscle was assayed as described in Fig. 7.3. Values represent means 
of 4 experiments. 
Table 7.2. Effect of 2-oxoglutarate and pyruvate on the oxidation of leucine and valine. 
Relative activity 
Addition Leucine Valine 
2-Oxoglutarate 100 100 
No keto acid 39 ±2 29 ±7 
Pyruvate 16 ± 3 14 + 2 
2-Oxoglutarate and pyruvate 46 ± 17 53 ± 6 
Oxoacids were added in 1 mM concentrations, coenzyme A and L-camitine were present 
in the concentrations given in Table 7.1. Results are expressed in percent of the activity 
in the presence of 2-oxoglutarate. Values represent means with SD for 4 experiments. 
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Table 7 3 . Cofactor dependence of leucine, valine and 2-oxoisocaproate oxidation by rat 
skeletal muscle mitochondria. 
Addition Leucine Valine 2-Oxoisocaproate 
None 0.26 ±0.05 1.36 ±0.09 1.29 ±0.28 
Coenzyme A 0.51 ±0.14** 1.56 ±0.24 1.45 ±0.17 
L-camitine 0.78 ±0.14* 2.56 ±0.29* 2.12 ±0.47*** 
Coenzyme A and L-camitine 0.92 ±0.15* 2.68 ± 0.05* 2.28 ±0.35** 
* Ρ < 0.001 ; ** Ρ < 0.01 ; *** Ρ < 0.05. 
As substrates were used 0.5 mM [l-Hcjleucine, 2 mM [l-14c]valine and 0.5 mM [l-14c]-
2-oxoisocaproate. Results (in nmol 14c02.mm"l .mg protein"!) were obtained in the pres­
ence of 1 mM 2-oxoglutarate, 0.1 mM coenzyme A and 2 mM L-camitine. Means with SD 
from 8 (leucine) or 4 experiments (valine and 2-oxoisocaproate) are given. The effects of 
the cofactors were analyzed by means of Student's t-test. Means after addition of coen­
zyme A or L-camitine were compared to those without addition; those after addition of 
both coenzyme A and L-camitine with those in the presence of coenzyme A alone. 
from 0.5 mM [l-14C]leucine and 0.15 ± 0.04 nmol ^CC^.muWmg protein"1 from 0.5 
mM [l-14C]2-oxoisocaproate. Although in muscle homogenates branched-chain amino 
acid transaminase activity greatly exceeds the activity of oxidative decarboxylation 
(Shinnick & Harper, 1976; Dohm et al., 1976), it still seems probable that after addition 
of leucine the concentration of 2-oxoisocaproate will remain below 0.5 mM. This suggest­
ion will be confirmed in chapter 9 (section 9.3). 
The effects of addition of coenzyme A and L-carnitine on oxidation of branched-
chain amino acids were similar to those observed in homogenates. Coenzyme A signifi­
cantly stimulated the 1 4 C02 production from [l-14C]leucine. The effect of coenzyme A 
on [l-'4C]valine oxidation was less, and was seen to be significant only when the paired 
t-test of Student was used (P < 0.001 without L-camitine, Ρ < 0.05 in the presence of 
L-camitine). Remarkably, coenzyme A had no effect on the 1 4 C02 production from 
[l-14C]2-oxoisocaproate. It is not clear why coenzyme A preferentially stimulated the 
oxidation of leucine. Stimulation of leucine oxidation was nearly maximal at 5 μΜ coen­
zyme A. The effect is not due to stabilization of enzymes by the SH-moiety of coenzyme 
A, since neither the addition of 1 mM glutathione, nor that of 1 mM dithiothreitol in­
fluenced the stimulation of leucine oxidation by coenzyme A. 
In the absence of coenzyme A, L-camitine stimulated the oxidation of [1-14C]-
labeled leucine, valine and 2-oxoisocaproate in mitochondria by 200, 87 and 64 % , res­
pectively. In the presence of coenzyme A, stimulation was about 72 % in all cases. 
Long-chain fatty acyl-CoA esters are known to be potent inhibitors of the mitochon­
drial adenylate translocator at very low concentrations (Pande & Blanchaer, 1971; Shug 
et al., 1971). Due to this inhibition they change the metabolic state of the mitochon-
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drion, which may influence the oxidative decarboxylation of the branched-chain amino 
acids. L-Camitine might indirectly stimulate oxidation of these amino acids by removing 
endogenous long-chain fatty acyl-coenzyme A esters. This effect does not seem to operate 
since the addition of 15 μΜ fatty acid-free dialyzed albumin had no effect on the stimu­
lation of leucine oxidation by L-carnitine. In section 8.3 further data are given, which ex­
clude the involvement of long-chain acyl-CoA esters. 
7.4. Discussion 
The rate of 1 4 C02 production from [l-14C]leucine should be 29 nmol ^CC^-h^.g 
tissue"' in the absence of coenzyme A and L-camitine, when it is assumed that the homo-
genate contains all mitochondria. This rate is about 25 % of that obtained in hemidia-
phragms (Buse et al., 1975) and comparable to that in rat muscle homogenates in the 
presence of coenzyme A and L-malate (Dohm et al. 1976). Addition of L-camitine and 
coenzyme A increased this rate to 117 nmol ^CC^.h^.g tissue"1. The rate of 1 4 C02 
production from [l-'4C]valine would be 239 nmol '4C02.h"'.g tissue"1 in the presence 
of carnitine and coenzyme A. This rate is higher than obtained with hemidiaphragms 
(Buse et al., 1975), partly since a higher substrate concentration was used. Since part of 
the mitochondria is precipitated by 600xg centrifugation, the oxidative capacity of the 
muscle tissue will be higher for both substrates. Thus the capacity of muscle homogenates 
for oxidation of branched-chain amino acids can be assayed optimally in the presence of 
Incarnitine. 
The effect of L-carnitine is found not to be due to removal of endogenous long-chain 
fatty acyl-CoA esters. Accumulation of branched-chain acyl-camitines was observed 
during oxidation of branched-chain amino acids in perfused rat hindquarters (Spydevold 
et al., 1976) and heart (Davis & Bremer, 1973) and by mitochondria of kidney and heart 
(Solberg & Bremer, 1970). This suggests that L-camitine is involved in or directly coupled 
to the transport or oxidative pathway of leucine and valine and their metaboUtes. The 
rate of ' 4 C 0 2 production from [l-l4C]-labeled branched-chain amino acids may depend 
on either the transamination or decarboxylation reactions, but also on the subsequent 
oxidation route. Reactions after oxidative decarboxylation may influence 1 4 C02 prod­
uction by accumulation of intermediates (Tanaka et al., 1976). 
L-Camitine may stimulate by either one of two different mechanisms, depending on 
the localization of the enzymes involved in transamination and oxidative decarboxyla­
tion. If oxidative decarboxylation occurs on the outer side of the mitochondrial inner 
membrane, L-camitine may transport the branched-chain acyl-CoA esters into the mito­
chondrial matrix. The oxidation of branched-chain amino acids would, however, be ex­
pected to be camitine-dependent, since no transport of short-chain acyl-CoA esters into 
muscle mitochondria is known to occur without the involvement of L-camitine. There­
fore it appears to be more probable that the enzyme system of oxidative decarboxylation 
is situated on the inner side of the mitochondrial inner membrane. In that case L-cami­
tine may stimulate the transport of branched-chain acyl groups out of the mitochondrion, 
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and intramitochondrial 'coenzyme A will remain available for oxidative decarboxylation. 
This will be discussed in the following chapter. 
7.5. Summary 
An accurate and sensitive method was developed for measuring the oxidation rates of 
leucine, valine and 2-oxoisocaproate in rat skeletal muscle homogenates and mitochon-
dria. 14C02 production from [l-I4C]-labeled substrates was markedly enhanced by 
2-oxoglutarate and L-camitine. Thiamine pyrophosphate did not affect oxidation, while 
pyruvate was inhibitory. Carnitine may stimulate oxidation by transporting branched-
chain acyl-groups out of the mitochondria, which leaves coenzyme A available for oxi-
dative decarboxylation. 
106 
CHAPTERS 
ROLE OF CARNITINE IN LEUCINE OXIDATION BY RAT 
MUSCLE MITOCHONDRIA 
8.1. Introduction 
Branched-chain amino acids are preferentially oxidized in muscle, while other amino 
acids are mainly oxidized in liver (Miller, 1961). The carnitine concentration of muscle 
is considerably higher than that in other tissues, except in kidney (Brooks & Mcintosh, 
1975). Carnitine stimulates the oxidation of branched-chain amino acids and their oxo 
acids in mitochondria and homogenates of rat skeletal muscle (section 7.3; Paul & Adibì, 
1978a) and in mitochondria of rat heart (Bremer & Davis, 1978). This stimulation may, 
therefore, be of physiological importance. Since the products of branched-chain oxo acid 
decarboxylation are branched-chain acyl-CoA esters, carnitine might be involved in the 
transport of their acyl-residues over the mitochondrial membrane. On the other hand, 
carnitine might stimulate branched-chain amino acid oxidation indirectly by removal of 
long-chain acyl-CoA esters, which are known to be potent inhibitors of various enzymes 
(Shrago, 1978). In this study we examine both possibilities, and make a proposal on the 
role of carnitine in leucine oxidation by muscular tissues. 
8.2. Materials and methods 
Male albino Wistar rats (180 - 240 g) were used, one rat per experiment. The animals 
were fasted for 18 - 24 h before they were sacrificed. Mitochondria were prepared as de-
scribed in section 2.3. Heparin was omitted during preparation of mitochondria of non-
muscular tissue. Oxidation rates were measured in a medium containing 10 mM potassium 
phosphate, 75 mM Tris-HCl (pH 7.4), 25 mM sucrose, 35 mM KCl, 1 mM EDTA, 5 mM 
MgCl2, 1 mM 2-oxoglutarate, 1 mM NAD+ , 25 μΜ cytochrome c, 0.1 mM coenzyme A, 
5 mM ADP and 2 mM L-camitine (unless otherwise mentioned). As substrate 0.5 mM L-
[l-^C]leucine or 0.5 mM [U-1^C]2-oxoisocaproate (spec. act. 100 дСі/ттоІ) was used. 
Incubation occurred in a final volume of 1.0 ml, containing 0.10-0.15 mg mitochondrial 
protein, at 370C for 30 min. ' 4 C 0 2 was trapped in 0.2 ml ethanolamine/ethyleneglycol 
(1:2, by vol). Reactions were terminated by the addition of 0.2 ml 30 % trichloroacetic 
acid. The vials were then incubated for 75 min at 0oC. Radioactivity of ^ C 0 2 was 
measured in a liquid scintillation counter with 0.4 % Omnifluor in toluene/methanol (2:1, 
by vol). [l^CJcamitine-esters were obtained in the supernatant of the incubation mixture. 
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Fig. 8.1. Effect of thiamine pyrophosphate on oxidative decarboxylation of 2-oxoiso-
caproate by intact and broken mitochondria of rat skeletal muscle. 
14C02 production from 0.5 mM [l-14c]2-oxoisocaproate was determined as 
described in section 8.2. Mitochondria were broken by triple freezing (- 60oC) 
and thawing at a concentration of 0.8 mg/ml mitochondrial protein. Thiamine 
pyrophosphate (0.15 mM)and dithiothreitol ( 1 mM) were added when indicated. 
0 - 0 intact mitochondria; · - · intact mitochondria + thiamine pyrophosphate 
and dithiothreitol; Δ - Δ broken mitochondria; A . A broken mitochondria 
+ thiamine pyrophosphate and dithiothreitol. 
They were separated from trichloroacetic acid and most of the 2-oxoisocaproate by two 
extractions with diethyl ether (Solberg & Bremer, 1970). After drying the residue was 
dissolved in ethanol/water (1:1, by vol) and the camitine-esters were separated by thin-
layer chromatography on silicagel G. The chromatograms were developed in diethylether/ 
formic acid (9:1, by vol) and after drying in methanol/chloroform/water/conc. ammonia/ 
formic acid (55:50:10:7.5:2.5, by vol) (Solberg & Bremer, 1970). Camitine-esters were 
identified by co-chromatography of unlabeled camitine-esters. This twofold thin-layer 
chromatography appeared to be adequate to separate the camitine-esters from 2-oxoiso­
caproate, 2-oxoglutarate and citrate. 
Palmitoyl-CoA concentration was determined by measuring the amount of coenzyme 
A (Allred & Guy, 1969) of the perchloric acid-insoluble fraction, which washydrolyzedat 
pH 11 (Oram et al., 1975). Protein concentration was determined as described in section 
2.8. 
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8.3 Results 
In contrast to pyruvate (section 7.3) and 2-oxoisovalerate, 2-oxoglutarate does not 
inhibit 2-oxoisocaproate oxidation when ADP is present (cf. section 9.3). Since 2-oxo-
glutarate was used in experiments with leucine for transamination, it was also added in 
experiments with 2-oxoisocaproate. In intact mitochondria oxidative decarboxylation of 
2-oxoisocaproate is independent of addition of thiamine pyrophosphate and is linear for 
40 min (Fig. 8.1). In frozen and thawed mitochondria the oxidation rate is reduced and 
can only be partially restored by the addition of thiamine pyrophosphate and dithiothrei-
tol. Restoration by thiamine pyrophosphate was equal from 0.05 -1.00 mM. The oxida­
tion rate in broken mitochondria was linear for 10-30 min. 
Oxidation of 2-oxoisocaproate by intact mitochondria of skeletal and heart muscle 
was stimulated 2.6 and 1.7 times, respectively, by addition of L-camitine (Table 8.1). In 
liver, kidney and brain mitochondria this process was not or only slightly stimulated by 
carnitine. Carnitine did not increase 2-oxoisocaproate oxidation in skeletal muscle mito­
chondria, which were broken by freezing and thawing (data not shown). Addition of car­
nitine to skeletal muscle, heart and kidney mitochondria during oxidation of [U-'4C]2-
oxoisocaproate caused accumulation of [^C]isovaleryl-camitine (Table 8.2). The amount 
of this substance always equaled or exceeded the increase in ^^COj production. No for­
mation of [14C]acetyl-camitine or [^CJpropionylcamitine was observed with skeletal 
muscle mitochondria. In liver and brain mitochondria much less ['4C]isovaleiylcamitine 
accumulated. A slight accumulation of [ ' 4C]acetylcamitine occurred in liver mitochon­
dria. 
Since long-chain fatty acids might be present in the skeletal muscle mitochondria and 
coenzyme A is present in the incubation system, some long-chain acyl-CoA esters might 
be formed during leucine oxidation. Therefore, the effect of palmitoyl-CoA on the rate of 
oxidative decarboxylation of leucine was tested in order to check whether carnitine might 
artificially stimulate leucine oxidation by skeletal muscle mitochondria. No effect was ob­
served after addition of 30 μΜ palmitoyl-CoA (Fig. 8.2). Addition of 40 μΜ palmitoyl-
CoA or more strongly decreased leucine decarboxylation. In intact mitochondria 2-oxo­
isocaproate oxidation was decreased to a similar extent at palmitoyl-CoA concentrations 
above 30 μΜ, but not in broken mitochondria (data not shown). 
The decrease of the oxidative decarboxylation rate of leucine and 2-oxoisocaproate 
coincides with a decreased oxygen consumption during palmitoyl-CoA oxidation (Fig. 
8.2). The latter decrease is known to be caused by inhibition of the adenylate transloca· 
tor (Pande & Blanchaer, 1971; Shug et al., 1971). Hence, the effect of high palmitoyl-
CoA concentrations on leucine and 2-oxoisocaproate oxidation may also be caused by the 
elevated redox state of the mitochondrion. During assay of leucine oxidation palmitoyl-
CoA concentration appeared, however, to be less than 2 μΜ. We can, therefore, exclude 
the possibility that carnitine stimulates leucine oxidation by removal of long-chain acyl-
CoA esters. 
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Table 8.1. Effect of L-camitine on [U-14C]2-oxoisocaproate oxidation by mitochondria 
of rat tissues. 
Tissue 
Muscle 
Liver 
Heart 
Kidney cortex 
Brain 
(8) 
(6) 
(3) 
(3) 
(3) 
nmol 1 4C02jnm" 
- L-camitine 
0.36 ± 0.06 
0.90 ± 0.29 
1.57 ±0.01 
2.69 ± 0.25 
0.62 ± 0.03 
1
 jng protein"1 
+ L-camitine 
0.94 ±0.14 
1.00 ±0.25 
2.71 ±0.08 
2.93 ±0.16 
0.72 ± 0.06 
+ L-camitine 
- L-camitine 
2.65 ±0.51** 
1.15 + 0.16 
1.72 ±0.04* 
1.10 ±0.06 
1.16 ±0.03 
* * P < 0.001 ; * P < 0.01. 
14C02 production from 0.5 mM [U-l4C]2-oxoisocaproate was determined as described 
in section 8.2. The ratios between 14C02 production in the presence and absence of L-
camitine (2.0 mM) were separately determined in each experiment. Values are means 
with SD for the number of experiments indicated between parentheses. Statistical signi­
ficance was calculated by the paired t-test. 
Table 8.2. Increase in production of 1 4 C02 and [14C]isovaleryl-camitine by carnitine 
during oxidation of [U-14C]2-oxoisocaproate by mitochondria of rat tissues. 
Tissue η AC02 Isovaleryl-camitine 
Muscle 
Liver 
Heart 
Kidney cortex 
Brain 
6 
6 
3 
3 
3 
0.51 ±0.09 
0.10 ±0.13 
0.81 ±0.10 
0.24 ±0.18 
0.10 ±0.01 
0.64 ± 0.07 
0.19 ±0.07 
132 ±0.04 
0.99 ±0.10 
0.24 ± 0.04 
Production of 1 4 C02 and [ 14C]isovaleryl-camitine from 0.5 mM [U-l4C]2-oxoisocapro-
ate was determined with and without addition of carnitine as described in section 8.2. 
Without addition of carnitine no isovaleryl-camitine was detected. Values of increase (in 
nmol l4C-labeled product .min"1.mg protein-!) represent means with SD for the number 
of experiments indicated under n. 
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Fig. 8.2. Effect of palmitoyl-CoA concentration on oxygen consumption and leucine de­
carboxylation by rat skeletal muscle in mitochondna. 
Decarboxylation of 0.5 mM [l-14c]leucine was determined in the presence of 
2.0 mM L-camitine as described in section 8.2. Oxygen consumption during oxi­
dation of palmitoyl-CoA was determined polarographically in a similar medium 
as leucine oxidation, but 0.5 mM L-malate was substituted for 2-oxoglutarate. 
о - о oxygen consumption; · - · leucine decarboxylation. Values represent 
means with SEM of 4 and 6 experiments, respectively. 
8.4. Discussion 
Although several authors have reported the occurrence of branced-chain acyl-cami-
tine esters during oxidation of branched-chain amino acids or oxo acids in several tissues 
(Solberg & Bremer, 1970; Davis & Bremer, 1973; Spydevold et al., 1976; Bieber& Choi, 
1977), the role of these esters is still unknown (Bieber & Choi, 1977). Using [3H]cami-
tine, Spydevold et al. (1976) observed accumulation of ^H-labeled isovaleryl-camitine 
and acetyl-carnitine during oxidation of 2-oxoisocaproate by rat skeletal muscle. In other 
tissues propionyl-camitine was observed (Solberg & Bremer, 1970; Davis & Bremer, 1973). 
These camitine-esters were also extracted from skeletal muscle, heart, liver and testis of 
rats that had been fasted for 18 hr (Bieber & Choi, 1977; Choi et al., 1977). With skeletal 
muscle mitochondria and [U-l^Cp-oxoisocaproate as substrate we could only demon­
strate formation of [^Cjisovaleryl-camitine. Acetyl-carnitine and propionyl-camitine 
must therefore be formed from other substrates in this tissue. The exclusive accumulation 
of [14C]isovaleryl-camitine agrees with the observation that skeletal muscle tissue lacks a 
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3-hydroxy-3-methyl-glutaryl-CoA lyase (McGarry & Foster, 1969). [ ' 4C]Isovaleryl<anii-
tine also accumulated during oxidation of [U-14C]2-oxoisocaproate by heart and kidney 
cortex mitochondria. 
It is interesting to note that [^4C]isovaleryl-camitine markedly accumulated with 
mitochondria of those tissues (skeletal muscle, heart, kidney) which physiologically con-
tain a high concentration of carnitine (Brooks & Mcintosh, 1975), but only slightly in 
liver and brain mitochondria which have low carnitine concentrations. The latter tissues 
probably have a limited activity of a suitable carnitine transferase or translocase. Such a 
limitation might also explain why 2-oxoisocaproate oxidation is not stimulated by carni-
tine in brain mitochondria which are deficient in 3-hydroxy-3-methyl-glutaryl-CoA lyase 
activity (McGarry & Foster, 1969), whereas carnitine markedly stimulated in mitochondria 
of skeletal muscle and heart. 
Bieber and Choi (1977) proposed that carnitine might cany isovaleryl-residues into 
the mitochondrion. The suggestion that the branched-chain oxo acid dehydrogenase com-
plex of liver would be situated at the outer surface of the inner mitochondrial membrane 
(Johnson & Connelly, 1972) would favor this proposal, but this location was recently 
questioned (Bremer & Davis, 1978). The proposed mechanism would not be advantageous 
in muscular tissue, since it cannot further degrade the isovaleiyl-group (McGarry & Foster, 
1969). Our study presents evidence that carnitine is involved in leucine oxidation in mus-
cular tissue by removal of isovaleryl-residues out of the mitochondrion to liberate intra-
mitochondrial coenzyme A for further oxidation. 
Formation of isovaleryl-CoA within the mitochondrion is indicated by the following 
observations: (a) oxidation of 2-oxoisocaproate was stimulated by thiamine pyrophos-
phate only in broken mitochondria, (b) carnitine stimulated this oxidation only in intact 
mitochondria. An inner mitochondrial localization of the branced-chain oxo acid dehy-
drogenase complex is also suggested by the parallel effects of palmitoyl-CoA on the ade-
nylate translocator and on the oxidation of leucine and 2-oxoisocaproate. The fate of 
isovaleryl-camitine in the cytoplasm of skeletal muscle is not clear. In kidney and liver 
isovaleryl-camitine may act as a reservoir of substrate, which would be further oxidized 
after depletion of 2-oxoisocaproate. In muscle it appears more likely that the isovaleryl-
residues will leave the muscular tissue to be degraded in other tissues. Since transamination 
and 2-oxoisocaproate decarboxylation are largely performed in muscle (Paul & Adibi, 
1978), leucine oxidation appears to take place in more than one tissue. 
8.5. Summary 
Oxidative decarboxylation of 2-oxoisocaproate, the oxo acid derivative of leucine, by 
rat skeletal muscle mitochondria was determined. After rupture of the mitochondria, 2-
oxoisocaproate oxidation markedly decreased. Thiamine pyrophosphate could partly 
restore the activity of damaged mitochondria, but had no effect on intact mitochondria. 
Carnitine stimulated 2-oxoisocaproate oxidation in intact mitochondria of skeletal 
and heart muscle, but not in those of liver, kidney cortex and brain, nor in broken mito-
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chondria of skeletal muscle. The stimulation was accompanied by an accumulation of iso-
valeryl-camitine. 
At palmitoyl-CoA concentrations higher than 30 μΜ, both leucine oxidation and 
oxygen consumption by palmitoyl-CoA oxidation decreased. Since the concentration of 
long-chain acyl-CoA esters remained below 2 μΜ during oxidation of 2-oxoisocaproate, 
the carnitine stimulation of branched-chain amino acid oxidation was not caused by re­
moval of long-chain acyl-CoA esters. 
It is proposed that carnitine plays a role in leucine oxidation in muscle by transport 
of isovaleryl-residues out of the mitochondrion, and that these isovaleryl-residues have to 
be oxidized in other tissues. 
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CHAPTER 9 
2-OXOISOCAPROATE OXIDATION BY RAT SKELETAL MUSCLE MITOCHONDRIA 
LOCALIZATION OF THE 2-OXOISOCAPROATE DEHYDROGENASE COMPLEX 
9.1 Introduction 
Branched-chain amino acids play an important role in the protein balance of the or-
ganism (Goldberg &. Chang, 1978) and act as a substrate for energy production during 
starvation and exercise (Felig, 1976; Paul & Adibi, 1978a). During rest they are mainly 
stored in skeletal muscle (Goldberg & Chang, 1978), which has also the highest capacity 
for transamination of all tissues (Shinnick & Harper, 1976). However, capacity of ox-
idative decarboxylation is low in skeletal muscle and predominantly present in liver (Shin-
nick & Harper, 1976). 
Johnson & Connelly (1972) reported that the branched-chain oxo acid dehydrogenase 
(BCOA-DH) complex is situated on the outer surface of the mitochondrial inner mem-
brane, but their results have recently been questioned (Bremer & Davis, 1978; section 
8.4). If the BCOA-DH complex would be situated inside the mitochondrion, its activity in 
skeletal muscle might be underestimated, since it might be affected by a limitation in the 
distal part of the oxidation route (Tanaka, 1976). Such a limitation could exist, since no 
activity of hydroxy-methyl-glutaryl-CoA lyase was detected in skeletal muscle homo-
genates of the rat (McGarry & Foster, 1969). 
Recently, it has been shown that the flux through the BCOA-DH in skeletal muscle 
mitochondria and homogenates can be stimulated by the addition of carnitine (Paul & 
Adibi, 1978; sections 7.3 and 83). This enhancement of 2-oxoisocaproate oxidation was 
accompanied by a stochiometric accumulation of isovaleiyl-camitine (section 8.3). Since 
the carnitine concentration in muscle is relatively high compared to that in other tissues 
(Broekhuysen et al., 1965; Brooks & Mcintosh, 1975), the stimulatory effect of carnitine 
may reflect a physiological phenomenon. Short-circuiting the oxidation route of 2-oxo-
isocaproate by carnitine, has enabled us to reevaluate the localization of the BCOA-DH 
complex in rat skeletal muscle, and to examine the effects of citric acid cycle intermedi-
ates and the redox state of the mitochondrion on the uptake and oxidative decarboxyla-
tion of 2-oxoisocaproate by muscle mitochondria. 
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9.2. Materials and methods 
Male albino Wistar rats (180 - 240 g) were used, one rat per experiment. The rats 
were fasted for 18 - 24 h before they were killed. Homogenates (600xg supernatant) and 
mitochondria were prepared as described in section 2.3. The mitochondria appeared to 
be intact from their RCI values and ADP/O ratios (section 2.4). 
Oxidation rates were measured in a medium containing 10 mM potassium phosphate, 
75 mM Tris-HCl (pH 7.4), 25 mM sucrose, 35 mM KCl, 1 mM EDTA, 5 mM MgC^, 1 mM 
2-oxoglutarate, 1 mM NAD+ , 25 μΜ cytochrome c, 0.1 mM coenzyme A, 5 mM ADP 
and 2 mM L-camitine (unless otherwise mentioned). L-[l-14C]leucine or [l-1 4C]2oxo-
isocaproate was used as substrate (spec. act. 100 дСі/ттоІ). Incubation occurred in a 
final volume of 1.0 ml containing 0.10-0.15 mg mitochondrial protein at 370C for 30 
min. 1 4 C02 was trapped in 0.2 ml ethanolamine/ethyleneglycol(l:2,by vol). Reactions 
were terminated by the addition of 0.2 ml 3 M perchloric acid, and the vials were incu­
bated for 75 min at 0oC. Radioactivity of 1 4 C 0 2 was measured with 0.4%Omnifluor in 
toluene/ methanol (2 : 1, by vol). 
Transamination rates were determined by chemical decarboxylation of the oxo acids 
with eerie sulphate (Shinnick & Harper, 1976). Incubation time and conditions were iden­
tical to those for the determination of oxidative decarboxylation, but the final volume 
was 0.2 ml. The reaction was stopped and the 2-oxoisocaproate formed in the reaction 
mixture was decarboxylated by addition of 0.6 ml 0.2 M eerie sulphate in 2 M H2SO4 
with a syringe through the serum cap. Resulting 1 4 C 0 2 was bound to 0.2 ml 1 M Hyamine 
hydroxide 10-X in methanol, which was injected into the center well immediately before 
addition of the eerie sulphate solution. After 90 min incubation at 370C radioactivity of 
1 4 C02 was determined with 0.4 % Omnifluor in toluene/methanol (2 : 1, by volume). 
Samples containing various amounts of 2-oxoisocaproate were used to correct for the 
variable efficiency of decarboxylation by eerie sulphate. 
Cytochrome с oxidase activity and protein concentration were determined as de­
scribed in sections 2.5 and 2.8. 
9 3 . Results 
Concentration dependences of leucine transamination and 2-oxoisocaproate decarb­
oxylation in rat skeletal muscle homogenates and mitochondria are given in Fig. 9.1. When 
the rates with 0.5 mM L-leucine are expressed on the basis of cytochrome с oxidase ac­
tivity, the mean rates of transamination and oxidative decarboxylation were 0.61 and 
0.096 nmoLmin'^Oimol cyt с min"')"^ with homogenates and 0.51 and 0.125 nmol. 
jnin"10imol cyt с min"1)"1 with mitochondria, respectively. The rate of transamination 
exceeds markedly that of oxidative decarboxylation in both mitochondria and homo­
genates of rat skeletal muscle. The oxidation rates with homogenates might be somewhat 
underestimated by the presence of endogenous branched-chain amino acids or pyruvate, 
which is inhibitory (section 7 J ) . Oxidative decarboxylation appears to be maximal at 
0.2 - 0 3 mM leucine in mitochondria and homogenates. These values are comparable to 
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Fig. 9.1. Effect of substrate concentration on transamination and oxidative decarboxyla-
tion of leucine. 
Transamination and oxidative decarboxylation of L-[l-14c]leucine by homoge-
nates (600xg supernatant) and mitochondria of rat skeletal muscle were meas-
ured in the presence of 5 mM ADP, 1 mM 2-oxoglutarate and 2 mM L-camitine. 
Transamination was determined from the total amount of 14(Χ)2 after chemical 
decarboxylation of the resulting 2-oxoisocaproate. Details are given in section 
9.2. At all concentrations transamination and oxidative decarboxylation pro­
ceeded linearly for a 30 min period. Data represent the means of 3 experiments. 
Note the difference in scale. 
о - о transamination; · - · oxidative decarboxylation. 
those previously reported for rat skeletal muscle homogenates (Paul & Adibì, 1975). 
Oxidation of 2-oxoisocaproate showed biphasic kinetics. At low concentrations of 2-
oxoisocaproate an increase in oxidative decarboxylation was observed, which is com-
parable to that with leucine. At concentrations above 0.15 mM an additional increase in 
14C02 production from [l-14C]2-oxoisocaproate is noted (Fig 9.2). Two apparent Km 
values of 9.1 ± 4.7 μΜ and 0.78 ± 0.40 mM (means with SD of 5 experiments) could be 
calculated. Under our experimental conditions mitochondria produced about 40 nmol 2-
oxoisocaproate per ml during a 30 min oxidation period at 1.0 mM leucine. This explains 
why the biphasic kinetics of decarboxylation was not observed with leucine. Only one 
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Fig. 9.2. Effect of substrate concentration on oxidative decarboxylation of 2-oxoisoca-
proate by rat skeletal muscle mitochondria. 
Oxidative decarboxylation of [l-14C]2-oxoisocaproate was determined in intact 
( · - · ) and broken (A - A) mitochondria in the presence of 5 mM ADP, 1 mM 2-
oxoglutarate and 2 mM L-camitine. Mitochondria were disrupted by thrice 
freezing and thawing after dilution with 0.25 M sucrose - 10 mM Tris-HCl (pH 
7.4) - 0.2 mM EDTA. Inset graphs represent Lineweaver-Burk plots of 2-oxoiso-
caproate oxidation by intact ( · - · ) and broken (A - A) mitochondria. 
Michaelis-Menten constant was found in studies with the purified BCOA-DH complex of 
rat and ox liver (Parker et al., 1978; Connelly et al., 1968), and in those with rat liver 
mitochondria (Wohlhueter & Harper, 1970). When we disrupted the mitochondria by 
freezing and thawing, not only the rate of oxidative decarboxylation decreased (cf. sec-
tion 83), but also the pattern of a high affinity at low 2-oxoisocaproate concentrations 
disappeared. This phenomenon may suggest that an accumulation of 2-oxoisocaproate 
inside the mitochondrion favours oxidative decarboxylation. 
A prerequisite for this suggestion is that the BCOA-DH complex is situated at the 
inner surface of the inner membrane of the mitochondrion. Isovaleryl-CoA inhibits the 
partially purified BCOA-DH complex (Parker et al., 1978a), but this molecule cannot 
penetrate through the mitochondrial inner membrane. Isovaleiyl-camitine can be trans-
ported into the matrix, where it will be converted to isovaleryl-CoA (cf. section 8 J;Paul 
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Fig. 9.3. Effect of isovaleryl-CoA and isovaleryl-L-camitine on oxidative decarboxylation 
of 2-oxoisocaproate by rat skeletal muscle mitochondria. 
Oxidative decarboxylation of 0.5 mM [l-14c]2-oxoisocaproate was determined 
in the presence of 5 mM ADP, 1 mM 2-oxoglutarate and 0.1 mM coenzyme A. 
The effects of isovaleryl-CoA and isovaleryl-L-camitine were measured in the 
presence and absence of L-camitine. · - · isovaleryl-CoA; о - o isovaleryl-L-cami­
tine; A . A isovaleryl-CoA + 2 mM L-camitine; Δ - Δ isovaleryl-L-camitine + 2 
m M L-camitine. 
& Adibi, 1978). Therefore, the effects of addition of these isovaleryl esters on oxidative 
decarboxylation of 2-oxoisocaproate will be different when the BCOA-DH complex is 
localized inside the mitochondrion, but similar when the complex is situated at the outer 
surface of the inner membrane. Fig. 9.3 shows that isovaleryl-CoA has no effect on the 
oxidation of 2-oxoisocaproate by intact rat muscle mitochondria, and slightly stimulated 
in the presence of L-camitine. Isovaleryl-camitine inhibited 2-oxoisocaproate oxidation. 
This inhibition increased with increasing isovaleryl-camitine concentrations. 
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Table 9.1. Effect of metabolic state and cosubstrates on 2-oxoisocaproate oxidation by 
rat skeletal muscle mitochondria. 
Addition 
None 
L-malate (ImM) 
Succinate (1 mM) 
2-Oxoglutarate (1 
2-Oxoglutarate (1 
2-Oxoglutarate (1 
mM) 
mM) +rotenone (4дм; 
mM)+FCCP(^M) + 
valinomycine (1 μΜ) 
Relative oxidation rate 
-ADP 
100 
127 ±13(3) 
68 ± 17 (3) 
74+12(4) 
) -
-
+ 5mMADP 
152 ± 6(4) 
174 ± 1(3) 
172 ± 9(3) 
201 ± 7(4) 
14 ± 4(3) 
48±11(4) 
Rat skeletal muscle mitochondria were prepared as described in section 2.3, but ATP was 
omitted from the media. Oxidation of 0.1 mM [l-14c]2-oxoisocaproate occurred for 15 
min in the medium described in section 9.2, but 2-oxoglutarate was only added when in­
dicated. Relative values are expressed as the means with SD of the rate obtained without 
additions (0.37 nmol 14c02.min"l.mg protein"!) for the number of experiments indi­
cated between parentheses. 
These data indicate that the BCOA-DH complex is located at the inner side of the 
mitochondrial inner membrane. This is further supported by the observation that oxi­
dative decarboxylation is affected by the metabolic state of the mitochondrion. Addition 
of ADP causes an increase in the rate of 1 4 C02 production from [l-14C]2-oxoisocapro-
ate by rat skeletal muscle mitochondria (Table 9.1). In the presence of ADP, addition of 
malate, succinate and 2-oxoglutarate slightly stimulated this rate, while palmitoyl-L-cami-
tine did not. Under these conditions pyruvate and 2-oxoisovalerate at 1 mM concentra­
tion reduced oxidation of 2-oxoisocaproate by 74 and 51% , respectively. Without ADP 
succinate and 2-oxoglutarate were inhibitory, whereas malate was not. 
Elevation of the redox state of the mitochondrion by the addition of rotenone in­
hibited oxidative decarboxylation by more than 90%. The presence of 1 mM NAD+ in 
the incubation system had no effect on oxidative decarboxylation. ^4C02 production 
from [l-14C]2-oxoisocaproate was also inhibited by the simultaneous addition of FCCP 
and valinomycine. The effects of 2-oxoglutarate with FCCP or valinomycine alone were 
smaller and rather variable. 
9.4. Discussion 
From the rates of leucine oxidation by homogenates and mitochondria of rat skeletal 
muscle expressed on the basis of cytochrome с oxidase activity it can be concluded that 
the BCOA-DH activity is localized in the mitochondria, as it is in kidney, liver and heart 
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(Dawson et al., 1967; Wohlhueter & Harper, 1970; Johnson & Connelly, 1972). From 
studies on bovine liver mitochondria Johnson & Connelly (1972) concluded that the 
BCOA-DH complex would be situated on the outer surface of the mitochondrial inner 
membrane. However, their conclusions were solely based on experiments with ferricyani-
de, which require intactness of the mitochondria. The intactness of their mitochondria 
has recently been questioned (Bremer & Davis, 1978), since coenzyme A and NAD"1"were 
required for maximal activity. 
In intact rat skeletal muscle mitochondria coenzyme A or thiamine pyrophosphate 
had no effect on the rate of oxidation of 2-oxoisocaproate (sections 7.3 and 8.3). Nor 
could addition of NAD+ overcome the nearly complete inhibition of the oxidative de-
carboxylation by rotenone. On the contrary, thiamine pyrophosphate markedly stimu-
lated the oxidation in broken mitochondria (section 8.3). Oxidation of 2-oxoisocaproate 
by rat liver and heart mitochondria was also unaffected by the addition of coenzyme A 
and NAD+ (Noda & Ishihara, 1974; Bremer & Davis, 1978). On the basis of these data it 
was suggested that the BCOA-DH complex is situated inside the mitochondrion (section 
8.4; Bremer & Davis, 1978). The effects of isovaleryl-CoA and isovaleryl-camitine on the 
oxidative decarboxylation of 2-oxoisocaproate reported in this chapter confirm this sug-
gestion. 
Evidence for the location of the BCOA-DH complex inside the mitochondrion is 
further strengthened by the inhibitory effects of rotenone and FCCP and valinomycine. 
Addition of FCCP and valinomycine causes a collapse of the potential over the mitochon-
drial inner membrane (Green, 1977). This might cause the mitochondria to deteriorate or 
the uptake of 2-oxoisocaproate to be impaired, comparable to what happens with the up-
take of pyruvate (Halestrup, 1978). In any case, the decrease would only occur when the 
BCOA-DH complex is situated inside the mitochondrion. The decrease of ketogenesis in 
liver mitochondria by dinitrophenol (Noda & Ishihara, 1974) may probably be due not 
only to the decrease of carboxylation of 3-methyl-crotonyl-CoA by depletion of ATP, 
but also to inhibition of the uptake or decarboxylation of 2-oxoisocaproate. 
Citric acid cycle intermediates and adenine nucleotides affect the rate of ketogenesis 
from 2-oxoisocaproate by rat liver mitochondria (Noda & Ishihara, 1974) and homo-
genates (Krebs & Lund, 1975). An explanation of these effects was mainly sought in the 
availability of oxaloacetate and in the carboxylation of 3inethyl-crotonyl-CoA. Under 
our experimental conditions rat skeletal muscle mitochondria did not further oxidize 
isovaleryl-CoA, but converted it to isovaleryl-camitine (section 8.3). This means that the 
effects of citric acid cycle intermediates and ADP reflect a direct action on the uptake or 
decarboxylation of 2-oxoisocaproate by these mitochondria. The inhibition by 2-oxoglu-
tarate in the absence of ADP cannot be due to competition like in the case of pyruvate, 
2-oxoisovalerate and 2-oxo-3-methyl-valerate, because it would then also inhibit in the 
presence of ADP. It seems more probable that an increase of the succinyl-CoA concen-
tration leads to this inhibition, since both succinate and 2-oxoglutarate are inhibitory in 
the absence of ADP, whereas L-malate is not, like in heart mitochondria (Bremer & Davis, 
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1978). It is uncertain whether succinyl-CoA itself inhibits the BCOA-DH complex, or that 
removal of coenzyme A decreases the activity of oxidative decarboxylation. 
Partially purified or solubilized rat liver 2-oxoisocaproate dehydrogenase showed a 
single K
m
 value ranging from 8.7 to 32 μΜ (Parker et al., 1978; Danner et al. 1978). 
With rat liver mitochondria the apparent K
m
 appeared to be 200 μΜ (Wohlhueter & Har­
per, 1970). At concentrations of 2-oxoisocaproate above 0.5-2.0 mM inhibition was ob­
served (Parker et al., 1978; Wohlhueter & Harper, 1970). With rat heart mitochondria half 
maximal rate of oxidation was obtained with 0.1 mM 2-oxoisocaproate (Bremer & Davis, 
1978). Studies on skeletal muscle only considered substrate dependence of 2-oxoisoca­
proate oxidation by intact pieces of muscle (Odessey & Goldberg, 1972; Buse et al., 
1975) and can therefore not be used for comparison. With rat skeletal muscle mitochon­
dria we observed two K
m
 values. The biphasic kinetics and particularly the high affinity 
at low 2-oxoisocaproate concentration may reflect accumulation of 2-oxoisocaproate in 
the mitochondrion by the transport mechanism, since it disappeared after freezing and 
thawing. However, it must be noticed that after disruption of the mitochondria the acti­
vity of 2-oxoisocaproate and other oxo acid dehydrogenases is markedly decreased (sec­
tion 8.3; Araki, 1977). A second possibility might be that the low K
m
 value observed on 
rat skeletal muscle mitochondria reflects a BCOA-DH which is comparable to the purified 
or solubilized liver enzyme. The higher K
m
 value might then be explained by the ability 
of an other oxo acid dehydrogenase to decarboxylate 2-oxoisocaproate. 
Fig. 9.4 summarizes the oxidation pathway of leucine in rat skeletal muscle. Trans­
amination mainly proceeds in the cytoplasm (Taylor & Jenkins, 1966; Paul & Adibì, 
1975), but our data showed that a considerable part may be associated with the mito-
chondria. This was recently confirmed by Cappucinoetal. (1978). Oxidative decarboxy-
lation occurs within the mitochondrion. Data on the further oxidation of isovaleryl-CoA 
are conflicting. No hydroxy-methyl-glutaryl-CoA lyase activity could be detected in rat 
skeletal muscle homogenates (McGarry & Foster, 1969) and '^C02 production from 
[l-14C]leucine was six times that from [U-14C]leucine at the same specific activity in 
slices and homogenates of gastrocnemius muscle (Paul & Adibi, 1975). We could confirm 
this latter observation with m. quadriceps in our experimental conditions. The accumu-
lation of isovaleryl-camitine during oxidation of leucine and 2-oxoisocaproate by perfused 
rat skeletal muscle (Spydevold et al., 1976) and mitochondria of rat muscle (section 8.3) 
also indicates a limitation in the further oxidation. On the other hand, in intact dia-
phragm muscle 14C02 production from [l-14C]leucine was only 1.5 times that of 
[U-14C]leucine at the same specific activity (Odessey & Goldberg, 1972;Buseetal., 1975). 
Dohm et al. (1977) reported 14C02 production from [U-14C]leucine, which was40%of 
that of [l-14C]leucme in rat skeletal muscle homogenates. Calculations of the oxygen 
consumption during leucine oxidation in intact diaphragm muscle of the rat also lead to 
the conclusion that leucine is totally oxidized (Chang & Goldberg, 1978). The production 
of 14C-labeled sterols from [14C]leucine by skeletal muscle indicates that hydroxy-methyl-
glutaryl-CoA can be formed (Rosenthal et al., 1974). The discrepancy between these re-
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Fig. 9.4. Leucine oxidation in rat skeletal muscle. 
suits suggests that further oxidation may take place under certain conditions, or else that 
differences may exist between different types of skeletal muscle. 
9.5. Summary 
Oxidation of 2-oxoisocaproate showed biphasic kinetics. Two apparent Кд, values of 
9.1 μΜ and 0.78 mM were determined. In broken mitochondria the rate of 2-oxoisoca­
proate decarboxylation decreased and only the higher K
m
 value was found. 
Isovalerylomitine inhibited 2-oxoisocaproate decarboxylation in the presence and 
absence of carnitine. Isovaleryl-CoA had no inhibitory effect on 2-oxoisocaproate oxida­
tion. 
Addition of ADP enhanced 2-oxoisocaproate decarboxylation. In the presence of 
ADP, malate, succinate and 2-oxoglutarate increased additionally the rate of decarboxyla­
tion, but in the absence of ADP succinate and 2-oxoglutarate inhibited, probably by re­
moval of coenzyme A for succinyl-CoA formation. Addition of rotenone and simultane­
ous addition of FCCP and valinomycine markedly decreased 2-oxoisocaproate decarb­
oxylation. These observations indicate that the branched-chain oxo acid dehydrogenase 
complex is situated on the inner site of the mitochondrial inner membrane. 
It is indicated that previous studies have probably underestimated the capacity of 
2-oxoisocaproate oxidation by skeletal muscle. It is discussed whether complete oxidation 
of leucine occurs in skeletal muscle. The final part of the oxidation route, however, ap­
pears to be limited in isolated mitochondria. 
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CHAPTER 10 
SURVEY AND SUMMARY 
10.1 Introduction 
Insight in the metabolic aspects of striated muscle is not only important for our 
understanding of locomotion, respiration and heart function. On account of its relatively 
large tissue mass, skeletal muscle may also play an important role in the metabolism and 
balance of proteins, lipids and carbohydrates in the whole body. The investigations pre-
sented in this thesis are concerned with two aspects of muscle metabolism: fatty acid ox-
idation by striated muscle of man and rat (chapters 3 - 6), and the capacity of rat skeletal 
muscle to oxidize branched-chain amino acids, particularly leucine (chapters 7 - 9). 
During the last three years several studies have been published on other aspects of 
metabolism of human skeletal muscle. These studies concern pyruvate metabolism, citric 
acid cycle and respiratory chain (Willems, 1978; Bookelman, 1978), glycogenolysis (Essen, 
1978), the effect of pH on muscle metabolism (Saltin, 1978) and metabohc studies on 
teased human muscle fìbers (Bylund et al., 1975). The studies presented in this thesis can 
be considered as an additional contribution to the insight in the metabolism of striated 
muscle of man obtained in the last three years. 
10.2 Fatty acid oxidation in striated muscle of man and rat 
Fatty acids are the main fuel for striated muscle under various conditions (section 
1.2.5). During rest the energy requirement of skeletal muscle is nearly completely supplied 
by fatty acids, while during moderate exercise fatty acids supply 40 - 80 % of the energy. 
After fasting the relative contribution of fatty acids is even higher. 
Interest of clinicians in fatty acid oxidation by skeletal muscle was stimulated by the 
observation of cases of deficiency in carnitine and carnitine palmitoyl transferase. Al-
though patients with these deficiencies are relatively rare, some thirty of them were re-
ported during the last five years, and the number still increases. The effect of long-chain 
acyl-esters of coenzyme A and carnitine on mitochondrial functions also received clinical 
attention as a result of the observation that the level of these compounds markedly in-
creases during myocardial ischemia. 
Fatty acid oxidation by homogenates of muscle is usually measured by determining 
the rate of 14C02 production from [14C]fatty acids. However, 14C02 production by 
homogenates and mitochondria of human and rat skeletal and cardiac muscle only re-
123 
presents a small part of the total oxidative capacity (chapters 3 - 6). The main part of de­
gradation products consists of citric acid cycle intermediates and acetyl-carnitine. Several 
authors reported accumulation of citrate during fatty acid oxidation in intact muscle 
(Fitts et al., 1976; Hiltunen & Hassinen, 1977) , but with isolated mitochondria we found 
mainly 2-oxoglutarate, malate and succinate as citric acid cycle intermediates. Since it is 
suggested that fatty acids decrease glycolysis in skeletal muscle by elevating the citrate 
concentration in the cytoplasm (Rennie et al., 1976), future investigations are necessary 
on the origin of the citrate present in the cytoplasm of muscle. 
Measurement of l^CC^ production from [^CJfatty acids is particularly unsuited for 
studies of human muscle, since the 1 4 C02 production depends on the palmitate/albumin 
ratio in the assay system and is only measurable at unphysiologically high values of this 
ratio (chapter 5). Considerable variation is observed in the rate of 1 4 C02 production 
from [14C]palmitate by human muscle homogenates, even when this rate is expressed on 
the basis of the mitochondrial marker enzymes cytochrome с oxidase and monoamine 
oxidase (chapter 5). 
Polarographie determination of the oxygen consumption is a more adequate measure­
ment of fatty acid oxidation by mitochondria (chapter 3 and 5). However, it is not suit­
able for measurements of fatty acid oxidation in homogenates of muscle, since the pre­
sence of endogenous substrates and probably that of the oxygen binding protein myoglo­
bin interfere. The assay of oxygen consumption of mitochondria requires more muscular 
tissue than a radiochemical assay. Therefore we prefer to measure the sum of ^ 4C02 and 
14C-labeled acid-soluble products formed during oxidation of [14C]fatty acids. Such 
measurements gave similar rates of fatty acid oxidation by mitochondria as obtained by 
Polarographie assay of oxygen consumption (chapters 3 and 5). 
The sum of 1 4 C02 and '4C-labeled acid-soluble products depends on the position of 
the label in the [14C]pa]mitate used as substrate. The amounts of these products formed 
from [l-14C]pa]mitate exceeded that from [U-14C]palmitate (chapters 3 - 6), which in 
tum was larger than that from [16-'4C]palmitate (chapter 4). These differences arise 
during oxidation by mitochondria and homogenates and are caused by the accumu­
lation of /3-oxidation intermediates. The intermediates are mainly present as free fatty 
acids and carnitine esters in our system (chapter 4). Their production is not related to the 
composition of the incubation medium and is observed with mitochondria of rat and 
human skeletal and cardiac muscle (chapters 4 - 6). Since muscular tissue of rat and par­
ticularly man contain high concentrations of carnitine (section 2.7), accumulation of car­
nitine esters of ß-oxidation intermediates may occur in vivo. The observation by Elovson 
(1965) that 10-20% of the injected [3-,4C]stearate was found as [l-14C]palmitate in 
the intact rat supports the suggestion that intermediates of 0-oxidation are formed in 
vivo. However, it remains questionable whether the presence of a steady state level of β-
oxidation intermediates in the muscle fiber is of physiological interest. 
The assay of the sum of 1 4 C02 and 14C-labeled acid-soluble products was adapted 
to a microscale, which permits measuring fatty acid oxidation in muscle biopsies of about 
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10 mg. No marked differences were observed in various types of human striated muscle, 
when palmitate oxidation rates were expressed relative to cytochrome с oxidase activity. 
When these oxidation rates were expressed on the basis of protein content, human heart 
muscle showed a markedly higher capacity for palmitate oxidation than skeletal muscle 
(chapter 5). 
Palmitate oxidation by human and rat skeletal and cardiac muscle shows many simi­
larities (chapters 3, 5 and 6). Therefore, observations on rat skeletal and cardiac muscle 
can in general be considered to be indicative for the fatty acid oxidation in human muscles. 
However, differences are observed between man and rat in the carnitine concentration of 
skeletal muscle (section 2.7) and the oxidative capacity per mg homogenate protein (chap­
ter 5). Furthermore, at palmitate/albumin ratios of 5 : 1 as well as 8 : 1 fatty acid ox­
idation in human muscle mitochondria is inhibited at a lower palmitate concentration 
than in rat muscle mitochondria. The amount of 14C02 produced from [^C]palmitate 
by human muscle mitochondria depends on the palmitate/albumin ratio, but this ratio 
has no effect on the 1 4 C02 production by rat muscle mitochondria. A possible explana­
tion for these observations may be that mitochondrial functions of human muscle (ade­
nylate translocation, dicarboxylate exchange, carnitine palmitoyl transferase) are more 
sensitive to palmitoyl-CoA inhibition than those of rat muscle. The 4 - 5 fold higher car­
nitine concentration of human muscle compared to that of rat muscle may be due to a 
lower tolerance for palmitoyl-CoA. This may be of importance in myocardial ischemia 
and in carnitine and carnitine palmitoyl transferase deficiencies. 
10.3. Branched-chain amino acid oxidation in striated muscle of the rat 
Skeletal muscle acts as a reservoir of amino acids, bound in the form of protein, 
which can be utilized for the supply of energy during fasting or prolonged exercise. The 
branched-chain amino acids leucine, valine and isoleucine represent an important part of 
this pool, and are involved in the regulation of the protein balance in muscle. In contrast 
to other amino acids, the branched-chain amino acids are mainly transaminated in skeletal 
muscle to the corresponding oxo acid derivative. Until recently, it was assumed that these 
oxo acids were predominantly oxidized in liver and kidney. The studies reported in chap­
ters 7 - 9 demonstrate that skeletal muscle has a marked capacity for the oxidation of 
branched-chain oxo acids. 
A suitable method for the assay of the oxidative decarboxylation of leucine, valine 
and 2-oxoisocaproate was developed, and the effects of various cofactors were investigated 
(chapter 7). 2-Oxoglutarate is a good ammo-group acceptor for both leucine and valine. 
Pyruvate markedly inhibits oxidation of leucine and valine, presumably by competition 
with the resulting oxo acids. 
Carnitine stimulates the oxidation of leucine, valine and 2-oxoisocaproate in rat 
skeletal muscle mitochondria (chapter 7). This stimulation of 2-oxoisocaproate oxidation 
was accompanied by an accumula ¡on of isovaleryl-camitine (chapter 8). Carnitine proba-
bly plays a role in leucine oxida ·ι in muscle by mediating the transport of isovaleryl-
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residues out of the mitochondrion. Since addition of isovaleryl-camitine inhibited the 
oxidation of 2-oxoisocaproate, and isovaleryl-CoA had no effect, it was postulated that 
the branched-chain oxo acid dehydrogenase complex is located on the inner surface of 
the mitochondria] inner membrane in skeletal muscle mitochondria (chapters 8 and 9). 
Control of the 2-oxoisocaproate dehydrogenase activity by mitochondrial processes 
was indicated by several observations. The absence of ADP and the inhibition of ADP/ 
ATP exchange by palmitoyl-CoA limited the oxidative degradation of leucine and 2-oxo-
isocaproate (chapters 8 and 9). Inhibition of the respiratory chain by rotenone and im-
pairment of the mitochondrial metabolism by simultaneous addition of FCCP and valino-
mycin decreased 2-oxoisocaproate decarboxylation. In the absence of ADP, succinate and 
2-oxoglutarate inhibited 2-oxoisocaproate oxidation, whereas malate did not. The seques-
tration of intramitochondrial coenzyme A for succinyl-CoA formation probably caused 
this inhibition. 
In chapter 9 we considered the question whether complete oxidation of leucine 
occurs in skeletal muscle. In some types of striated muscle (e.g. diaphragm) leucine can be 
completely oxidized. In isolated mitochondria of m. quadriceps we observed no further 
oxidation of isovaleryl-CoA. This was not due to the absence of bicarbonate in the incu-
bation system, since addition of bicarbonate had no effect on 2-oxoisocaproate oxidation. 
However, we cannot exclude that it is due to loss of enzyme activity during homogeniza-
tion or purification of the mitochondria. This must be verified by studies on 2-oxoiso-
caproate oxidation by intact skeletal muscle tissue. 
Previous estimations of the capacity of skeletal muscle mitochondria or homogenates 
to oxidize leucine have been too low, due to the limitation of the complete oxidation route 
of leucine. Addition of carnitine and optimal metabolic conditions enabled us to estimate 
oxidation of branched-chain amino acids more accurately. A marked capacity for the de-
carboxylation of 2-oxoisocaproate was found in skeletal muscle. Under our experimental 
conditions, the capacity of rat skeletal muscle mitochondria for the decarboxylation of 
leucine (expressed in nmol per mg protein) was 30 - 40 % of the capacity for palmitate de-
gradation. Although the yield of ATP per molecule leucine is considerably less than that 
per molecule palmitate, the amount of energy arising from this amino acid is considerable. 
An interesting aspect of branched-chain amino acid oxidation may be the exit of the 
intermediates from muscle. Although in liver valine and isoleucine can be used for glu-
coneogenesis.and leucine and isoleucine for ketogenesis, skeletal muscle lacks the ability 
for these processes. Liver, however, has a limited capacity for the transamination of 
branched-chain amino acids. During fasting the pool of branched-chain amino acids and 
the transaminase and oxo acid dehydrogenase activities towards these amino acids in-
crease in muscular tissue. Depending on the metabolic state of the mitochondrion, 
branched-chain oxo acids or acyl residues may be formed in skeletal muscle and released 
in the blood stream. These compounds can be further utilized by liver and kidney as glu-
cogenic or ketogenic precursors. In this way skeletal muscle may contribute considerably 
to energy homeostasis during fasting. Further investigations of the effects of fasting and 
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other conditions in whole muscle may enlarge our insight in energy metabolism of skel-
etal muscle. 
Our results on leucine oxidation indicate that at least part of the oxidation of 
branched-chain amino acids proceeds in skeletal muscle of rat. Future investigations have 
to verify whether, and to what extent, this capacity exists in human muscle under various 
metabolic conditions. Since leucine also plays a role in the regulation of the protein 
balance and in sterol synthesis in muscle, it would be important to evaluate the effects of 
changes in the protein intake on the metabolism of muscular tissue and their conse-
quences for human health. 
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SAMENVATTING 
Het metabolisme van de dwarsgestreepte spier is niet alleen van belang voor bewe-
ging, ademhaling en hartfunctie, maar speelt vermoedelijk ook een belangrijke rol bij de 
homeostase van eiwitten, lipiden en koolhydraten in het lichaam, omdat de totale massa 
spierweefsel een relatief groot gedeelte van het lichaamsgewicht vormt. Het onderzoek dat 
in dit proefschrift uiteengezet wordt, betreft twee aspecten van het spiermetabolisme: (1) 
de oxidatie van vetzuren door de skelet- en hartspier van mens en rat, en (2) de oxidatie 
van leucine door de skeletspier van de rat. 
In hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis omtrent de mor-
fologie van de skeletspiervezel en het gebruik van energie leverende substraten door de 
skeletspier, en worden metabole aspecten van carnitine beschreven. Voorts geven we 
een korte karakteristiek van myopathiën, welke veroorzaakt worden door een storing in 
de oxidatie van vetzuren en vertakte aminozuren. 
In hoofdstuk 2 worden enkele methoden, welke in het verdere onderzoek gebruikt 
worden, uiteengezet. Deze omvatten de isolatie en kwaliteitscontrole van mitochondriën, 
en de bepaling van de activiteit van cytochroom с oxidase en monoamine oxidase in 
mitochondriën en homogenaten van spierweefsel. Ten slotte wordt een methode ter bepa-
ling van carnitine in spierweefsel beschreven, en worden de carnitine concentraties gege-
ven, die gevonden werden in verschillende typen skeletspier van mens en rat. 
In hoofdstuk 3 worden een drietal methoden ter bepaling van de vetzuuroxidatie 
door mitochondriën van de skeletspier van de rat vergeleken. In hoofdstuk 5 en 6 wordt 
nagegaan of de bevindingen met deze methoden ook gelden voor de skelet- en hartspier 
van de mens, en worden waarden gegeven voor de snelheid van palmitaatafbraak door ho-
mogenaten en mitochondriën van skelet- en hartspier van mens en rat. 
De productie van ^4C02 uit [^CJvetzuren weerspiegelt slechts een klein gedeelte 
van de hoeveelheid vetzuur, die afgebroken wordt (hoofdstuk 3 - 6). Het grootste deel van 
de radioactiviteit wordt teruggevonden in citroenzuurcyclusintermediairen en acetylcami-
tine (hoofdstuk 3 en 6). In mitochondriën van humaan spierweefsel blijkt de productie 
van ^ C 0 2 bovendien afhankelijk van de verhouding tussen palmitaat en albumine in het 
incubatiesysteem. Een aanzienlijke variatie in de snelheid van 14C02 productie uit [14C]-
palmitaat wordt gevonden, ook wanneer deze snelheid gerelateerd wordt aan de mito-
chondriële marker enzymen cytochroom с oxidase en monoamine oxidase. 
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Het meten van de zuurstofconsumptie gedurende palmitaat oxidatie door spiermito-
chondriën is een juiste en accurate meetmethode (hoofdstuk 3 en 5). Deze methode is 
echter niet bruikbaar voor metingen in spierhomogenaten, omdat zij gestoord wordt door 
o jn. de verbranding van endogene substraten. Bovendien is voor deze techniek aanzienlijk 
meer spierweefsel nodig dan voor een radiochemische bepaling. Als parameter voor de 
vetzuuroxidatie wordt nu de som van ^4C02 en 14C-gelabelde zuur-oplosbare producten, 
welke gevormd worden uit [^4C]vetzuren, bepaald. De waarden, verkregen met deze be-
palingsmethode, komen overeen met die welke uit meting van het zuurstofverbruik ver-
kregen wordt (hoofdstuk 3 en 5). 
De hoeveelheid radioactiviteit, die gevonden wordt in CO2 en zuur-oplosbare produc-
ten gedurende oxidatie van [ ' 4C]palmitaat, wordt beïnvloed door de positie van de label 
in het palmitaatmolecuul. Met [l-l4C]palmitaat is deze hoeveelheid groter dan met 
[U-14C]palmitaat, en met [16-14C]palmitaat kleiner (hoofdstuk 4). De verschillen wor-
den zowel met mitochondriën als met homogenaten gevonden. Ze worden veroorzaakt 
door accumulatie van ß-oxidatie intermediairen, die vooral als vrije vetzuren en camitine-
esters in het incubatiesysteem worden teruggevonden (hoofdstuk 4). De vorming ervan 
hangt niet af van de samenstelling van het incubatiemedium, en vindt plaats met prepara-
ten van skelet- en hartspier van rat en mens (hoofdstuk 4 - 6). 
De bepaling van 14C02 en 14C-gelabelde zuur-oplosbare producten uit [14C]palmi-
taat kan zodanig in schaal verkleind worden, dat het mogelijk is de vetzuuroxidatie te me-
ten in een spierbiopt van ca. 10 mg. (hoofdstuk 5). Geen duidelijke verschillen in palmi-
taat oxidatie worden gevonden in verschillende typen dwarsgestreepte spier van de mens, 
wanneer de snelheid gerelateerd wordt aan de activiteit van cytochroom с oxidase. Wan­
neer de oxidatiesnelheid uitgedrukt wordt per mg eiwit, blijkt de hartspier een veel gro­
tere capaciteit voor vetzuuroxidatie te bezitten dan de skeletspier (hoofdstuk 5). 
Uit de gegevens van hoofdstuk 3, 5 en 6 blijkt dat er vele overeenkomsten zijn in de 
vetzuuroxidatie in skelet- en hartspier van rat en mens. Opvallende verschillen tussen de 
skeletspier van beide species worden gevonden in het carnitine gehalte en de oxidatieve 
capaciteit per mg homogenaat-eiwit. Voorts duiden verschillende waarnemingen op een 
grotere gevoeligheid van de humane spiermitochondriën voor palmityl-CoA dan die van de 
spiermitochondriën van de rat (sectie 10.2). 
In hoofdstuk 7 wordt een geschikt meetsysteem voor de oxidatieve decarboxylering 
van vertakte aminozuren en corresponderende oxozuren beschreven. De invloed van ver-
schillende cofactoren is nader onderzocht. Carnitine stimuleert de oxidatie van leucine en 
valine in intacte mitochondriën en homogenaten van de skeletspier van de rat. In hoofd-
stuk 8 wordt het mechanisme van deze stimulatie onderzocht. De oxidatie van 2-oxoiso-
caproaat, het corresponderende oxozuur van leucine, wordt door carnitine gestimuleerd 
in mitochondriën van de skelet- en hartspier en de nier, maar niet of nauwelijks in die van 
lever en hersenen. Deze stimulatie gaat gepaard met een accumulatie van isovaleiyl-cami-
tine. Op grond van deze en andere bevindingen wordt gepostuleerd dat het dehydrogenase 
complex voor vertakte oxozuren zich aan de binnenzijde van de mitochondriéle binnen-
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membraan bevindt. 
In hoofdstuk 9 worden een reeks van ondersteunende gegevens voor deze hypothese 
gegeven. De metabole toestand van het mitochondrion blijkt bepalend voor de activiteit 
van het dehydrogenase voor vertakte oxozuren. Tevens worden kinetische parameters van 
de oxidatieve decarboxylering van 2-oxoisocaproaat gerapporteerd. 
Uit de gegevens van hoofdstuk 7 - 9 kan geconcludeerd worden dat in tegenstelling 
tot vroegere bevindingen een aanzienlijke oxidatie van vertakte aminozuren, met name 
leucine, kan geschieden in de skeletspier van de rat. In hoofdstuk 9 wordt bediscussieerd 
in hoeverre een volledige oxidatie van het leucine-molecuul in de spier plaats vindt. Het 
lijkt waarschijnlijk dat gedurende de afbraak van vertakte aminozuren intermediairen van-
uit de spier in de bloedbaan worden afgegeven, en dat deze intermediairen in andere orga-
nen aangewend kunnen worden voor gluconeogenese, ketogenese en eventueel voor ver-
dere oxidatie. 
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